

Transposon Mutagenesis in *Chlamydia trachomatis* Identifies CT339 as a ComEC Homolog Important for DNA Uptake and Lateral Gene Transfer

Scott D. LaBrie,^a Zoë E. Dimond,^a Kelly S. Harrison,^a Srishti Baid,^a Jason Wickstrum,^a Robert J. Suchland,^b P. Scott Hefty^a

^aDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA ^bDepartment of Medicine, University of Washington—Seattle, Seattle, Washington, USA

ABSTRACT Transposon mutagenesis is a widely applied and powerful genetic tool for the discovery of genes associated with selected phenotypes. Chlamydia trachomatis is a clinically significant, obligate intracellular bacterium for which many conventional genetic tools and capabilities have been developed only recently. This report describes the successful development and application of a Himar transposon mutagenesis system for generating single-insertion mutant clones of C. trachomatis. This system was used to generate a pool of 105 transposon mutant clones that included insertions in genes encoding flavin adenine dinucleotide (FAD)-dependent monooxygenase (C. trachomatis 148 [ct148]), deubiquitinase (ct868), and competence-associated (ct339) proteins. A subset of Tn mutant clones was evaluated for growth differences under cell culture conditions, revealing that most phenocopied the parental strain; however, some strains displayed subtle and yet significant differences in infectious progeny production and inclusion sizes. Bacterial burden studies in mice also supported the idea that a FAD-dependent monooxygenase (ct148) and a deubiguitinase (ct868) were important for these infections. The ct339 gene encodes a hypothetical protein with limited sequence similarity to the DNA-uptake protein ComEC. A transposon insertion in ct339 rendered the mutant incapable of DNA acquisition during recombination experiments. This observation, along with in situ structural analysis, supports the idea that this protein is playing a role in the fundamental process of lateral gene transfer similar to that of ComEC. In all, the development of the Himar transposon system for Chlamydia provides an effective genetic tool for further discovery of genes that are important for basic biology and pathogenesis aspects.

IMPORTANCE Chlamydia trachomatis infections have an immense impact on public health; however, understanding the basic biology and pathogenesis of this organism has been stalled by the limited repertoire of genetic tools. This report describes the successful adaptation of an important tool that has been lacking in *Chlamydia* studies: transposon mutagenesis. This advance enabled the generation of 105 insertional mutants, demonstrating that numerous gene products are not essential for *in vitro* growth. Mammalian infections using these mutants revealed that several gene products are important for infections *in vivo*. Moreover, this tool enabled the investigation and discovery of a gene critical for lateral gene transfer; a process fundamental to the evolution of bacteria and likely for *Chlamydia* as well. The development of transposon mutagenesis for *Chlamydia* has broad impact for the field and for the discovery of genes associated with selected phenotypes, providing an additional avenue for the discovery of molecular mechanisms used for pathogenesis and for a more thorough understanding of this important pathogen.

KEYWORDS Chlamydia trachomatis, genetic competence, mutagenesis, transposons

Citation LaBrie SD, Dimond ZE, Harrison KS, Baid S, Wickstrum J, Suchland RJ, Hefty PS. 2019. Transposon mutagenesis in *Chlamydia trachomatis* identifies CT339 as a ComEC homolog important for DNA uptake and lateral gene transfer. mBio 10:e01343-19. https://doi .org/10.1128/mBio.01343-19.

Editor Joanne Engel, University of California, San Francisco

Copyright © 2019 LaBrie et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to P. Scott Hefty, pshefty@ku.edu.

Received 24 May 2019 Accepted 28 June 2019 Published 6 August 2019 Transposon (Tn) mutagenesis is among the more effective strategies for discovering specific genetic components associated with a given phenotype. This genetic tool has been successfully applied for a better understanding of many basic biological processes as well as for the discovery of gene products associated with host infection and pathogenesis in diverse bacterial species (1, 2). Over a decade of optimization of naturally occurring transposon systems such as Sleeping Beauty and Tc1/mariner has resulted in a repertoire of successful genetic insertion systems.

One of the more widely applied transposons is the hyperactive form of the *Himar1* mariner system (3). This variant has resulted in robust transposition efficiencies and has revolutionized the study of genotype-phenotype correlation (4). The Himar system has many benefits that have allowed applications in phylogenetically diverse bacteria (5-11), most importantly, the simplified "cut-and-paste" mechanism that requires a single transposase for recognition of inverted repeat sequences on flanking ends of DNA. This allows direct transposition of DNA to DNA, without the requirement of additional cofactors. Additionally, the Himar hyperactive transposase has minimal target DNA specificity, inserting between T/A nucleobases (7, 12) and allowing relatively nonspecific insertion across an entire genome (13–15). These advantages have proven beneficial for the study of pathogenesis in a diverse set of bacteria, including obligate intracellular organisms such as Coxiella and Ehrlichia. Research in Coxiella has demonstrated the use of *Himar1* Tn mutagenesis to identify genes critical for cellular growth and division in vitro (9, 10), whereas Tn studies in Ehrlichia revealed genes important for mammalian infection (8). Thus far, a transposon mutagenesis system has not been comprehensively described for the globally prevalent and obligate Chlamydia intracellular pathogens.

Chlamydia trachomatis is the most commonly reported cause of sexually transmitted bacterial infection in the United States and worldwide. *C. trachomatis* infections result in a range of health issues that include pelvic inflammatory disease, sterility, blindness, and pneumonia (16, 17). *C. trachomatis* contains a single, circular chromosome of \sim 1.04 Mb and a plasmid of \sim 7,500 bp (18, 19). Lateral gene transfer has likely played a critical factor in shaping chlamydial genomes. Moreover, lateral gene transfer occurs readily between strains, and genetic exchange between *C. trachomatis* genomes allows the interchange of polymorphic loci, such as the immunodominant major outer membrane porin gene (*ompA*), often resulting in enhanced tissue tropism and fitness against host defenses (20–26). Despite this key role, the components that participate in and the process involved in lateral gene transfer and DNA uptake are virtually unknown in *Chlamydia*. Similarly, many aspects of basic *C. trachomatis* biology and pathogenesis are poorly understood. This has been largely due to the limitations of the genetic tools that have been available for *Chlamydia*.

There has been a recent surge of introductions of molecular tools and methods developed for genetic manipulation in *Chlamydia* that has been enabled by the discovery of a transformation method and effective selectable antibiotic markers (27-32). TargetTron (29) and allele-specific recombination (33, 34) are two reverse genetic tools that have been developed for targeted gene disruption and have enormous potential for functional and phenotypic studies for candidate genes. However, only chemical mutagenesis has been developed for random and unbiased strategies (35–37). This method has been effectively employed to introduce multiple-base mutations, including nonsense mutations, allowing an association of gene products with noteworthy alterations to physiological pathways (36). While chemical mutagenesis is effective, it has certain limitations, including those represented by the acquisition of multiple mutations and the challenge of correlating a phenotype to a specific genetic disruption. Furthermore, identifying the mutations requires whole-genome sequencing (WGS) and revertant or compensatory mutations may be acquired during continued passaging. Thus, the development of a random single-insertion system, such as a Himar1 transposon containing a selectable marker, allows straightforward generation of stable, single-site mutations and simplified identification of insertion sites.

Here, the development and application of a single-plasmid Himar1 Tn system for C.

trachomatis are described. An initial subset of Tn insertion mutant strains was evaluated for potentially contrasting *in vitro* (tissue culture) and *in vivo* (mouse genital tract infection model) growth features. One of the transposon insertions occurred in a gene (*ct339*) that exhibits sequence similarity to that encoding an inner membrane DNA uptake protein termed ComEC. This mutant was investigated for the ability to perform lateral gene transfer and transformation-based DNA uptake.

RESULTS

Generation and genomic characterization of Tn insertion mutant clones using pCMA. A plasmid termed pCMA (plasmid <u>Chlamydia Ma</u>riner) (see Fig. S1 in the supplemental material) was designed to encode the widely utilized C9 *Himar1* transposase (3). To reduce acquisition of deleterious mutations associated with plasmid propagation in *Eschericha coli*, the chlamydial *ct559* promoter and ribosomal binding site were cloned upstream of the C9 transposase. The *ct559* promoter has been characterized previously (38) and exhibited transcriptional activity in *Chlamydia* but limited activity in *E. coli*. The *bla* gene was cloned with flanking inverted repeats for recognition and transposition by the *Himar1* transposase. Finally, the plasmid contains only the *colE1* origin of replication for plasmid propagation in *E. coli*, which is nonfunctional in *Chlamydia*, resulting in a nonreplicative (suicide) vector upon transformation into *Chlamydia*.

The pCMA plasmid was used in a C. trachomatis transformation procedure with β -lactams for selection (39). This procedure typically requires three passages (i.e., infection-growth-lysis-reinfection) under conditions of antibiotic selection to ensure that the resulting organisms encoding β -lactamase (bla) are indeed able to form infectious progeny in the presence of β -lactams. In order to decrease the potential for normally growing mutants to outcompete fitness-compromised mutant clones in a mixed infection, as well as to evaluate transformation and transposon efficiency, transformation reactions (DNA and elementary bodies [EBs]) were mixed and incubated before being split into individual wells of a 12-well plate. Each well was passaged twice with selection, and after the second passage, cultures were allowed to continue growing, with daily monitoring of C. trachomatis growth. Within 2 days of cultivation, C. trachomatis growth was observed in approximately 4 of the 12 wells, although certain samples took longer than 2 days. A total of 23 transformations were performed with 105 resistant growth cultures and a range of 0 to 9 wells with resistant growth for each transformation. These observations suggest that the transformation efficiency in C. trachomatis is very low and/or that the genome may be less tolerant of transposon insertions. This efficiency was mirrored in five independent transformations performed with pGFP::SW2 which resulted in an average of 4.8 wells (range, 4 to 8) with resistant growth (data not shown), supporting the idea that transformation efficiency likely represents the limitation rather than transposon expression or function.

To identify the site(s) of transposon insertion and other potential mutations, wholegenome sequencing was applied to the 105 mutant strains as well as to the parental L2 strain (LGV 434/Bu Hefty; CP019386.1). All mutant strains contained a single transposon insertion in an expected insertion site (T/A). The absence of mixed Tn insertion strains supports the idea that clonal isolates were obtained following the distribution of transformation sample into individual 12 wells and multiple passaging with selection.

In total, 81 unique Tn insertion mutants were generated within coding regions (Fig. 1) (Table 1), with seven genes (*ct054*, *ct153*, *ct170*, *ct333*, *ct392*, *ct414*, and *ct550*) incurring transposon insertions in multiple sites of the coding region. While all of the studies were performed using *C. trachomatis* LGV 434/Bu, *C. trachomatis* serovar D gene nomenclature is utilized due to recognition and field familiarity. The gene *ct333* (*uvrA*) had 5 Tn insertions throughout the relatively large coding region (5,361 bp). Predominantly, Tn insertions resulted in the truncation of a protein-coding region with the addition of a short protein extension provided by the Tn insertion, depending on the insertion site and reading frame. Most of these insertions were found to have occurred

LaBrie et al.




FIG 1 Map of transposon insertions in *C. trachomatis* chromosome and plasmid. (A) Sites of transposon insertions within coding regions (red) and noncoding regions (blue) throughout the *C. trachomatis* L2 434/Bu chromosome. (B) Sites of transposon insertions within the coding regions (red) and noncoding regions (blue) throughout the *C. trachomatis* L2 434/Bu plasmid. ori, origin of replication.

CLUCX (COM) ADM Pronouncidie montane Conditional Conditional <thconditional< th=""> <thconditional< th=""></thconditional<></thconditional<>	6fb Pendokuridhae 3327 3441.00 rikh (rikh) Bendokuridhe synthae 3327 3441.00 inportherical Bendokuridhe synthae 3327 3441.00 inportherical Bendokuridhe setting 12347.1 12347.1 intrins liportherical Bendokuridhe setting 12347.1 12347.1 intrins liportherical Bendokuridhe 12347.1 12347.1 intrins liportherical Bendokuridhe 12347.1 12347.1 intrins liportherical Bendokuridhe 22399.0 1237.71 intrins lipor Bendokuridhe 2335.6 747.30 intrins lipor Bendokuridhe 2335.6 747.30 intrins lipor Bendokuridhe 2335.6 747.30 intrins lipor Bendokuridhe 2333.6 747.30 intrins lipor Bendokuridhe 233.3 239.0 intrins lipor Bendokuridhe 233.1 237.1 intrins lipor Bendokuridhe 233.2 232.7 intrins lipor Bendokuridhe	ctl gene (ct ^c)::Tn bla Gene name	me Predicted function	of TN insertion ^a	gene length (bp)	Modified protein sequence ^d	length] (bp) ^d
Time Time <th< td=""><td>Non-there is a standard of training training standard building build</td><td></td><td>Pseudouridine svnthase</td><td>33827</td><td>544/1,008</td><td>OVKKI X</td><td>[Y182X: 182/335]</td></th<>	Non-there is a standard of training training standard building build		Pseudouridine svnthase	33827	544/1,008	OVKKI X	[Y182X: 182/335]
Link Constrained Constraind Constrained C	 tidd (riks) tidd (ri)	76200	17/969		[G8R+ 16/322]
1110 12230 122311 12331 12331 <td< td=""><td>rible (ribb) 6.7°-Dimerichy-1-rible by Linearine synthase murr Dyrocher (al. phosphatic) 4-rible by Linearine shinding proceeding more than the second and the second and</td><td>C+10065 (C+696) e</td><td>Hymothetical</td><td>79500</td><td>1 039/1 179</td><td>MRVIIX</td><td>[0277X - 346/302]</td></td<>	rible (ribb) 6.7°-Dimerichy-1-rible by Linearine synthase murr Dyrocher (al. phosphatic) 4-rible by Linearine shinding proceeding more than the second and	C+10065 (C+696) e	Hymothetical	79500	1 039/1 179	MRVIIX	[0277X - 346/302]
Matrix for the field of production of matrix and matri	murr University of a standard set of the finding 12300 197/453 murr University of a standard set of the constant set of the finding 12301 197/453 murr University and set of the constant set of the consthe set of the constant set of the consta		A Dimothing - S-vibitillinmerine				
multiplemultip	marg proponent cat, probability of the protection protectin protectin protectio				107 / 107		
mutry up/ore-domains/any protection 139/11 1.230	marg Uppercention 1.328/1.353 ptr Dimension Dimension Dimension ptr Enclusion Dimension Dimension ptr Enclusion Dimension Dimension ptr Enclusion Dimension Dimension ptr Enclusion Dimension Dimension ptrono Stype Dimension Dimension ptrono Stype Dimension Dimension ptrono Stype Dimension Dimension ptrono Dimension Dimension Dimension <td>(DC/10) CATATO</td> <td></td> <td>000 F 7 T</td> <td>СС#/ТАТ</td> <td></td> <td></td>	(DC/10) CATATO		000 F 7 T	СС#/ТАТ		
Distribution Control Contro Contro Contro Contro Contro Contro Contro Contro C	marg UDF-Macecynamismoyl-retipeptidase Log1A Li3B/L1353 PCr Textion membrane protein 23556 74/200 Protipiamic Jara 23756 74/200 23757 Protipiamic Jara 23756 74/200 23757 Protipiamic Jara 23756 74/200 23757 Protipiamic Jara 23756 74/200 2377/100 Protipictial membrane protein 233256 74/200 2377/100 Protipictial Protipictial 23326 121/71 23256 Protipictial Protipictial 23336 121/71 23256 Protipictial Protipictial 23336 127/71 200 Protipictial Protipictial 23336 127/71 200 Protipictial 2000000000000000000000000000000000000		proteins				
Det Tathle Lights Calibration Lights Lights NELPTRUDGFW Color Color <thcolor< th=""> Color Color <</thcolor<>	Dtr alatine ligase alatine ligase <thalatine ligase<="" th=""> alatine ligase</thalatine>		UDP-N-acety1muramoy1-tripeptide-p-alany1-p-	169474	1,328/1,353	ELEILIGWMISPKSDAQWNENSKX	[L404T; 462/450]
Ptr Tertifiants: C.:-Generation: C.:-G	ptr Periplamic Zn-dependent methyltransferase 22399 11.256.2.671 House in multican membrane protein 23556 74/00 Pyportherical multican methyltransferase 23576 74/100 Pyportherical multicane associated protein 23556 74/00 Pyportherical multicane associated protein 23556 74/00 Pyportherical multicane 23245 184/306 Phylomethic outer methyltransferase 23245 184/306 Phylomethic outer methyrans for and aneddylase 23256 74/100 Phylomethic outer methyrans for and aneddylase 23256 247/106 Phylomethic outer methyrans for and aneddylase 23256 247/11/100 Phylomethic outer methyrans for and aneddylase 200287 240/11/107 Phylomethic outer methyrans for an outer anon and aneddylase 200287 240/11/107 Phylomethic outer methyrans for an outer anon anon and aneddylase <td></td> <td>alanine ligase</td> <td></td> <td></td> <td></td> <td></td>		alanine ligase				
Tachlain and management 355/36 355/36 7500 <th7500< th=""> 7500 7500 <th< td=""><td>The length of the len</td><td></td><td>Periplasmic Zn-dependent peptidase</td><td>223999</td><td>1,236/2,871</td><td>INSLE<u>Y</u>NRLDDKSPVX</td><td>_</td></th<></th7500<>	The length of the len		Periplasmic Zn-dependent peptidase	223999	1,236/2,871	INSLE <u>Y</u> NRLDDKSPVX	_
Pyperhetical members/ protection 23355 71/30 FGGT_TownSPSDA0WNENSR 7227-3 CMM Provide and characteria 23940 71/30 FGGT_TOWNSPSDA0WNENSR 7247-3 CMM Provide and characteria 23940 71/30 FGGT_MOWNSPSDA0WNENSR 7247-3 CMM Provide and characteria 23940 71/30 FGGT_MOWNSPSDA0WNENSR 727-3 CMM Provide and characteria 23940 71/30 FGGT_MOWNSPSDA0WNENSR 7293-35 CMM Provide and characteria 23936 71/31-30 FGGT_MOWNSPSDA0WNENSR 7293-35 CMM Provide and characteria 23936 71/31-30 FGGT_MOWNSPSDA0WNENSR 7293-75 Provide and characteria 20440 20441 2047-73 FGGT_MOWNSPSDA0WNENSR 7293-75 Provide and characteria 20440 2047-73 2047-73 FGGT_MOWNSPSDA0WNENSR 7270-76 Provide and characteria 20400 20707-71 FGGT_MOWNSPSDA0WNENSR 7270-76 Provide and characteria 20401 20471-71 FGGT_MOWNSPSDA0WNENSR 727	trmBtypothetical membraine -associated protein23255574/300trmBPixelive SMA Tablitor232340127/17trmBPixelive SMA dependent methyltransferase259340127/17trmBPixelive SMA dependent methyltransferase259340127/11.020Publicitinaseand demedylase292430127/11.020cdu2Publicitinase302.887887/11.020Publicitinase302.887887/11.020Publicitinase302.897887/11.020Publicitinase302.897887/11.020Publicitinase302.897887/11.020Publicitinase302.8971.277/11.305Publicitinase302.8971.277/11.305Publicitinase302.8971.277/11.305Publicitinase302.8971.277/11.305Publicitiase302.8971.277/11.305Publicitiase302.8971.277/11.305Publicitiase302.8973.717.106Publicitiase302.8973.717.106Publicitiase302.8973.717.105Publicitiase302.8973.777.105Publicitiase302.8973.777.105Publicitiase3.99458.777.1106Publicitiase3.99458.777.1109Publicitiase3.99458.777.1109Publicitiase3.97041.777.1109Publicitia3.97041.777.1109Publicitia3.97041.777.1109Publicitia3.97041.777.1109Publicitia3.777.1051.9	ct10184 (ct813) ^h	Inclusion membrane protein	235508	355/795	QFRIVTGWMISPRSLVAQR-35AA-YFX ^f	[M120T;
Time Time <th< td=""><td>true<!--</td--><td>C+10185 (C+814) e</td><td></td><td>236256</td><td>74/300</td><td>EGGEI TGWMISPRSDAOWNENSRX</td><td>ГА26Т· 2</td></td></th<>	true </td <td>C+10185 (C+814) e</td> <td></td> <td>236256</td> <td>74/300</td> <td>EGGEI TGWMISPRSDAOWNENSRX</td> <td>ГА26Т· 2</td>	C+10185 (C+814) e		236256	74/300	EGGEI TGWMISPRSDAOWNENSRX	ГА26Т· 2
Cristical Solution Control Solution <thcontrol solution<="" th=""> <thcontrol solution<<="" td=""><td>LrmBVerter and interfactor2433011/11/1CM2Debuiguitinaeand the attrylicanaferase2433011/565ERNHouniquitinaesand deneddylaes2934511/565ERNPosphate-responsive ArPase, PhOH-like protein30310387/1.000Papperheticaland deneddylaes30430887/1.100Papperheticaland deneddylaes30430887/1.100Papperheticalputprintinaesand deneddylaes30430887/1.100Papperheticalputprintinaesand deneddylaes30430887/1.100Papperheticalputprintinaesand deneddylaes30430887/1.100Papperhetical2-0xoglutarate delydrogenaes5104536364621/1.105Papperhetical2-0xoglutarate delydrogenaes363362,122/2.711Papperhetical2-0xoglutarate delydrogenaes383352,122/2.711Paperhetical2-0xoglutarate delydrogenaes36366621/1.105Papperheticalpapperhetical4170411071.005Papperheticalproprinting2704330571.105Papperheticalproperting473944522/1.206Papperheticalproperting473944522/1.206PapperheticalmacpMonospecific ademite473944PapperheticalMonospecific ademite4730441767/1.405PapperheticalMonospecific ademite930466937/1.105PapperheticalMonospecific ademite930466937/1.205Papperhetical<td></td><td></td><td></td><td></td><td></td><td></td></td></thcontrol></thcontrol>	LrmBVerter and interfactor2433011/11/1CM2Debuiguitinaeand the attrylicanaferase2433011/565ERNHouniquitinaesand deneddylaes2934511/565ERNPosphate-responsive ArPase, PhOH-like protein30310387/1.000Papperheticaland deneddylaes30430887/1.100Papperheticaland deneddylaes30430887/1.100Papperheticalputprintinaesand deneddylaes30430887/1.100Papperheticalputprintinaesand deneddylaes30430887/1.100Papperheticalputprintinaesand deneddylaes30430887/1.100Papperhetical2-0xoglutarate delydrogenaes5104536364621/1.105Papperhetical2-0xoglutarate delydrogenaes363362,122/2.711Papperhetical2-0xoglutarate delydrogenaes383352,122/2.711Paperhetical2-0xoglutarate delydrogenaes36366621/1.105Papperheticalpapperhetical4170411071.005Papperheticalproprinting2704330571.105Papperheticalproperting473944522/1.206Papperheticalproperting473944522/1.206PapperheticalmacpMonospecific ademite473944PapperheticalMonospecific ademite4730441767/1.405PapperheticalMonospecific ademite930466937/1.105PapperheticalMonospecific ademite930466937/1.205Papperhetical <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Link Early Lander methyl transferace 23/47 1/56 Advicition Method Methods Constrained State Constrain	trmbtrmbtrmbcddtrmbttativeV(7)-1-metryltransferase25870266/75pypotheticalDeliguitinase and demedylase298445184/306cdulPulymorphic outer membrane protein312311677/613,039pmpOPulymorphic outer membrane protein31331617/565pmpOPulymorphic outer membrane protein333361.27711,305pmpOPulymorphic outer membrane protein333361.27713,05pmpOPulymorphic outer membrane protein333361.27713,05pmpOPulymorphic outer membrane protein333361.27713,05pmpOPulymorphic outer membrane protein3359352.12727,122pmpOnlogiaPulymorphic outer membrane protein336945620/1109pmpOnlogiaPulymorphic outer membrane protein336945620/1109pmpNPulymorphic outer membrane protein336945620/1109pmpNPulymorphic outer membrane protein336945620/1109pmpNPulymorphic formorphic outer membrane protein336945620/1109pmpNPulymorphic formorphic473041.089/1.109pmpAPulymorphic formorphic473041.089/1.109pmpAPulymorphicPulymorphic47313pmpAPulymorphic4731447314pmpAPulymorphic1.089/1.109pmpAPulymorphic4731447314pmpAPulymorphic1.091/1.209pmpAPulymorphic1.091/1.209	CCIULAI (CC019)	YCCA-BAA INNIDICOT	242330	/ T / / T / T / T		
Hotative Sold-dependent methyltransferae 29440 17/51 MutGTGWNBSFRS.MOWNBSKR C077, 10 Publiditiziae Bigointica Bigointica Bigointica CG378, 2033 CG378, 2	Puterive SAN-dependent methyltransferase2944017/558Puterive SAN-dependent methyltransferase2994017/565PutyorbhictcalPulymorphic and Gareddylase2082587/1/100Pulymorphic Santase and demeddylase30430389/1/106Pulymorphic Santase30336460/1/158Phosphate-responsive ATbase, PhoH-like protein33336460/1/158Phosphate-responsive ATbase, PhoH-like protein33945660/1/158Phosphate-responsive ATbase, PhoH-like protein33934560/1/158Puterive Inc2-0xequitatrate dehydrogenase E1 component3859222.122/2/712Puterive Inc3859222.122/2/71230945660/1/169PapP01900011pase D superfamily3395222.122/2/712PapP01900011pase D superfamily470041.064/1.905PapP01900011pase D superfamily470041.064/1.902PapP01900011pase D superfamily470041.064/1.902PapP01900011pase D superfamily470041.064/1.902PapP01900011pase D superfamily470041.064/1.902PapP019000011pase D superfamily470041.064/1.902PapP019000011pase D superfamily470041.064/1.902PapP0190000011pase D superfamily470041.064/1.902PapP01900000011pase D superfamily470041.064/1.902PapP01900000001100000000000000000000000000	(<i>ctr829</i>)		258702	68/675	IANHVTGWMISPRSDAQWNENSRX	
Bubble interactionBubble interactionBubbl	Cdu2Hydrotherical hydrothericalSouth and demeddylaseSouth and demeddylasecdu1Peubliquitinase and demeddylase302878071.200pmpcPeubliquitinase302878071.200Phosphate-responsive ArPase, PhoF-like protein333361.277/1.305Phosphate-responsive ArPase, PhoF-like protein333361.277/1.305Phosphate-responsive ArPase, PhoF-like protein333361.277/1.305Phosphate-responsive ArPase, PhoF-like protein3353552.692/2.712Putative Brock2-0xoglutarated dehydrogenase El component3553552.122/2.712Such2-0xoglutarated dehydrogenase El component3553552.692/2.712Putative Montane-spanning protein3553552.692/2.712Protentive Arborate Behydrogenase El component3553552.692/2.712Protentive Arborate Behydrogenase El component3553552.122/2.712Protentive Arborate Behydrogenase A4.72046.697/1.206Arborate Edehydrogenase A4.72046.697/1.206Arborate Arborate Behydrogenase A4.72045.697/1.205Arborate Arborate Arborat	C+10202 (C+830)		259440	17/585		[D7T. 16/194]
EditHome interaction20381317.1.0.0FULMFULM102.0.1Polynamic of the markane protein3.02.813.02.1.0.0PT.M. 10.0PT.M. 10.0PT.M. 10.0PT.M. 10.0Polynamic of the markane protein3.02.813.02.1.0.0PT.M. 10.0PT.M. 10.0PT.M. 10.0PT.M. 10.0Polynamic of the markane protein3.02.813.02.1.1.0PL.M. 10.0PT.M. 10.0PT.M. 10.0PT.M. 10.0Polynamic of the markane protein3.33.846.0.1.1.1.0PL.M. 10.0PL.M. 10.0PL.M. 10.0Polynamic of the markane protein3.33.346.0.1.1.1.0PL.M. 10.0PL.M. 10.0PL.M. 10.0Polynamic of the markane protein3.33.346.0.1.1.1.0PL.M. 10.0PL.M. 10.0PL.M. 10.0Polynamic of the markane protein3.33.41.0.1.1.0.0PL.M. 10.0PL.M. 10.0PL.M. 10.0Polynamic of the markane protein4.3.1.41.0.0.1.1.0.0PL.M. 10.0PL.M. 10.0PL.M. 10.0Polynamic of the markane protein4.3.1.41.0.0.1.1.0.0PL.M. 10.0PL.M. 10.0PL.M. 10.0<	CdL2Physochesteat292431437/1,00cdL1Publiquitinase301301309/1,206cdL1Polymorphic outer membrane protein3133161,277/1,305pmp6Polymorphic outer membrane protein3133161,277/1,305Physochesteat333361,277/1,305Physochesteat3033356/1,136Suck2-Oxegulurated dehytorgenase3534652/1,132Phospholipase3334652/7,123Suck2-Oxegulurated dehytorgenase3534652/7,132Phospholipase3394662/1,136Suck2-Oxegulurated dehytorgenase3534263/7,1035Phospholipase3394663/7,1035Phospholipase336/1,304336/1,305Phospholipase336/1,304336/1,305Phospholipase7/1,323336/1,305Phospholipase7/1,323336/1,305Phospholipase7/1,323336/1,305Phospholipase7/1,324336/1,305Phospholipase7/1,324336/1,305Phospholipase7/1,324336/1,305Phospholipase7/1,324336/1,305Phospholipase1019294411/6/1,325Phospholipase7/1,324336/1,305Phospholipase1019204640/1,192Phospholipase11/6/1,51511/1,922Phospholipase11/1,92211/6/1,922Phospholipase11/6/1,51511/1,922Phospholipase11/6/1,51511/1,922Phospholis		01100110400				
cdu2Deminjuti.imaseand demiddylase328/339/1,2/30Gr.M.M.75/3/175/3/3pupoPolymorphic outer membrane protein3383650/1,2/30BS/1,2/30BS/1,2/30BS/1,2/30BS/1,2/30Phypotherical, public/restPolymorphic outer membrane protein3383650/1,2/30BS/1,2/30BS/1,2/30BS/1,2/30Pupotherical, public/restPolymorphic20000H150/MISFS/MOVENSK75/3/1BS/1,2/30BS/1,2/30BS/1,2/30Proteinerical, public/rest20000H150/MISFS/MOVENSK75/3/1BS/1,2/30BS/1,2/30BS/1,2/30BS/1,2/30Proteinerical, public/rest20000H150/MISFS/MOVENSK20000H150/MISFS/MOVENSKPS/2000Proteinerical, public/rest20000H150/MISFS/MOVENSKPD/2000H150/MISFS/MOVENSKPS/2000Proteinerical, public/rest20000H150/MISFS/MOVENSKPD/2000H150/MISFS/MOVENSKPS/2010Proteinerical, public/rest20000H150/MISFS/MOVENSKPD/2000H150/MISFS/MOVENSKPS/2010Proteinerical20000H150/MISFS/MOVENSKPD/2000H150/MISFS/MOVENSKPS/2010Proteinerical20000H150/MISFS/MOVENSKPD/2000H150/MISFS/MOVENSKPS/2010Proteinerical201200H150/MISFS/MOVENSK20000H150/MISFS/MOVENSKPS/2010Proteinerical20000H150/MISFS/MOVENSK20000H150/MISFS/MOVENSKPS/2010Proteinerical20000H150/MISFS/MOVENSK20000H150/MISFS/MOVENSKPS/2010Proteinerical20000H150/MISFS/MOVENSK20000H150/MISFS/MOVENSKPS/2010Proteinerical20000H150/MISFS/MO	Cdu2Deubiquitinaseand deneddylase977.1.1020pmp0Polymorphic outer membrane protein303887877.1.1020pmp0Polymorphic outer membrane protein3133161.277/1.305Phosphate-responsive ATPase, PhOH-like protein3333861.277/1.305Phosphate-responsive ATPase, PhOH-like protein33336563.1.2,001Phosphate-responsive ATPase, PhOH-like protein33335663.1.2,001Phosphate-responsive ATPase, PhOH-like protein33335561.1.1.138Sucd2-0xoqlutearte dehydrogenase El component38535663.1.2.01Phosphilipase D superfamily38531441.1.0.05Phosphilipase D superfamily38531441.1.01Phosphilipase D superfamily38532661.1.1.201Phosphilipase D superfamily38532661.1.1.201PophOligoendopeptide ransport system binding protein410045837.1.1.201Phosphilipase D superfamily42034465.0.625411.1.2.41Phosphilipase D superfamily42034467.0.1.2.61Phosphilipase D superfamily42034467.0.1.2.61Phosphilipase D superfamily470401.767.1.81Phosphilipase D superfamily470401.767.1.82Phosphilipase D superfamily470401.767.1.82PhosphilipasePhosphilipase93.61.1.20PhosphilipasePhosphilipase93.61.1.20PhosphilipasePhosphilipase93.61.1.20PhosphilipasePhosphilipase93.61.1.20PhosphilipasePhosphilipase<	CT10238D	Hypothetical	C78242	184/306	PYQYUX	[T0T/29 ; X20Y]
cdp1Demixing timeDemixing time </td <td>cdulDeubiquitinase30333889/1.206pugcPolymorphic outer membrane protein312316786/3.039Phosphere-responsive ArPase, PhoH-like protein36386450.0.1.158Phosphere-responsive ArPase, PhoH-like protein363864681/2.001Putative divorgenase El component3638552.1.277/1.305suck2-0xoglutarate dehydrogenase El component38933562.1.277/1.305such2-0xoglutarate dehydrogenase El component38933552.1.227.7122-0xoglutarate dehydrogenase El component38933562.1.277/1.485Putative divorgenase El component38933562.1.277.1.1022-0xoglutarate dehydrogenase El component38933562.1.201.1.092Phosphelipase Dudoridine synthase A4.100454.1.201.1.092pppOligomopptidarae1.00071.1.1034.1.201.1.103scc1Type III secretion chaperone4.2.20141.1.641.1.992pppOligomopptidarae1.0.0011.1.1.844.1.204pppOligomopptidarae4.1.0014.1.204pppOligomopptidarae4.1.0011.1.641.1.992pppOligomopptidare1.0.011.1.1.844.1.204pppOligomopptidare1.0.011.2.1.234.1.2.1.1.23pppOligomoptidare1.0.021.2.1.1.234.1.2.4.1.992pppOligomoptidare1.0.011.2.1.234.1.2.4.1.992pppOligomoptidare1.0.011.2.1.234.1.2.4.1.992pppPhotencialND-dependent NN Ligase4.1.2.4.1.992ppp<</td> <td></td> <td>Deubiquitinase and deneddylase</td> <td>302887</td> <td>877/1,020</td> <td>QFLAWX</td> <td></td>	cdulDeubiquitinase30333889/1.206pugcPolymorphic outer membrane protein312316786/3.039Phosphere-responsive ArPase, PhoH-like protein36386450.0.1.158Phosphere-responsive ArPase, PhoH-like protein363864681/2.001Putative divorgenase El component3638552.1.277/1.305suck2-0xoglutarate dehydrogenase El component38933562.1.277/1.305such2-0xoglutarate dehydrogenase El component38933552.1.227.7122-0xoglutarate dehydrogenase El component38933562.1.277/1.485Putative divorgenase El component38933562.1.277.1.1022-0xoglutarate dehydrogenase El component38933562.1.201.1.092Phosphelipase Dudoridine synthase A4.100454.1.201.1.092pppOligomopptidarae1.00071.1.1034.1.201.1.103scc1Type III secretion chaperone4.2.20141.1.641.1.992pppOligomopptidarae1.0.0011.1.1.844.1.204pppOligomopptidarae4.1.0014.1.204pppOligomopptidarae4.1.0011.1.641.1.992pppOligomopptidare1.0.011.1.1.844.1.204pppOligomopptidare1.0.011.2.1.234.1.2.1.1.23pppOligomoptidare1.0.021.2.1.1.234.1.2.4.1.992pppOligomoptidare1.0.011.2.1.234.1.2.4.1.992pppOligomoptidare1.0.011.2.1.234.1.2.4.1.992pppPhotencialND-dependent NN Ligase4.1.2.4.1.992ppp<		Deubiquitinase and deneddylase	302887	877/1,020	QFLAWX	
protect <t< td=""><td>puppedpolymorphic outer membrane protein31216766/3/030Phosphate-responsive ArPase, FhoH-like protein35346620/1.158Hypotherical, putative Inc35346620/1.158Hypotherical, putative Inc35346620/1.158Buck2-0xoqhutarate dabydrogenase El component353522.1227/1.0012-0xoqhutarate dabydrogenase El component3353222.059/2.712Patetive membrane-spanning3353222.009/2.712Patetive membrane-spanning3353222.1227/1.086Patetive membrane-spanning335322.1227/1.012Patetive membrane for component3353222.059/2.712Patetive membrane-spanning335322.1227/1.128PaperA/G-specific adenine glycosylase447044137441Paper0100900050005005103064170441926/1.206Phosphale01100900510400010108-1yding43714343741.524Phosphale111004432441108/1.1179Phosphale111004432441106/1.118-1/41Phosphale111041110443244Phosphale111041110443244Phosphale111041110443244Phosphale111041110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104</td><td></td><td>Dentrimase</td><td>201203</td><td>889/1 206</td><td></td><td></td></t<>	puppedpolymorphic outer membrane protein31216766/3/030Phosphate-responsive ArPase, FhoH-like protein35346620/1.158Hypotherical, putative Inc35346620/1.158Hypotherical, putative Inc35346620/1.158Buck2-0xoqhutarate dabydrogenase El component353522.1227/1.0012-0xoqhutarate dabydrogenase El component3353222.059/2.712Patetive membrane-spanning3353222.009/2.712Patetive membrane-spanning3353222.1227/1.086Patetive membrane-spanning335322.1227/1.012Patetive membrane for component3353222.059/2.712Patetive membrane-spanning335322.1227/1.128PaperA/G-specific adenine glycosylase447044137441Paper0100900050005005103064170441926/1.206Phosphale01100900510400010108-1yding43714343741.524Phosphale111004432441108/1.1179Phosphale111004432441106/1.118-1/41Phosphale111041110443244Phosphale111041110443244Phosphale111041110443244Phosphale111041110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104Phosphale1110411104		Dentrimase	201203	889/1 206		
pendo Polytophilo Polytoli Polytophilo Po	pmp6Polymorphic outer membrane protein31216706/3/03Phosphetical, putative inc3638661/2/01Phosphetical, putative inc3638661/2/01Phosphetical, putative inc3638661/2/01Phosphetical, putative inc363552/12/2/2/212Suck2-0xoqlutarate dabydrogenase El component383552/12/2/2/212Suck2-0xoqlutarate dabydrogenase El component383552/12/2/2/212Phosphilpase D superfamily390466401/1/03Phosphilpase D superfamily330466401/1/036Phosphilpase D superfamily330466401/1/036Phosphilpase D superfamily330466401/1/036Phosphilpase D superfamily330466401/1/036Phosphilpase D superfamily4239442394Phosphilpase D superfamily40044004Phosphilpase D superfamily41244626/85Phosphilpase D superfamily41244626/85Phosphilpase D superfamily41244626/126Phosphilpase D superfamily41244620/1.197Phosphilpase D0190909016116/1.922Phosphilpase118/24470041.06/1.192Phosphilpase118/24470041.076/1.126Phosphilpase118/24470041.076/1.126Phosphilpase118/24470041.06/1.127Phosphilpase119/245470141.06/1.127Phosphilpase119/245470141.06/1.127Phosphilpase119/245118/245 <t< td=""><td></td><td></td><td></td><td>007/1/200</td><td></td><td></td></t<>				007/1/200		
Hosphate-responsive ArPsas, Piol-Like protein333.61,277/1,305ERSLTGWMISPSSAQWMENSR7357/1, 12000Burdive glycosyl hydrolase333.64620,11380.00-1000000-10000000000000Burdive glycosyl hydrolase333.64620,11380.00-1000000000000000000Burdive glycosyl hydrolase333.652,127,211ABTR00000000000000000000Burdive glycosyl hydrolase1393.652,127,1100000000000000000000000000Burdive glycosyl hydrolase390.65401.1000000000000000000000000000Bordina glycosyl as popolaricia0.1000Bordi0.100000000.100000000000000000000000000001000	Phosphate-responsive ArPase, PhoH-like protein333361,277/1,305Hypothetical, putative Inc53364530443620/1,158Hypothetical, putative much ambrane-spanning protein3853552,122/2,712Putative much ambrane-spanning protein3853552,122/2,712Popholpholpase D synthase3,473446,6885Popholpholpase D synthase4,70041,009/1,107Poph010gomptide transport system binding protein4,70041,009/1,107Hypothetical110/34,70041,009/1,107Hypothetical100/34,70041,009/1,107Hypothetical4,70041,009/1,107Hypothetical4,30344,1004Hypothetical4,30344,1004Hypothetical4,30344,1004Hypothetical4,30344,1074Hypothetical1,1034,3034Hypothetical1,1034,3034Hypothetical1,1034,3034Hypothetical1,1034,3034Hypothetical1,1034,3045Hypothetical1,1034,3045Hypothetical1,1034,3045Hypothetical1,1034,3045Hypothetical1,1035,11/179Hypothetical1,		Polymorphic outer membrane protein	312316	786/3,039	HPICYENKKSSSKFFQKYCGKVX	[G738F;
Brosphet responsive ArPase, FloH-like protein333361.271/1.305ERELCOMMSPGSAONNENSK202001Byoohterical, putative Tace190001200011200011200011200011200011200011Byoohterical, putative Tace20001120001120001120001120001120011Putative Tace delay/cogenase El component355352.122/1.10820011200011Putative Tace delay/cogenase El component355352.039/1.1102001120011Perderical perclanity20052.122/1.1082001120011Pact Streame2001120011200112001120011Pact Streame2001322012220122001120011Pact Streame20130001122012220122201220011Pact Streame20130001122012220122201222012Pact Streame2013001122012220122201222011Pact Streame2013001122012220122201222011Pact Streame2013001122012220122201222012Pact Streame2013001122012220122201222012Pact Streame2013001122012220122201222012Pact Streame2013001122012220122201222012Pact Streame2013001122012220122201222012Pact Streame2013001122012220122201222012Pact Streame20130011<	Hosphete-responsive ArPase, PhoH-like protein338361,2771,305Rypochete-responsive ArPase, PhoH-like protein3538662/11158suck2-oxoglutrarte dehydrogenase El component353552,122.7712suck2-oxoglutrarte dehydrogenase El component3553552,122.7712Putative giycosylataer Demonting protein3553552,122.7712suck2-oxoglutrarte dehydrogenase El component3553552,122.7712Putative giycosylataer Demonting protein3593552,122.7712suck70011904582771,086Non-specific adanine giycosylase470041,089.11.07oppA011gopetide transport system binding protein470041,089.11.07Hypochopspride transport system binding protein4209741,6771,325MacPMon-dependent monoxymase43916611/2.433MacPMon-dependent monoxymase43916611/2.433MacPMonbrane attack complex5064328471.109HypocheticalMonbrane attack complex512551511/2179MacPMonbrane attack complex512551512/51351MacPMonbrane						755/1,012]
Byte the contraction33536620/1,1138COOHLTGOMPRESSANGWINSIGN720807such2.0004114 strete derlytropenase E1 component355352.122/27127103077081such2.0004114 strete derlytropenase E1 component355352.122/27127103077081such2.0004114 strete derlytropenase E1 component355352.122/27127103077081Platity membrane-spanning protein335322.122/2712710617700077081Pope1141,0020011,00200011,0027700077000Pope110000000000000043174411737771000000000000000000000000000000000000	Bypothetical, putative Inc35364620/1,158such2-oxoglutarte dehydrogenase El component353458680/1,1092such2-oxoglutarte dehydrogenase El component3553522,122/2,712such2-oxoglutarte dehydrogenase El component3553552,122/2,712putative membrane-spanning protein3553552,122/2,712propholipase D such3553552,122/2,712propholipase D such3553552,122/2,712popholipase D such3553552,122/2,712popholipase D such3553552,122/2,712popholipase D such4700441704popholipase D such47034461/1,092popholipase D such01/100871441704popholipase D01/100871441704popholipase P01/100871441704popholipase P01/100871441704popholipase P01/100871441704popholipase P01/100871441704popholipase P01/100871441704popholipase P01/100871441704popholipase P01/100871441704popholipase P01/1008750/11179popholipase P01/100871441704popholipase P01/1008751/1179propholipase P00/042261/1179popholipase P01/20042261/1179popholipase P50/042284/2/244popholipase P50/042284/2/244popholipase P50/042284/2/244popholipase P50/0422 <td< td=""><td>ct10270 (ct015)</td><td></td><td>338386</td><td>1,277/1,305</td><td>ERSELTGWMISPRSDAQWNENSRX</td><td></td></td<>	ct10270 (ct015)		338386	1,277/1,305	ERSELTGWMISPRSDAQWNENSRX	
EndEventionSector	BuckPutative diversionSectorSectorPutative diversionSectorSectorPutative diversionSectorSectorPutative diversionSectorSectorPutative diversionSectorSectorPutativeSectorPutativeSectorSectorPutativeSectorS			263864	620/1 158		
Buck Perturve of component SSS Conditience of component SSSS Conditience of component Conditience Conditience of component Conditience Conditience <thconditience< th=""> <thconditence< th=""> Conditi</thconditence<></thconditience<>	 Buck Partative dehydrogenase El component 505356 Buck Partative dehydrogenase El component 505356 Coxoglutarate dehydrogenase El component 305356 Popoholipase f Alexa expanning protein 412044 Popothetica in glycosylase Mapothetica in a glycosylase Membrane attack complex Morban synthase, beta subunit Mypothetica in the synthase in the synthetica						
 2-Conciditatate dehydrogenase El component 35536 2.122.7.12 7-ONGULTATATE de dehydrogenase El component 35536 2.00000 7-ONGULTATATE de dehydrogenase El component 3500 7-ONGULTATATE de dehatine gytocs/lase 7-ONGULTATATE de dehatine gytocs/lase 7-ONGULTATATE defatine gytocs/lase 7-ONGULTATATE defatine gytocs/lase 7-ONGULTATATE defatine gytocs/lase 7-000000000000000000000000000000000000	such 2-Oxoglutarate dehydrogenase El component 385356 $2,122/2,712$ such 2-Oxoglutarate dehydrogenase El component 38535 $2,122/2,712$ such 7-Oxoglutarate dehydrogenase El component 38535 $2,1344$ ssc1 Type Flutarate dehydrogenase El component 38535 $2,1344$ ssc1 Type Flutarity 50,46 417,1,06 Popholipase Advouridine suprismity 445244 626,825 Advouridine suprismit 445244 626,825 447044 Advouridine suprismit 445244 626,825 Advouridine suprismit 445244 626,825 Advouridine suprismit 445244 626,825 Advouridine suprismit 445244 626,825 Advouridine suprismit 479190 36/1,292 Mpochencial Mboloperate suprismit 479190 Mpochencial Mboloperate suprismit 479190 Mpochencial Mboloperate suprismit 479190 Mpochencial Mpochencial 479190 Mpochencial Mpochencial <	Ct10298 (Ct042)"	Putative glycosyl hydrolase	369458	681/2,001	PSKKY <u>N</u> KLUUKSPVX	
such2.0000/literate element355322.699.2,712DisFiGWMRPRSDAOMMENSK[1337]suchPutative membrane-spanning protein304663071.102CMMCTGWMRPSDAOMMENSK[1337]suchPage Lit secretion chapteranity433943771.106FPOIGWMRPSDAOMMENSK[1337]suchPage Lit secretion chapteranity433942771.106FPOIGWMRPSDAOMMENSK[1337]pepDigopatities D superianity433942771.106FPOIGWMRPSDAOMMENSK[1337]pepOligopetide transport system binding protein439341.08911.107FEOIGWMRPSDAOMMENSK[1336]pepOligopetide transport system binding protein437141.08911.107FEOIGWMRPSDAOMMENSK[1337]pepOligopetide transport system binding protein437141.08911.107FEOIGWMRPSDAOMMENSK[1337]lighND-dependent DRA ligase437141.08911.107FEOIGWMRDSSAW[1327]machMembrane strack complex437141.08911.107FEOIGWMRDSSAW[1323]machMembrane strack complex437141.08911.107FEOIGWMRDSSAW[1323]machMembrane strack complex437141.08911.107[1247][1233]machMembrane strack complex4372354412.443[1267][1234]machMembrane strack complex55040151231[1247][1247][1233]machMembrane strack complex530411.107[1247][1233][1247]trackTryytophan synthase, beta submit<	such2-Oxoglutarate dehydrogenase El component385322,699/2,712RuckPutetive membrane-spanning protein390466401/1,092Putetive membrane-spanning protein419045827/1,086Putetive membrane-spanning protein419046827/1,085PaperConstruction experime419046827/1,086PaperOligoendopetidae F4170441,767/1,825PaperOligoendopetidae transport system binding protein4770441,767/1,825PaperOligoendopetidae transport system binding protein479190336/1,281PaperOligoendopetidae transport system binding protein4771491,767/1,825PaperOligoendopetidae transport system binding protein47043336/1,292PaperOligoendopetidae transport system binding protein47714347714,543PaperMandement tack600339040396/1,206PaperMandement ettack60048284/2,43384/2,433PaperProsphatidyloholine-hydrolyzing phospholipase D50040395/1,197PaperProsphatidyloholine-hydrolyzing phospholipase D50040395/1,197PaperProsphatidyloholine-hydrolyzing phospholipase D50040395/1,197PaperProsphatidyloholine-hydrolyzing phospholipase D50040395/1,197PaperProsphatidyloholine-hydrolyzing phospholipase D50040395/1,197PaperProsphatidyloholine-hydrolyzing phospholipase D50040395/1,197PaperProsphatidyloholine-hydrolyzing phosphatidyl	(ct054) ^h	딘	385356	2,122/2,712	ARIERX	-
outaccounted active membrane-spanning protein3040040011,000Current membrane-spanning protein20000sec1Type III secretion chapter family304044011,000FIPOI (GWMISPRSDAQMWENSR)123777sec1Type III secretion chapter family430441006FIPOI (GWMISPRSDAQMWENSR)1336717peppOid-specific adamine glycosylase43534455/35FIPOI (GWMISPRSDAQMWENSR)1336717peppOid-specific adamine glycosylase43534455/35FIPOI (GWMISPRSDAQMWENSR)1336713peppOid-specific adamine glycosylase43534455/35FIPOI (GWMISPRSDAQMWENSR)1336713peppOid-specific adamine glycosylase43734933671,206FIPOI (GWMISPRSDAQMWENSR)1336713peppOid-specific adamine glycosylase43734933671,231FIPOI (GWMISPRSDAQMWENSR)133777peppMDD-dependent monooxygenase43734933671,233FIPOI (GWMISPRSDAQMWENSR)133773macPMmD-amedent monooxygenase43734933671,534FIPOI (GWMISPRSDAQMWENSR)133773macPMmD-amedent monooxygenase43734933671,534FIPOI (GWMISPRSDAQMWENSR)133773macPMmD-amedent monooxygenase43734933671,534FIPOI (GWMISPSDAQMWENSR)133773macPMmD-amedent monooxygenase43734933671,534FIPOI (GWMISPSDAQMMENSR)133773macPMmD-amedent monooxygenase4373493471,524FIPOI (GWMISPSDAQMENSR)133773macPMmD-amedent monooxygenase	outComputationComputationComputationssc1Type III secretion chapterse300466410/1,005PepFType III secretion chapterse415044417441Type III secretion chapterse4450444150441,009/1,107PepFOligopentidine system binding protein4450441,009/1,107PepFOligopentidine represent4350441,009/1,107PepFOligopentidine system binding protein4791941,009/1,107PipotheticalNAD-dependent DNA ligase477193477143PipotheticalNAD-dependent DNA ligase4871491,06/1,1825PipotheticalNAD-dependent DNA ligase49316348714,524PipotheticalNAD-dependent DNA ligase4936348171,524PipotheticalNAD-dependent DNA ligase5004325017,179PipotheticalNAD-dependent DNA ligase5004325017,179PipotheticalTryptophan synthase, beta submit51276351271,179PipotheticalUvrABC system protein A69703351271,179PipotheticalUvrABC system protein A69703351271,179PipotheticalUvrABC system protein A69703351271,179Pirot bina-1, 4 glucan phosphorylase5064731,850/5,361PipotheticalUvrABC system protein A697033512763PipotheticalUvrABC system protein A697033512763PipotheticalUvrABC system protein A697033512763PipotheticalUvrABC system protein A<	1 ~+ 0 5 4 \ h	þ	205020	0 K00/0 710		
Relative membrane spanning protein39466 $4011,092$ $00WCIGWMBSRSDAOWNENSKN123.371SsciType III serretionTayretianity123.341123.741123.771Parative membrane spanning protein313.441120.77123.771123.771Parative membrane system binding protein430.341.0871,1.83123.781123.691Parative system binding protein4470.411.0871,1.83123.781123.781Parative system binding protein430.341.0871,1.83123.781123.781Parative system binding protein430.341.051,1.83123.781123.781Parative system binding protein430.341.051,233123.781123.781Parative system binding protein437.121.051,233123.781123.733Parative system protein437.2611.052,433116.723123.2333Parative system protein437.261437.1,234116.723123.2333Parative system protein239.2433123.1,179116.723123.2333Parative system protein123.2333123.2333123.2333123.2333Parative system protein123.2333123.2333123.2333123.2333Parative system protein123.2333123.2333123.2333123.2333Parative system protein123.2333123.2333123.2333123.2333Parative system protein123.2333123.2333123.2333<$	Putatuve membrane-spanning protein 390466 401/1/092 $Putatuve$ membrane spanning protein 390466 401/1/092 $Propolotipase D superfamily 419045 827/1.086 Propolotipase D superfamily 419045 626/885 Propolotipase D superfamily 419045 1.757/1.865 Propolotipase D superfamily 435244 626/885 Propoloticas F 011goendopeptidae F 435244 626/885 Propoloticas F 011goendopeptidae F 437149 1.767/1.825 Propoloticas F 011goendopeptidae F 437149 1.767/1.825 Propolaticas F 011goendopeptidae F 437145 1.767/1.825 Propolaticas F 011goendopeptidae F 437145 1.767/1.825 Propolaticas F 011goendopeptidae F 437145 1.767/1.825 Propolaticas F Nub-dependent monocygenase 437145 1.767/1.825 Propolaticas F Nub-dependent monocygenase 437145 1.767/1.795 Propolaticas F Propolaticas F 437145 1.8771.524 Propolaticas F $	(CCU34)	H H	20000	2,033/2,112		
Rescretion chaperone43045827/1.066PPOLTGWMRSBSDAOWNENSSB[132777 $7yre III secretion chaperone7yre III secretion chaperone4323441.089/1.1.07[EDOLTGOWNENSSDAOWNENSSK[122777PepF7yre III secretion chaperone432341.089/1.1.07[EDOLTGOWNENSSPACYMRENSK[122771PepFOligopeptide transport system binding protein470441.089/1.1.07[EDOLTGOWNENSSPACYMRENSK[122734]PapFOligopeptide transport system binding protein47919336/1.281TSNPSBLOAKWENSK[123734]11gANAD-dependent DMA ligase47919336/1.281TSNPSBLOAKWENSK[123734]11gANAD-dependent DMA ligase437181.089/1.1.07[EDOLTGOWNENSK[123734]11gANAD-dependent DMA ligase437181.068/1.1.07[EDOLTGOWNENSK[123734]11gANAD-dependent DMA ligase437181.068/1.1.07[III6X[12374]11gANAD-dependent DMA ligase437181.068/1.1.07[III6X[12374]11gANAD-dependent DMA ligase4371847123[11124711gANAD-dependent DMA ligase43715437123[1162.1.23711gANAD-dependent DMA ligase5040355/1.266[III124711gANAD-dependent DMA ligase5040355/1.126[III24711gANAD-dependent DMA ligase56/1.23151/1.127[1123711gAHAD-dependent DMA ligase56/1.23251/1.127[1124711gB$	Biopholipase D superfamily41004582/1,106Ssc1Type III secretion chaptere413/4482/1,107Type III secretion chaptes4170441,686/825AG-specific adenine glycosylase4470441,686/825AG-specific adenine glycosylase4470441,686/825AG-specific adenine glycosylase4470441,686/1182AD01igopeductar transport system binding protein45244626/825AD01igopeductar by the binding protein4371091,767/1,825AD01igopeductar by an ligase4771891,161/1,922ADND-dependent DNA ligase4371891,164/1,922ADND-dependent by an ligase4371891,164/1,922ADND-dependent by an ligase439545481/1,173ADND-dependent by an ligase439545481/1,173ADND-dependent by an ligase439545481/1,179ADPhycothetical181/2,016112/2,433ADAD112/2,433512/1,179ADAD512/1,179512/1,179ADAD512/1,179512/1,179ADAD512/1,179512/1,179ADAD512/1,179512/1,179ADAD512/1,179512/1,179ADAD431003512/1,179ADADAD512/1,179ADADAD512/1,179ADADAD512/1,179ADADAD512/1,365ADADA		Putative membrane-spanning protein	390466	401/1,092	GWNCITGWMISPRSDAQWNENSRX	
sc1Type III secretion chaperone 42334 $413/41$ $410/41$ <	ssc1Type III secretion chaperone 423934 $413/441$ RRM pesuduridine synthase A 47004 $1.089/1.107$ pepA/G-specific adenine glycosylase 47004 $1.089/1.107$ $A/G-specific adenine glycosylase470041.089/1.107DepOligopeptide transport system binding protein470041.089/1.107Pep^{A}Oligopeptide transport system binding protein470041.089/1.107Hypotherical470041.080/1.281336/1.281IigAND-dependent NNA ligase48718936/1.281Membrane attack complex497034971.1,232Membrane attack complex497034971.1,232Membrane attack complex497035040394/1.1,932Membrane attack complex49703118/282511/1.79Membrane attack complex500433842/1.303512/1.179Membrane attack complex50043394/1.1524512/1.179Membrane attack complex50043350/1.1.97512/1.179Membrane attack complex50043384/2.44360/1.203Membrane attack complex812/2.44361/2.433512/1.179Membrane attack complex812/2.44361/2.44361/2.443Membrane attack complex812/2.44361/2.44561/2.445MarballMarballMarballMarballMarballMarballMarballMarballMarballMarballMarball$		Phopholipase D superfamily	419045	827/1,086	TPYOL T GWMISPRSDAQWNENSRX	
TryTryTryTryTryTryTryTryPBF01jopeptidae1/50/11,8131/50/11,8131/50/11,8131/50/11,8131/50/11,813PBF01jopeptidae1/50/11,8131/50/11,8131/50/11,8131/50/11,8131/51/13PBF01jopeptidae1/50/11,8131/50/11,8131/50/11,8131/51/131/51/13PBF01jopeptidae1/50/11,8131/50/11,8131/51/131/51/13PBAND-dependent DNA ligase471991/51/131/51/131/51/13PBAND-dependent DNA ligase471191/50/11,8131/51/13PBAND-dependent monoxygenase437191/51/131/51/131/51/13PBAND-dependent monoxygenase437191/51/131/51/131/51/13PBAND-dependent monoxygenase437191/51/131/51/131/51/13PBAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/51/131/51/131/51/13PAPRONK1/51/131/	SolutionThe sector of the complexationThe sector of the complexationThe sector of the complexation pep 01 specific adenine glycosylase 47004 $1,089/1,107$ pep 01 specific adenine glycosylase 47004 $1,689/1,107$ pep 01 specific adenine glycosylase 47004 $1,66/825$ pep 01 specific adenine glycosylase 47004 $1,767/1,825$ pep 01 specific adenine glycosylase 47004 $1,767/1,825$ pep 01 specific adenine glycosylase 49094 $10,68/1,1990$ mph mbh and attack complex 49054 $611,192$ mph $membrane attack complex49036411.64/1,992macpmembrane attack complex49054611/2,433macpmembrane attack complex490336448/1,1,524macpmembrane attack complex49036411.64/1,992macpmembrane attack complex490356348/1,1,524macpmembrane attack complex490356348/1,1,524macpmembrane attack complex493663748/2,433macpmembrane attack complex506473118/292macpmbrane attack complex512511,197machmbrane attack complex512763596/1,206machmbrane attack complex512763596/1,206machmbrane attack complex512763596/1,206mrachmrachmrachmrach<$	1000+01		150501	112/011		
FERM pepr point for demine giveosytase445.44 $0.65/R23$ HoldLioMunDisSPUX HoldLioMunDisSPUXHoldLioMunDisSPUX 	PRPh $A12344$ $626/832$ PPP $A10044$ $1,6771,835$ PPP $A1004$ $1,6771,335$ PPP $A1004$ $1,6771,535$ PPP $A1004$ $1,671,535$ PPP $A1004$ $1,671,535$ PPP $PPPP$ $1,671,535$ $PPPP$ $PPPPP$ $1,671,535$ $PPPPPP$ $PPPPPPPP$ $1,671,535$ $PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP$	10001	TYPE ILL SECTELLUI CHAPELUIE	4403334	144/15		
MG^{-} MG^{-	$pepr\lambda/G-specific admine glycosylase4470041,008/1,107pepr0ligoendopetide transport system binding protein4509741,767/1,825ppj10 oppid10 oppid1008/6431.767/1,8251igAND-dependent DNA ligase487199108/6431.767/1,825niphARD-dependent DNA ligase487199108/6431.1647/1,524macPNembrane attack complex49954611.167/1,524macPNembrane attack complex49954311.12,433macPNembrane attack complex99954311.12,433macPNembrane attack complex99954311.12,433macPNembrane attack complex99954311.12,433macPNembrane attack complex99954311.127,433macPNembrane attack complex999543912/1,197macPNembrane attack complex506473118/282macPNaptothetical506473118/282macANapothetical506473118/282macANapothetical506473118/282macANapothetical506473118/282macANapothetical0005plotylase500/73macANapothetical0005plotylase500/73macA000285000330003265macA00028500033macA00028500033macA000285$		tRNA pseudouridine synthase A	445244	626/825	HQIRLTGWMISPRSDAQWNENSRX	
pepr pepr oligoendopertidase F45074 oligoendopertidase F4577/1,855 oligoendopertidase F455074 oligoendopertidase F15677/1,855 oligoendoser System binding protein display475171,815 oligoendoser System binding protein display15677/1,855 oligoendoser System binding protein display156771,1351 oligoendoser System binding protein display475171,813 oligoendoser System binding protein display475171,813 oligoendoser System binding protein display475171,813 oligoendoser System binding protein display475171,813 oligoendoser System binding protein display475171,523 display1163233 display1163233 display1163333 display1176333 	pepr peprOligoendopeptidase F 450974 $1,767/1,825$ oppaOligoepeptide transport system binding protein 479190 $336/1,281$ nypotheticalHypothetical $336/1,281$ nypothetical 493189 $708/843$ nyphaRND-dependent UNA ligase 493563 $487/1,524$ mphaFAD-dependent monooxygenase 493563 $487/1,524$ macPMembrane attack complex 493563 $487/1,524$ macPMembrane attack complex 499544 $611/2,433$ macPMembrane attack complex 499564 $611/2,433$ macPMembrane attack complex 506473 $118/282$ nacPMembrane attack complex 506473 $118/282$ trpBTryptophan synthase, beta subunit 512763 $72/1,179$ trpBTryptophan synthase, beta subunit 512763 $72/1,179$ trpBMypothetical $118/282$ $70/1,545$ uvrAUvrAUvrABC system protein A 69732 $670/1,545$ uvrAUvrABC system protein A 697874 $3,601/5,361$ uvrAUvrABC system protein A 697874 $3,601/5,361$ uvrAUvrABC system protein A 697874 $3,601/5,361$ uvrAUvrABC sys		A/G-specific adenine glycosylase	447004	1,089/1,107	LEKDGNRLDDKSPVX	
ppsoutpotnet4791055/1.2501ANGHTARDKSWX[71.3070]11gANhD-dependent DNA ligase4791035/1.2501ANGHTARDKSWX[71.3270]11gANhD-dependent DNA ligase4371971.161.292NGN MSRDDKSWX[71.3231]mpDAFAD-dependent monoxygenase437191.161.1.233PNUNI[71.3231]mpDAFAD-dependent monoxygenase4371.5364371.5361.167.2333[72.3231]mpDAFAD-dependent monoxygenase43955611.2.433PPNUNI[72.3231]msoPMembrane attack complex506473511.2.433PPNUNI[72.3231]msoPMembrane attack complex506473511.2.433PPNUNI[72.321]HypotheticalTryptophan synthase, beta subunit512.1.199FMHRIDUKSPVX[72.321]HypotheticalTryptophan synthase, beta subunit512.1.199FMHRIDUKSPVX[72.321]HypotheticalTryptophan synthase, beta subunit512.1.199FMHRIDUKSPVX[72.421]HypotheticalTryptophan synthase, beta subunit512.1.199FMHRIDUKSPVX[72.421]HypotheticalTryptophan synthase50.1.1367723.1.179FMHRIDUKSPVX[72.421]HypotheticalUVXABUXAMSPSDAQWNENSRX[63.87][63.87][72.421]HypotheticalUVXABUXAMSPSDAQWNENSRX[63.87][63.87][63.87]HypotheticalUVXABUXAMSPSDAQWNENSRX[63.87][63.87][63.87]HypotheticalUVXABUVXAB[63.91	OppOutgopertubertunderYangOppOutgopertubertunderYangYangIigANaD-dependent NA ligaseYangYangHypotheticalHypothetical49179Xang/1, 281NaD-dependent NA ligase4971891,164/1, 992maphRAD-dependent monoxygenase493563487/1, 524macpMembrane attack complex499564611/2, 433macpMembrane attack complex499564611/2, 433Membrane attack complex50048284/2, 433Membrane synthase, beta subunit512551512/1, 179Hypothetical51263723/1, 179Hypothetical51263723/1, 179Hypothetical51263723/1, 179Hypothetical5126356/1, 197Hypothetical51263512/1, 197Hypothetical51263512/1, 197Hypothetical51263512/1, 197Hypothetical51263512/1, 197Hypothetical51263512/1, 197Hypothetical51263512/1, 197Hypothetical51263512/1, 197Hypothetical51263512/1, 197Hypothetical10000512631, 850/5, 361Hypothetical100006970442, 771/5, 561UvradUvraBC system protein A6970442, 771/5, 361UvradUvraBC system protein A6970442, 771/5, 361UvradUvraBC system protein A6970442, 771/5, 361UvradUvraBC system protein	(0+110)	Olimoandonentidase E	150971	1 767/1 875		
OptimultOptimul	oppaUntil gradies 1100 $3.501, 1.241$ $1igA$ Hypothetical $3.501, 1.241$ $3.501, 1.241$ $1igA$ NAD-dependent UNA ligase 487193 $781/481$ $781/481$ $macP$ Rembrane attack complex 487195 $4871, 524$ $macP$ Membrane attack complex 49954 $611/2, 433$ $macP$ Membrane attack complex 500482 $84/2, 433$ $macP$ Hypothetical $118/282$ 512163 512163 $mardA$ Hypothetical 512163 $723/1, 179$ $mrAdA$ Alpha-1, 4 glucan phosphorylase 512163 $723/1, 179$ $mrAdA$ UvrAbC system protein A 696123 $1.850/5, 361$ $uvrA$ UvrAbC system protein A 696123 $1.850/5, 361$ $uvrA$ UvrAbC system protein A 697044 $2.771/5, 361$ $uvrA$ UvrAbC system protein A 697044 $3.601/5, 361$ $uvrA$ UvrAbC system protein A 697044 $3.601/5, 361$ $uvrA$ UvrAbC system protein A 697044 $2.771/5, 361$ $uvrA$ UvrAbC system protein A 697044 $2.771/5, 361$ $uvrA$ UvrAbC system protein A 697044 $3.601/5, 361$ $uvrA$ UvrAbC system pro	(00770)					
If and the protectical422984708/843TSYNSMRLDOKSPVXT2370XIf and the protectionND-dependent monorygenase4371691.164/1.992RNLAMLDOKSPVX(11633) $mpha$ RD-dependent monorygenase4371691.164/1.992RNLAMLDOKSPVX(11633) $mpha$ Rembrane attack complex437694371.50RNLAMLDOKSPVX(1135) $macP$ Nembrane attack complex4395650.482847.1,243RPCINTGOWINSRY(1232) $macP$ Nembrane attack complex50.048295.1.206847.1,243RPCINTGOWINSRY(1232) $macP$ Rembrane attack complex50.048295.1.206KSAHMUDKSPVX(1232)(12127) $macP$ Rembrane attack complex50.043395.1.206KSAHMUDKSPVX(12127)(12127) $macP$ RypotheticalS0.043351.20684.7.2,445SCAMMSPSDAQWNENSRY(12127) $tryp topian synthase, beta subunit51.20351.1.179VULTGWMISPRSDAQWNENSRY(12127)tryp topian synthase, beta subunit51.20351.1.179VULTGWMISPRSDAQWNENSRY(12127)tryp topian synthase, beta subunit51.20551.1.179VULTGWMISPRSDAQWNENSRY(12127)tryp topian synthaseNon-dependentNOCANNOCAN(22017)tryp topian synthaseNOCANS66473118/282NOCAN(2124)7tryp topian synthaseNOCANS6647311447(2124)7tryp topian synthaseNOCANS66917845/2.445SCMUSSPSAQMSNSRN<$	IgAHypothetical482984708/843 $1igA$ NAD-dependent DNA ligase4871891,1641,992 $mphA$ FAD-dependent monoxygenase4935634871,524 $macP$ Membrane attack complex4935634871,524 $macP$ Membrane attack complex4935634871,524 $macP$ Membrane attack complex4935634871,524 $macP$ Membrane attack complex4935634872,433 $macP$ Membrane attack complex50403956/1,206 $macP$ Tryptophan synthase, beta subunit512763512/1,179 $macP$ Tryptophan synthase, beta subunit512763723/1,179 $macP$ Tryptophan synthase, beta subunit512763723/1,179 $macA$ Mypothetical512763723/1,179 $macA$ Mypothetical512763723/1,179 mrA UvrABC system proteinA512763512/1,179 mrA UvrABC system proteinA691042,771/5,361 mrA UvrABC system proteinA6970442,771/5,361 mrA UvrABC system proteinA5961231,850/5,361 mrA UvrABC system proteinA597043,601/5,361 mrA UvrABC system proteinA5,165/5,361 mrA UvrABC system protein A6980913,818/5,361 mrA UvrABC system protein A6970445,165/5,361 mrA UvrABC system protein A6970495,165/5,361	(<i>c</i> t139) ⁿ		479190	336/1,281	AWEHI MKLDDKSPVX	
12gANAD-dependent DNA ligase 437189 $1.6441.922$ $GMNARDDKSPX$ $(R390)$ $mpDA$ RD-dependent UNA ligase 4371.524 $1.6441.524$ 71.632 $(R230)$ $(R230)$ $macP$ Rembrane attack complex 493563 $611.2.433$ $RCMRIPRSDAQWNENSRY$ $(R230)$ $(R230)$ $macP$ Rembrane attack complex 504303 $611.2.433$ $RCMRIPRSDAQWNENSRY$ $(R230)$ $macP$ Rembrane attack complex 504303 $647.1.206$ $KGAHMLDDKSPVX$ $(R230)$ $(R230)$ $Rembrane attack complex5043035647.1.206KGAHMLDDKSPVX(R230)(R230)Rembrane attack complex5540035547.1.206KGAHMLDDKSPVX(R230)(R230)Rembrane attack complex5540035547.1.206KGAHMLDKSPXX(R230)(R230)Rembrane attack complex5540035547.1.206KGAHMLDKSPXX(R230)(R230)Rembrane synthase, beta submit51203512763723.1.1.79VULGWMISPRSDAQWNENSRX(R230)Rip< AttachAlpha-1.4 glucan phosphorylase5540.1.206569.1.206596.1.206597.1.206KGALGWMSPRSDAQWNENSRX(R230)attachUvrabC system proteinA512763723.1.1.79VULGWMISPRSDAQWNENSRX(R240)attachUvrabC system proteinA590.1.206597.1.206KGALGWMSPRSDAQWNENSRX(R240)attachUvrabC system proteinAVLTGWMISPRSDAQWNENSRX(R280$	lighNAD-dependent DNA ligase 487189 $1.164/1.992$ mphaFAD-dependent monooxygenase 4877189 $1.164/1.922$ macPMembrane attack complex 499554 $611/2.433$ macPMembrane attack complex 500482 $847/1.524$ macPMembrane attack complex 500482 $847/1.952$ Phosphatidylcholine-hydrolyzing phospholipase D 500482 $847/1.206$ HypotheticalTryptophan synthase, beta subunit 512763 $723/1.179$ Tryptophan synthase, beta subunit 512763 $723/1.179$ Hypothetical $723/1.179$ 512763 $723/1.179$ Tryptophan synthase, beta subunit 512763 $723/1.179$ Hypothetical $815/2.445$ 650265 $429/1.565$ MA <repair protein<="" td="">$650265$$429/1.565$UvrABC system protein A$697044$$2.771/5.361$uvrAUvrABC system protein A$699439$$5,165/5.361$uvrAUvrABC system protein A$697044$$5,165/5.361$uvrAUvrABC system protein A$699439$$5,165/5.361$</repair>		Hypothetical	482984	708/843	TSLYS <u>N</u> RLDDKSPVX	
mp/aFAD-dependent monooxygenase493563 $467/1, 524$ $FWWX$ $FWWX$ $T1633$ maceMembrane attack complex500482 $847, 433$ $FFWWX$ $T232N$; $T232N$;maceMembrane attack complex500482 $847, 433$ $SISDNILDNSFWX$ $T232N$; $T232N$;macePhotheticalTryptochetical 504473 516473 512761 $T272N$ $T232N$;trypTryptochenical $TxyptochenicalT2321, 179FHHFIRLDNSFWXT232N;trypTryptochenicalT272051271, 179FLABT242NtrypTryptochenicalT272051271, 179FHNENDSFWXT242NtrypTryptochenicalT27205127635121, 179WOAIFGWMISFRSDAQWNENSFYT242NtrypTryptochenicalT27205127635121, 179WOAIFGWMISFRSDAQWNENSFYT242NtrypTryptochenicalT272075, 1231, 179WOAIFGWMISFRSDAQWNENSFYT242NtrypTryptochenicalS961, 197WOAIFGWMISFRSDAQWNENSFYT242NtrypUVAIECSystem proteinS0613, 197WOAIFGWMISFRSDAQWNENSFYT242NuvralUvralCSystem proteinS0613, 197WOAIFGWMISFRSDAQWNENSFYT1447uvralUvralCSystem proteinS06123L971/5, 55S1171/5, 500MISFRSDAQWNENSFYS16477uvralUvralCSystem proteinS06123L9505, 361UOIFSSDAQWNENSFYT14477$	mphAFAD-dependent monooxygenase493563487/1,524macPMembrane attack complex499954611/2,433macPMembrane attack complex50003956/1,206Phosphatidy1choline-hydrolyzing phospholipase D504003956/1,206Phosphan synthase, beta subunit512551512/1,179Tryptophan synthase, beta subunit512551512/1,179Tryptophan synthase, beta subunit512763723/1,179Phosphatical512763723/1,179Tryptophan synthase, beta subunit512763723/1,179Phypothetical512763723/1,179UrradANA repir protein596/1,197Hypothetical596/1,365670/1,545UvrAUvrABC system protein A6970442,771/5,361UvrAUvrABC system protein A6970443,601/5,361uvrAUvrABC system protein A6970445,165/5,361uvrAUvrABC system protein A6970445,71/5,361uvrAUvrABC system protein A6970445,765/5,361uvrAUvrABC system protein A6970445,765/5,361uvrAUvrABC system protein A6970445,765/5,361	(ct146)	NAD-dependent DNA ligase	487189	1,164/1,992	GINLANRLDDKSPVX	
machmachmonospectationmon	machmach499955011212machmach499956112,433machmach5661,2066112,433machmach566473118,282hypotherical51263512/1,179trpBTryptophan synthase, beta subunit512763512/1,179trpBTryptophan synthase, beta subunit512763512/1,179trpBTryptophan synthase, beta subunit512763723/1,179trpBTryptophan synthase, beta subunit512763723/1,179glgPAlpha-1,4 glucan phosphorylase596/1,197512/1,179srdANNA repair protein6101231,850/5,361uvrAUvrABC system protein A6970442,771/5,361uvrAUvrABC system protein A6970445,165/5,361	10+140	EAD-donordont monocurrenses	102562	107/1 FON		
macrMembrane attack complex99954 $611/2, 1433$ FD0MILDNSPVX $[22301, 3]$ macrMembrane attack complex54003 $956/1, 206$ $KESAHIRDDKSPVX$ $[72203, 3]$ HypotheticalTryptophan synthase, beta subunit 512763 $956/1, 206$ $KESAHIRDDKSPVX$ $[72303, 3]$ Tryptophan synthase, beta subunit 512763 $956/1, 179$ $KESAHIRDDKSPVX$ $[72423]$ Tryptophan synthase, beta subunit 512763 $723/1, 179$ $WOLTGWMSFRSDAQWKENSRX$ $[72423]$ Tryptophan synthase, beta subunit 512763 $723/1, 179$ $WOLTGWMSFRSDAQWKENSRX$ $[72423]$ Tryptophan synthase, beta subunit 512763 $723/1, 179$ $WOLTGWMSFRSDAQWKENSRX$ $[12423]$ Tryptophan synthase, beta subunit 512763 $723/1, 179$ $WOLTGWMSFRSDAQWKENSRX$ $[12423]$ Tryptophan synthase, beta subunit 512763 $723/1, 179$ $WOLTGWMSFRSDAQWKENSRX$ $[12423]$ Tryptophan synthase, beta subunit 512763 $723/1, 179$ $WOLTGWMSFRSDAQWKENSRX$ $[12423]$ JuradAlpha-1, 4 glucan phosphorylase 59637 $845/2, 445$ $ECOLTGWMSFRSDAQWKENSRX$ $[12423]$ uvradUvrabC system protein A 05732 $670/1, 545$ $FWT_TGWMSFRSDAQWKENSRX$ $[12423]$ uvradUvrabC system protein A 05734 $3, 601/5, 361$ $WOLTGWMSFRSDAQWKENSRX$ $[12423]$ uvradUvrabC system protein A 057874 $3, 601/5, 361$ $WWSFSDAQWKENSRX$ $[1, 796]$ uvradUvrabC system protein A 057874 <	macy Membrane attack complex 499954 611/2/433 macP Membrane attack complex 99954 611/2/433 macP Membrane attack complex 956/1,206 956/1,206 Hypothetical Tryptophan synthase, beta subunit 51251 512/1,179 Tryptophan synthase, beta subunit 512551 512/1,179 956/1,107 Tryptophetical 512763 723/1,179 956/1,197 Tryptophetical 512763 512/1,179 512/1,179 Tryptophetical 512763 512/1,179 512/1,179 Tryptophetical 512763 512/1,179 512/1,179 Tryptothetical 512763 512/1,179 512/1,179 Mypothetical 512763 512/1,179 512/1,179 UvrABC NA repair 556937 845/2,445 650/1,545 UvrABC UvrABC System protein A 696123 1,850/5,361 UvrAB UvrABC System protein A 697044 2,771/5,361 UvrA UvrABC System protein A 697044						
macpMembrane attack complex500482 $84/2,433$ $81/2,433$ $SIDSDWILDKSPVX$ $(R230W)$ ReportedHypothetical566473 $556/1,206$ $KEAHINILDKSPVX$ $(7320W)$ HypotheticalTryptophan synthase, beta subunit 51251 $512/1,179$ $WOALIGWMISPRSLVAOR.35AA-YFX'(2172)HypotheticalTryptophan synthase, beta subunit512/1,179WOALIGWMISPRSLVAOR.35AA-YFX'(2172)HypotheticalTryptophan synthase, beta subunit512/1,179WOALIGWMISPRSDAOWNENSRX'(2127)RippotheticalTryptophan synthase, beta subunit512/1,179WOALIGWMISPRSDAOWNENSRX'(2127)RippotheticalTryptophan synthase, beta subunit512/1,179WOALIGWMISPRSDAOWNENSRX'(2127)RippotheticalTryptophan synthase, beta subunit512/1,179WOALIGWMISPRSDAOWNENSRX'(2127)RippotheticalMOARIGMISPRSDAOWNENSRX'(2120)(2120)/1,295(29/1,197)(210)/1,295RippotheticalWraBC system protein A650265429/1,365(50/1,5361)(5187)/1,475(582)/1,265WraBC system protein AUvrABC system protein A(5702)/1,545(500/1,5,361)(5107)/1,545(51201)/1,766WraBC system protein AUvrABC system protein A(5707)/1,545(71/1,545)/1,365(71/1,545)/1,766(71/1,76)/1,766WraBC system protein AUvrABC system protein A(5707)/1,545(71/1,545)/1,766(71/1,76)/1,766(71/1,76)/1,766/1,766/1,766/1,766/1,766/1,766/1,766/1,766/1$	macPMembrane attack complex 500482 $84/2,433$ macPMembrane attack complex 506473 $118/282$ Hypothetical $956/1,179$ $552/1,179$ Tryptophan synthase, beta subunit 512551 $512/1,179$ Tryptophan synthase, beta subunit 512753 $723/1,179$ Tryptophan synthase, beta subunit 512763 $723/1,179$ TradaNUXABC system protein A 690265 $429/1,365$ uvraUvrABC system protein A 697044 $2,771/5,361$ uvraUvrABC system protein A 697044 $5,165/5,361$ uvraUvrABC system protein A $5,96973$ $5,165/5,361$		Membrane attack complex	499954	611/2,433		
Phosphatidylcholine-hydrolyzing phospholipase D50403956/1,206KESAHMRDKFVX(7320N; (Y320X)Hypotheticial Tryptophan synthase, beta subunit51251512/1,179WOGATY(7320X)Hypothetical Tryptophan synthase, beta subunit51251512/1,179WOGATY(7320X)Hypothetical Tryptophan synthase, beta subunit51251512/1,179WOGATY(7320X)Hypothetical Tryptophan synthase, beta subunit512551512/1,179WOGATY(7320X)S12PHypothetical591198596/1,197WOLTGWMISPRSDAQWNENSRX(72420X)UZAAlpha-1,4Glucan phosphorylase650265429/1,365620ErfGWMISPRSDAQWNENSRX(7144T)UVZAAlpha-1,4Glucan650265670/1,545FEVIVTGWMISPRSDAQWNENSRX(8363T)UVZAUVZABC system proteinA6901231,850/5,361(936/1,(936/1,UVZAUVZABC system proteinA6970442,771/5,361CIPULGWMISPRSDAQWNENSRX(6367/1,UVZAUVZABC system proteinA6970442,771/5,361CIPULGWMISPRSDAQWNENSRX(6367/1,UVZAUVZABC system proteinA6970442,771/5,361CIPULGWMISPRSDAQWNENSRX(636/17)UVZAUVZABC system proteinA6970442,771/5,361CIPULGWMISPRSDAQWNENSRX(636/17)UVZAUVZABC system proteinAUVZABC3,601/5,361UNHES(717201X)UVZAUVZABC system proteinA6978743,601/5,361UNHES(7	Phosphatidylcholine-hydrolyzing phospholipase D 50403 956/1,206 Hypotherical 512/1,179 512/1,179 Hypotherical 512763 718.282 Tryptophan synthase, beta subunit 51251 512/1,179 Hypotherical 512763 723/1,179 Phypotherical 51265 723/1,179 Phypotherical 51265 723/1,179 Phypotherical 512763 723/1,179 Pha-1,4 glucan phosphorylase 596/1,206 596/1,197 Phypotherical 51265 429/1,365 UVTABC system protein 696123 1,850/5,361 UVTABC system protein A 697044 2,771/5,361 UVTABC system protein A 697044 3,601/5,361 UVTABC system protein A 697044 3,601/5,361 UVTABC system protein A 697044 3,611/5,361 UVTABC system protein A 697044 3,610/5,361 UVTABC system protein A 697044 5,165/5,361 UVTABC system protein A 697044 5,165/5,361 UVTABC system protein A 69943	(<i>ct</i> 153)	attack	500482	84/2,433		
Hypothetical 506473 $118/282$ $MOGAYX$ $(Y39X; 3)$ trpBTryptophan synthase, beta submit 512763 $512/1, 179$ $WOALTGWMISPRSIVAOR.55A.YFY'$ $(2172r)$ trypTryptophan synthase, beta submit 512763 $512/1, 179$ $WOALTGWMISPRSIVAOR.55A.YFY'$ $(1242N)$ HypotheticalTryptophan synthase, beta submit 512763 $512/1, 197$ $WOALTGWMISPRSDAOWNENSRY$ $(1242N)$ HypotheticalBippa-1, 4 glucan phosphorylase 596937 $596/1, 197$ $VPLTGWMISPRSDAOWNENSRY$ $(1243T)$ $radA$ NNA repair protein 650265 $429/1, 365$ $510/1, 545$ $5106HMISPRSDAOWNENSRY$ $(1248T)$ $radA$ UvrABC system protein A 697044 $2, 771/5, 361$ $SINTGWMISPRSDAOWNENSRY$ $636/12$ $uvrA$ UvrABC system protein A 697044 $2, 771/5, 361$ $UNTGWMISPRSDAOWNENSRY$ $636/12$ $uvrA$ UvrABC system protein A 697044 $2, 771/5, 361$ $UNTGWMISPRSDAOWNENSRY636/12uvrAUvrABC system protein A6970442, 771/5, 361UNTGWMISPRSDAOWNENSRY636/12uvrAUvrABC system protein A6970442, 771/5, 361UNTGWMISPRSDAOWNENSRY636/12uvrAUvrABC system protein A6970442, 771/5, 361UNTGWMISPRSDAOWNENSRY636/12uvrAUvrABC system protein A6970442, 771/5, 361UNTGWMISPRSDAOWNENSRY612747uvrAUvrABC system protein A6980913, 818/5, 361UNTGWMISPRSDAOWNENSRY$	Hypothetical 506473 118/262 trpB Tryptophan synthase, beta subunit 512511 512/1,179 Tryptophan synthase, beta subunit 512512 512/1,179 Tryptophan synthase, beta subunit 512512 512/1,179 Tryptophan synthase, beta subunit 512763 512/1,179 Tryptophaeical 512763 512/1,197 Mypothetical 556937 845/2,445 NA <repair protein<="" td=""> 596937 845/2,445 NA<repair protein<="" td=""> 669265 429/1,365 UvrABC system protein A 697044 2,771/5,361 uvrA UvrABC system protein A 697044 2,771/5,361 uvrA UvrABC system protein A 697044 3,601/5,361 uvrA UvrABC system protein A 697044 2,771/5,361 uvrA UvrABC system protein A 697044 5,165/5,361</repair></repair>	ct10413 (ct157)			956/1,206	KESAHNRLDDKSPVX	[T320N; 329/401]
trpBTryptophan synthase, beta submit51251512.1.79WARTEGMISPRSLVAOR-35A-YFX' [01727]trpBTryptophan synthase, beta submit512.551512.1.179WARTEGMISPRSLVAOR-35A-YFX' [01727]HHFNDDKSPVXTryptophan synthase, beta submit512.551512.1.179WARTEGMISPRSDAQWNENSRX[12.421]Hypothetical512.65723/1.179FHHFNLDDKSPVX[12.471]Hypothetical845/2,445566LTGWMISPRSDAQWNENSRX[12.471]NUTABC system protein650265630215670/1.54555000HypotheticalUVTABC system protein6970442,771/5,361913/1.UVTABC system proteinA6970442,771/5,3611,7850AQWNENSRXUVTABC system proteinA6970442,771/5,3611,7850AQWNENSRXUVTABC system proteinA6970442,771/5,3611,7850AQWNENSRXUVTABC system proteinA6970442,771/5,3611,7861UVTABC system proteinA6970442,771/5,3611,7861UVTABC system proteinA6970442,771/5,3611,7861UVTABC system proteinA6970442,771/5,3611,7861UVTABC system proteinA6970442,771/5,3611,7861UVTABC system proteinA6980913,818/5,3611,7861UVTABC system proteinA5,165/5,3611,6601/5,3611,7861UVTABC system proteinA5,165/5,3615,165/5,3611,7861UVTABC system proteinA5,165/5,3611,78	trypTryptophan synthase, beta subunit502470 512763 $512/1,179$ trypTryptophan synthase, beta subunit 512763 $523/1,179$ trypTryptophan synthase, beta subunit 512763 $723/1,179$ Hypothetical 512763 $723/1,179$ glgPAlpha-1,4 glucan phosphorylase 596937 $845/2,445$ glgPNMA repair protein 650265 $429/1,365$ uvrAUvrABC system protein A 697044 $2,771/5,361$ uvrAUvrABC system protein A 697874 $3,601/5,361$ uvrAUvrABC system protein A 697874 $5,165/5,361$	C+10/17a (C+150)	4 4 9 1		118/202		
trypt	tryptophan synthase, beta subunit 512/1,179 512/1,179 tryptotherical 512763 723/1,179 Hypotherical 596/1,197 596/1,197 Hypotherical 596/1,197 596/1,197 Bipp Alpha-1,4 glucan phosphorylase 596/37 845/2,445 Bipp Alpha-1,4 glucan phosphorylase 596/37 845/2,445 Bipp Hypotherical 596/937 845/2,445 UvrAb DNA repair protein 650/265 429/1,545 UvrAb UvrAbC system protein A 696/123 1,850/5,361 UvrAb UvrAbC system protein A 697/044 2,771/5,361 UvrAb UvrAbC system protein A 697/044 3,601/5,361 UvrAb UvrAbC system protein A 697/044 3,601/5,361 UvrA UvrAbC system protein A 698/091 3,818/5,361 UvrA UvrAbC system protein A 699/439 5,165/5,361	_			110/202		
trpBTryptophan synthase, beta subunit512763723.1,179FFHHFMRLDNKSPWX[124212] $Hypothetical596/1,197VPULTGWMISPRSDAQWNENSRX[A2007]glgPAlpha-1,4glucan phosphorylase596/1,197VPULTGWMISPRSDAQWNENSRX[A237]glgPNuha-repair650265429/1,365[SSNITGWMISPRSDAQWNENSRX[A14417]radAUvrABC system protein650265429/1,545FFVTVTGWMISPRSDAQWNENSRX[G3671,uvrAUvrABC system protein6970442,771/55[LPVLTGWMISPRSDAQWNENSRX[G3671,uvrAUvrABC system proteinA6970442,771/5361[UINFRSDAQWNENSRX[G3671,uvrAUvrABC system proteinA6970442,771/5361[LPVLTGWMISPRSDAQWNENSRX[G3671,uvrAUvrABC system protein A6970442,771/5361LPVLTGWMISPRSDAQWNENSRX[G3671,uvrAUvrABC system protein A6970442,771/5,361LPVLTGWMISPRSDAQWNENSRX[G3671,uvrAUvrABC system protein A6970442,771/5,361LNLGWMISPRSDAQWNENSRX[G3671,uvrAUvrABC system protein A6970442,771/5,361LNLGWMISPRSDAQWNENSRX[F12012,uvrAUvrABC system protein A6980913,818/5,361LNLGWMISPRSDAQWNENSRX[G12747]uvrAUvrABC system protein A6980913,818/5,361LNLGWMISPRSDAQWNENSRX[G12747]uvrAUvrABC system protein A6994395,165/5,361LDEAMISPRSDAQWNENSRX[G1747]uvrA<$	trpB Tryptophan synthase, beta subunit 512763 723.1.179 B Hypothetical 596/1.197 596/1.197 B Albha-1.4 glucan phosphorylase 596/1.197 596/1.197 B Albha-1.4 glucan phosphorylase 596/1.197 596/1.197 B Albha-1.4 glucan phosphorylase 596937 845/2.445 NA repair protein 659055 429/1.365 UvrAbc UvrAbc system protein A 696123 1.850/5.361 uvrA UvrAbc system protein A 697044 2.771/5.361 uvrA UvrAbc system protein A 697044 3.601/5.361 uvrA UvrAbc system protein A 697044 3.601/5.361 uvrA UvrAbc system protein A 698091 3.61/5.361 uvrA UvrAbc system protein A 698091 3.61/5.361		beta	TGGZTG	512/T,T/J		(.T.Z./ TÕ]
Hypothetical591198596/1,197VPULTGWMISPRSDAQWNENSRX[22007]glgPAlpha-1,4glucan phosphorylase556937845/2,445EGOELTGWMISPRSDAQWNENSRX[R2387]radaDNA repair protein650265429/1,365ESNTTGWMISPRSDAQWNENSRX[R1447]HypotheticalUvrABC system protein A6961231,850/5,361USIPLTGWMISPRSDAQWNENSRX[5367]uvrAUvrABC system protein A6970442,771/5,361ELPVLTGWMISPRSDAQWNENSRX[5367].uvrAUvrABC system protein A6970442,771/5,361ELPVLTGWMISPRSDAQWNENSRX[9437].uvrAUvrABC system protein A6978743,601/5,361ELPVLTGWMISPRSDAQWNENSRX[92577]uvrAUvrABC system protein A6978743,601/5,361ELPVLTGWMISPRSDAQWNENSRX[71201X]uvrAUvrABC system protein A6978743,601/5,361LNHES <u>Y</u> [712747]uvrAUvrABC system protein A6980913,818/5,361LNHES <u>Y</u> [712747]uvrAUvrABC system protein A6994395,165/5,361LNHES <u>Y</u> [712747]uvrAUvrABC system protein A6980913,818/5,361ESLCLTGWMISPRSDAQWNENSRX[712747]uvrAUvrABC system protein A6994395,165/5,361LDEIAMISPRSDAQWNENSRY[71723N]uvrAUvrABC system protein A6994395,165/5,361LDEIAMISPRSDAQWNENSRY[71723N]uvrAUvrABC system protein A6994395,165/5,361LDEIAMISPRSDAQWNENSRY[71723N]	Hypothetical 591198 596/1,197 glgP Alpha-1,4 glucan phosphorylase 596/937 845/2,445 rada NNA repair protein 560/1,197 845/2,445 uvra UvrABC system protein 650265 670/1,545 uvra UvrABC system protein 696123 1,850/5,361 uvra UvrABC system protein 697874 2,771/5,361 uvra UvrABC system protein 697874 3,601/5,361 uvra UvrABC system protein 697874 3,601/5,361 uvra UvrABC system protein A 697874 3,601/5,361 uvra UvrABC system protein A 697874 3,601/5,361 uvra UvrABC system protein A 698091 3,818/5,361	(ct170)	beta	512763	723/1,179	FFHHFMRLDDKSPVX	
glgPAlpha-1,4 glucan phosphorylase596937845/2,445EGQELTGWMISPRSDAQWNENSRX[R2837; 1447;radADNA repair protein650265429/1,365ISSNITGWMISPRSDAQWNENSRX[I1447;Hypothetical650265429/1,545FEVINTGWMISPRSDAQWNENSRX[S1697;UvrABC system protein A6961231,850/5,361VSIPLTGWMISPRSDAQWNENSRX[G187;UvrABC system protein A6970442,771/5,361USIPLTGWMISPRSDAQWNENSRX[943/1,UvrABC system protein A6970443,601/5,361LNHEX[71201X;UvrABC system protein A6970443,601/5,361LNHEX[722747;UvrABC system protein A6970443,601/5,361LNHEX[71201X;UvrABC system protein A6970443,601/5,361LNHEX[71201X;UvrABC system protein A6980913,818/5,361LNHEX[71737]UvrABC system protein A6980913,818/5,361ESLCLTGWMISPRSDAQWNENSRX[71737]UvrABC system protein A6980913,818/5,361LNHEX[71737]UvrABC system protein A6980913,818/5,361LNHEX[71737]UvrABC system protein A6980915,165/5,361LDEAMISPRSDAQWNENSRX[717201X;UvrABC system protein A6980917,165/5,361LNHEX[71737]UvrABC system protein A6980917,165/5,361LDEAMISPRSDAQWNENSRX[71723]UvrABC system protein A6980917,165/5,361LDEAMISPRSDAQWNENSRX[71723]UvrABC system protein A699439	glgP Alpha-1,4 glucan phosphorylase 596937 845/2,445 radA DNA repair protein 650265 429/1,365 hypotherical 650265 429/1,365 uvrA UvrABC system protein A 696123 1,850/5,361 uvrA UvrABC system protein A 697044 2,771/5,361 uvrA UvrABC system protein A 697044 3,601/5,361 uvrA UvrABC system protein A 698091 3,818/5,361	ct10496 (ct244) ^h	Hypothetical	591198	596/1,197	VPVLI T GWMISPRSDAQWNENSRX	
UUXADUA repairULUALULUALNUXADUA repairULUALULUALULUALNUXAUVIABCSystemDUA repairULUARULUARUVIAUVIABCUVIABCSystemELPULGWMISPRSDAQWNENSRX55114UVIAUVIABCSystemELPULGWMISPRSDAQWNENSRX55114UVIAUVIABCSystemFUTUGWMISPRSDAQWNENSRX55114UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX561257UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX561271UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX593611UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX593611UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX593611UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX516115,361LNHESUVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX516515,3611,77861UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX516515,3611,77861UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX516515,361LDEAMMISPRSDAQWNENSRX1,77861UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX5,16515,361LDEAMMISPRSDAQWNENSRX1,77861UVIABCUVIABCSystemFUTUGWMISPRSDAQWNENSRX5,16515,361LDEAMMISPRSDAQWNENSRX1,77861UVIABCUVIABCSystemFUTUGWMISPRSDAQMISPRSDAQWNENSRX5,16515,361LDEAMMISPRSDAQWNENSRX1,77861 <td>UVZA DNA repair graden protein 550265 429/1/365 PAPP repair protein 650265 429/1/365 Hypotherical 650265 429/1/365 UVZA UVZABC system protein A 696123 1/850/5/361 UVZA UVZABC system protein A 697044 2/71/5/361 UVZA UVZABC system protein A 697874 3,601/5,361 UVZA UVZABC system protein A 697874 3,601/5,361 UVZA UVZABC system protein A 697874 3,601/5,361 UVZA UVZABC system protein A 697874 3,601/5,361</td> <td>1010401</td> <td>vister 4 clices vices is</td> <td>206027</td> <td>015/0 115</td> <td></td> <td></td>	UVZA DNA repair graden protein 550265 429/1/365 PAPP repair protein 650265 429/1/365 Hypotherical 650265 429/1/365 UVZA UVZABC system protein A 696123 1/850/5/361 UVZA UVZABC system protein A 697044 2/71/5/361 UVZA UVZABC system protein A 697874 3,601/5,361	1010401	vister 4 clices vices is	206027	015/0 115		
rackDNA Separt Protein6901265 $4.29/1,365$ DNALEOWNENSRX[114417]HypotheticalUVZABC system protein A696123 $1,850/5,361$ FEVTUTGWNISPRSDAQWNENSRX[63671, 0.1.545] $1,850/5,361$ $53671, 0.1.545$ $1,850/5,361$ $53671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $63671, 0.1.566187$ $636137, 0.1.566187$ $636137, 0.1.566187$ $636137, 0.1.566187$ $636137, 0.1.56617$ $94371, 0.1.76617$ $1,786117, 0.1.5617$ $1,786117, 0.1.5617$ $1,786117, 0.1.561767$ $1,78611776766176766666666666666666666666$	rack UNA repair protein 670/1,565 Hypothetical 670/1,545 uvrA UvrABC system protein A 696123 1,850/5,361 uvrA UvrABC system protein A 697044 2,771/5,361 uvrA UvrABC system protein A 697874 3,601/5,361 uvrA UvrABC system protein A 698091 3,818/5,361		υτρικα τ/τ θταφαιι ριιουρικοτγτασο				
Hypothetical 685322 670/1,545 FEVIVTGWMISPRSDAQWNENSRX [51687] uvrza UvrzBC system protein A 696123 1,850/5,361 VSIPLTGWMISPRSDAQWNENSRX [636/1, 635/1, 0437/1, uvrza UvrzBC system protein A 697044 2,771/5,361 LULGWMISPRSDAQWNENSRX [943/1, 943/1, 0437/1, uvrza UvrzBC system protein A 697044 2,771/5,361 LUNESPRSDAQWNENSRX [94371, 1,786] uvrza UvrzBC system protein A 697044 3,601/5,361 LNHES [1,786] uvra UvrzBC system protein A 698091 3,818/5,361 LNHES [1,786] uvra UvrzBC system protein A 699439 5,165/5,361 LDEAMISPRSDAQWNENSRX [71723]	Hypothetical 635322 670/1,545 uvrA UvrABC system protein A 696123 1,850/5,361 uvrA UvrABC system protein A 697044 2,771/5,361 uvrA UvrABC system protein A 697044 3,601/5,361 uvrA UvrABC system protein A 697044 3,601/5,361 uvrA UvrABC system protein A 697044 3,601/5,361 uvrA UvrABC system protein A 698091 3,818/5,361 uvrA UvrABC system protein A 698091 5,165/5,361		DNA repair protein	G020G9	429/l,365		
uvraUvraBC system protein A6961231,850/5,361VSIPLGGWISPRSDAQWNENSRX[66187;uvraUvraBC system protein A6970442,771/5,361UNHEX[9257;uvraUvraBC system protein A6978743,601/5,361UNHEX[71201X;uvraUvraBC system protein A6978743,601/5,361UNHEX[7123747;uvraUvraBC system protein A6978745,165/5,361UNHEX[7123747;uvraUvraBC system protein A6980913,818/5,3611,78611,7861uvraUvraBC system protein A6994395,165/5,361LDEIAMISPRSDAQWNENSRX[71723N;uvraUvraBC system protein A6994395,165/5,361LDEIAMISPRSDAQWNENSRX[71723N;uvraUvraBC system protein A6994395,165/5,361LDEIAMISPRSDAQWNENSRX[71723N;	uvrza UvrzbC system protein A 696123 1,850/5,361 uvrza UvrzbC system protein A 697044 2,771/5,361 uvrza UvrzbC system protein A 697874 3,601/5,361 uvrza UvrzbC system protein A 698091 3,818/5,361 uvrza UvrzbC system protein A 698091 5,165/5,361		Hypothetical	685322	670/1,545	FFVTV T GWMISPRSDAQWNENSRX	
uvrra UvrABC system protein A 697044 2,771/5,361 ELPVLIGWMISPRSDAQWNENSRX 636/1,7 uvrra UvrABC system protein A 697874 3,601/5,361 LNHESX 177861 uvrra UvrABC system protein A 697874 3,601/5,361 LNHESX 1,7861 uvrra UvrABC system protein A 698091 3,818/5,361 ESLCLIGWMISPRSDAQWNENSRX 1,7861 uvra UvrABC system protein A 699439 5,165/5,361 LDEIAMISPRSDAQWNENSRX 1,7861	uvrrå UvrÅBC system protein Å 697044 2,771/5,361 uvrrå UvrÅBC system protein Å 697874 3,601/5,361 uvrrå UvrÅBC system protein Å 698091 3,818/5,361 uvrå UvrÅBC system protein Å 699439 5,165/5,361	h		696123	1,850/5,361	VSIPLTGWMISPRSDAOWNENSRX	[G618T;
uvrza UvrzBC system protein A 697044 2,771/5,361 ELPVL <u>T</u> GWMISPRSDAQWNENSRX [P9257; 943/1,7 uvrza UvrzBC system protein A 697874 3,601/5,361 LNHES <u>X</u> [Y1201X; 1,786] 943/1,7 uvrza UvrzBC system protein A 698091 3,818/5,361 ESLCL <u>T</u> GWMISPRSDAQWNENSRX [71201X; 1,786] uvrza UvrzBC system protein A 698091 3,818/5,361 ESLCL <u>T</u> GWMISPRSDAQWNENSRX [71723]; 1,786]	uvrza UvrzBC system protein A 697044 2,771/5,361 uvrza UvrzBC system protein A 697874 3,601/5,361 uvrza UvrzBC system protein A 698091 3,818/5,361 uvrza UvrzBC system protein A 699439 5,165/5,361					T	636/1 7861
UVEA UVEADE System protein A 037044 2,7711,5701 LETLITUTION 94371,7 UVEA UVEADE System protein A 94371,7 94371,7 UVEA UVEADE System protein A 697874 3,601/5,361 LNHESY 1,7861 UVEA UVEADE System protein A 698091 3,818/5,361 ESLCLTGWMISPRSDAQWNENSRX [612747] UVEA UVEADE System protein A 699439 5,165/5,361 LDEIAMRLDKSPVX [71723N] UVEA UVEADE System protein A 699439 5,165/5,361 LDEIAMRLDKSPVX [71723N]	uvra UvraBC system protein A 697874 2,0115,361 uvra UvraBC system protein A 698091 3,818/5,361 uvra UvraBC system protein A 698091 3,818/5,361 uvra UvraBC system protein A 699439 5,165/5,361			10000	196 J/100 C		
uvral UvraBC system protein A 697874 3,601/5,361 LNHESA 94371/1 uvra UvraBC system protein A 698091 3,818/5,361 ESLCLTGWMISPRSDAQWNENSRX 1,7861 uvra UvraBC system protein A 699439 5,165/5,361 LDEAMRLDDKSPVX 1,7861 uvra UvraBC system protein A 699439 5,165/5,361 LDEAMRLDDKSPVX [71723N; uvra UvraBC system protein A 699439 5,165/5,361 LDEAMRLDDKSPVX [71723N;	uvrA UvrABC system protein A 697874 3,601/5,361 uvrA UvrABC system protein A 698091 3,818/5,361 uvrA UvrABC system protein A 699439 5,165/5,361			03/044	TQC'C/T//'7		
uvrza UvrzBC system protein A 697874 3,601/5,361 LNHESA [Y1201X; 1,786] 1,786] uvrza UvrzBC system protein A 698091 3,818/5,361 ESLCLIGWMISPRSDAQWNENSRX 1,786] uvrza UvrzBC system protein A 699439 5,165/5,361 LDEIAMRLDDKSPVX [T1723N; uvrza UvrzBC system protein A 699439 5,165/5,361 LDEIAMRLDDKSPVX [T1723N;	uvrza UvrABC system protein A 697874 3,601/5,361 uvra UvrABC system protein A 698091 3,818/5,361 uvra UvrABC system protein A 699439 5,165/5,361						<u> </u>
uvra UvraBC system protein A 698091 3,818/5,361 EsLCL_GWMISPRSDAQWNENSRX [G1274T] uvra UvraBC system protein A 699439 5,165/5,361 LDEIA <u>M</u> RLDDKSPVX [T1723N; uvra UvraBC system protein A 699439 5,165/5,361 LDEIA <u>M</u> RLDDKSPVX [T1723N;	uvrA UvrABC system protein A 698091 3,818/5,361 uvrA UvrABC system protein A 699439 5,165/5,361		system protein	697874	3,601/5,361		
uvra UvrabC system protein A 698091 3,818/5,361 ESLCLIGWMISPRSDAQWNENSRX [G1274T; 1,786] 1,786] uvra UvrabC system protein A 699439 5,165/5,361 LDEAMRLDDKSPVX [T1723N; 1,786]	uvrzá UvrzABC system protein A 698091 3,818/5,361 uvrzá UvrzABC system protein A 699439 5,165/5,361						
1,786] uvrá UvrábC system protein A 699439 5,165/5,361 LDEAMRLDDKSPVX [T1723N; 1,786]	uvrA UvrABC system protein A 699439 5,165/5,361			698091	3,818/5,361	ESLCLTGWMISPRSDAQWNENSRX	
uvrzá UvrzAC system protein A 699439 5,165/5,361 LDEAMRLDDKSPVX [T1723N; 1,786]	uvrzá UvrzABC system protein A 699439 5,165/5,361						
1,786] 1,265]				699439	5,165/5,361		
							l,786]

Downloaded from http://mbio.asm.org/ on October 25, 2019 at University of Kansas

TABLE 1 C. trachomatis coding region transposon insertion mutants

C1030 (c1259) Ometra in grant of control of contro of contro of control of control of contro of control of control	<i>ctl</i> gene (<i>ct</i> ^c)::Tn <i>bla</i>	Gene name	Predicted function	Genomic position of TN insertion ^a	Gene insert site/total gene length (bp)	Modified protein sequence ^d	[truncated/normal length] (bp) ^d
Intertion Tatk is intermediation T2223 T29/T01 PownTexmerran Result connerses Result connerse Result c	ct10593 (ct339) ^h	COMEC	Competence DNA uptake	705937	1,466/1,530	ILVYITGWMISPRSDAQWNENSRX	[G490T; 508/509]
 Protectional processin (17:21) Protriker inter membrane protein (17:22) Protriker inter membrane protein (17:23) Protriker inter membrane protein (17:23) Protriker inter membrane protein (17:23) Protriker inter membrane membrane membrane membrane (17:23) Protriker inter membrane membrane membrane membrane membrane membrane (17:22) Protriker inter membrane membrane membrane	ct10604 (ct350)		Putative lipoprotein	718288	179/1701	IQPVT R NSRIVFTTKLSLX	[R61T; 79/566]
A match in the interime interime protein 72559 64/76 KMUPDNENK 77571 A match inter membrane protein 73780 337/133 KWUPDNENK 73970 73970 A match inter membrane protein 75770 18/315 KWUPDNENK 73970 73970 A match inter membrane protein 73770 18/317 73770 73700 73700 A pape Norotherical 73770 73711 73731 73711 73711 73711 A pape Norotherical 73910 73710 11/1/111 7331 73711	ct10611A (ct357) ^h		Hypothetical	728274	212/333	DFSVLTGWMISPRSDAQWNENSRX	[R61T; 90/110]
Λ andpoint73381577/13573705737105737110573710573710573710	ct10625 (ct371)			742559	454/786	KANLPLTGWMISPRSDAQWNENSRX	[Y152L; 171/261]
Number Description Description <thdescripripriotion< th=""> Description</thdescripripriotion<>	ct10626 (ct372) ^h	aaxA	Porin	743881	837/1,329	KWSNL <u>N</u> RLDDKSPVX	[T280N; 289/442]
1 Title triad motif hydrolase 737/10 1000000000000000000000000000000000000	ct10639 (ct383)			755828	572/732	ERYTLTGWMISPRSDAQWNENSRX	[L192T; 210/243]
nBypothetical765.6875.7.1.131OCH2NNENDSCWA803.003 n Bypothetical764.0011.1.1.11NATGEWNENSENA803.003 n Bypothetical764.0011.1.1.11NATGEWNENSENA803.01 n PaperPolymorphic outer membrane protein7990911.353/5.325NASGEWNENSENA803.01 n PaperPolymorphic outer membrane protein803.3254.241/5.326APACPMENDSEVA803.01 n PaperPolymorphic outer membrane protein803.3254.241/5.326APACPMENDSEVA83.01 n PaperPolymorphic outer membrane protein803.3254.241/5.326APACPMENDSEVA83.01 n PaperPaperPaperPaperPaperPaperPaperPaper n PaperPaperPaperPaperPaperPaperPaperPaperPaperPaper n Paper <th< td=""><td>ct10641 (ct385)</td><td></td><td>Histidine triad motif hydrolase</td><td>757770</td><td>198/336</td><td>EAGKINRLDDKSP-35AA-SCX^g</td><td>[I67N; 112/111]</td></th<>	ct10641 (ct385)		Histidine triad motif hydrolase	757770	198/336	EAGKINRLDDKSP-35AA-SCX ^g	[I67N; 112/111]
h Spectrate and protection 766400 11/11/11 MSTGWWSBSADWWSBSA [02171] h pmpc Polymorphic outer membrane protein 799904 1.559/5.325 TMSDTGWWSBSADWWSBSA [93/17] h pmpc Polymorphic outer membrane protein 799904 1.559/5.325 TMSDTGWWSBSADWWSBSA [93/45] h pmpc Polymorphic outer membrane protein 802593 4.241/5.326 POGWMSPSDADWWSBSA [93/45] h pmpc Polymorphic outer membrane protein 802593 4.241/5.326 POGWMSPSDADWWSBSA [1737] h pmpc Polymorphic outer membrane protein 802593 4.241/5.326 POGWMSPSDADWWSBSA [1737] recol Single endenytransferase 83304 4.005/4.235 POGWMSPSDADWWSBSA [1737] recol Distriction Preprotein 83304 4.01/12 POGWMSPSDADWWSBSA [1737] recol Distriction Preprotein 83304 4.01/12 POGWMSPSDADWWSBSA [1737] recol Distriction Preprotein 83343	ct10648 (ct392) ^h		Hypothetical	765648	762/1,131	DGPLSINRLDDKSPVX	[S300X; 300/377]
0 mpc 0%-definite-specific DNA methylae 78374 69/233 HPGinksPRSDAGWRINK (0221) 02371 1 mpc E0lymorphic outer membrane protein 73990 1.559/5.325 MSGGFGWNSPRSDAGWRINK (0221) 02371 1 mpc Polymorphic outer membrane protein 803592 4.241/5.326 APGGFNRDAGWRINK (014401) 0.7451 1 Page Polymorphic outer membrane protein 803393 1.311/1.755 Polymorphic outer membrane protein 1.7751 1 Protein 83300 1.311/1.755 Polymorphic outer membrane protein 1.7751 1 Protein 83330 1.311/1.755 Polymorphic outer membrane protein 1.7751 1 Protein 83330 1.311/1.755 Polymorphic outer membrane protein 1.7751 1 Protein 83300 4.005/4.203 Low Marken 1.7751 1 Protein 83300 4.011/1.7175 Protein 1.7751 1 Protein 83304 4.005/4.203 Low Marken Litottata 1 Prot	ct10648 (ct392) ^h		Hypothetical	766400	11/1,131	MSSIT GWMISPRSDAQWNENSRX	[O5T; 23/376]
0 pmpc Polymorphic outer membrane protein 79900 1,559/5,325 TNSDTGWNERSK (05217) 03217 0 pmpc Polymorphic outer membrane protein 803292 4,241/5,326 APAGENMUDKSPVESSFUR (1,4407) 1,4607 0 pmpc Polymorphic outer membrane protein 803293 4,241/5,326 APAGENMUDKSPVESSFUR (1,4407) 1,4731 1 record Bifunctional preprotein translocase submit 83300 4,005/41/203 FFMEQMMEPSRSAQMWERSK (03351) 1,4017 1 record Bifunctional preprotein translocase submit 83300 4,005/41/203 FFMEQMMEPSRAQAQMESK (03351) 1,4017 1 record Bifunctional preprotein translocase submit 83300 4,005/41/203 FFMEQMMEPSRAQAQMESK (03351) 1,4003 1 record Bifunctional preprotein translocase submit 83300 4,005/41/203 FFMEQMMEPSRAQAQMESK 1,4013 1 Feed Bifunctional preprotein translocase submit 83300 4,005/41/203 FFMEQMEPSRAQAQMESK 1,4031 1 Feed Bifunctional protein 34001/205 FFMEQMENPSRAQAGMESK<	ct10661 (ct404)		N6-adenine-specific DNA methvlase	781874	690/828	HTPGHNRLDDKSPVX	[T231N: 240/275]
D Payc Polymorphic outer membrane protein 802592 4,2415,326 PONCYNRUDNSFWTGSSENUR 0.33071 0 payc Polymorphic outer membrane protein 802593 4,2425,326 PONCYNRUDNSFWT 1,7731 1 Paycothetical Hypothetical 804491 66/702 TSPFIGWMEPRSDAQWENSKX 1,7431 1 Paycothetical Preprotein translocase subunit 80360 4,0054,203 CMUCENCMACKX 1,4447 1 PERCOMPERSDAQWENSKX TAGAGT 1,7731 PONCTIGNERSDAQWENSKX 1,4447 1 PACO Bitunctical 93300 4,0054,203 CMUCENCMACKSC 1,4447 1 PACO Bitunctical 3,12,1,1,25 PERGENUSPONWENSKX 1,4447 1 PACO Glucose-1-phosphate ademyltransferase 83300 4,0054,203 CMUCEWMEPSDAQWENSKX 1,4447 1 PACO Glucose-1-phosphate ademyltransferase 93433 42/426 FRSINLDNSFVX 1,14475 1 PACO Bitunctical PACO 925031 418/456 1	ct10671 (ct414) ^h	DampC	Polymorphic outer membrane protein	799909	, 32	TNSDITGWMISPRSDAQWNENSRX	[D521T;
h pupc Polymorphic outer membrane protein 802532 4,241/5,326 POKGYMEDKSFWGSSENIR 1/730 h pupc Folymorphic outer membrane protein 802533 4,247/5,326 POKGYMEDKSFWX 1,773 h pupc Folymorphic outer membrane protein 802593 4,247/5,326 POKGYMEDKSFWX 1,773 rec Bifunctional preprotein translocease submit 80360 4,001/4,203 CMUTGWMSFSDAQWMENSK 1,471 rec Bifunctional preprotein translocease submit 80360 4,001/4,203 CMUTGWMSFSDAQWMENSK 1,470 rec DNA repair POSTA 1,471 1,770 1,740 rec DNA repair Colon-1-phosphate demyltransferase 80304 42/732 ESTM 1,740 rec DNA repair Colon-1-phosphate demyltransferase 80304 42/732 ESTM 1,740 rec DNA missuch Biftolo 432/732 ESTM 1,740 rec DNA missuch Biftolo 242/53 ESTM 1,740 rec DN							539/1,774]
Λ pupperpolymorphic outer membrane protein8025934,242/5,326POKGYWEDDKEWX[31,553,1771] Γ HypotheticalHypotheticalHypothetical804491686/70215791/217741 Γ Sinjol-strandad MA-specific econclease804491686/70215791/214741 Γ Sinjol-strandad MA-specific econclease804491686/70215791/214743 Γ Sinjol-strandad MA-specific econclease804491686/70215791/214743 Γ Sinjol-strandad MA-specific econclease804304492/133614711/35514701 Γ CDix rescoDix rescoDix resco1931/33614011/35514703 Γ Crycidine(31)-2 ⁻⁰)-methyltransferase88304492/13365517114703 Γ Protein9348342/436FRINLDNGYNX111087 Γ Mipopthetical9631642/436FRINLDNGYNX111087 Γ Mipopthetical9631642/436FRINLDNGYNX111087 Γ Mipopthetical963166261/3313260713733 Γ Mipopthetical963166261/331842/4361110887 Γ Mipopthetical96316970909847.207EGNUMSPRSDAQWNENSK111087 Γ Mipothetical96316973096847.207EGNUMSPRSDAQWNENSK1110887 Γ Mipothetical96316973096847.173197476111087 Γ Mipothetical96316 <td< td=""><td>ct10671 (ct414)^h</td><td>pmpC</td><td>Polymorphic outer membrane protein</td><td>802592</td><td>4,241/5,326</td><td>APQKG<u>Y</u>NRLDDKSPVFGSSENLR KTALOGGFF</td><td></td></td<>	ct10671 (ct414) ^h	pmpC	Polymorphic outer membrane protein	802592	4,241/5,326	APQKG <u>Y</u> NRLDDKSPVFGSSENLR KTALOGGFF	
HypotheticalB0440168/702STRFTGWMSRPSDAOWNENSK $[1,311,1,75]$ TSPFTGWMSRPSDAOWNENSK $[1,403]$ rec0Sigue-tranded DN-specific exonuclease83303 $1,311,1,75$ DFAGLWIDDNSYW $1,4003$ rec0DNRepair $1,005,4,203$ $(0,11,205)$ DFAGLWIDDNSYW $1,4003$ rec0DNrepair $(0,01,12,00)$ $(0,01,12,00)$ $(1,10,05,4,103)$ $(1,10,01)$ rec1DNrec1 $(0,01,12,00)$ $(0,01,12,00)$ $(1,10,01)$ $(1,10,01)$ rec1DNRPD $(0,11,20,01)$ $(0,01,12,00)$ $(1,10,01)$ $(1,10,01)$ rec1DNRPD $(0,01,12,01)$ $(1,01,01)$ $(1,10,01)$ $(1,10,01)$ rec1DPPAminopetidase P family protein 946403 $3,260,3,600$ $FISSMMSPSDAOWNENSK(1,10,01)rec1DNA mismatch repair endonuclease9334334,2/426FISSMMSPSDAOWNENSK(1,10,01)rec1DNA mismatch repair endonuclease96516387/1,011(0,00,00)(1,10,01)rec1DNA mismatch repair endonuclease96516387/1,011(0,00,00)(1,00,00)rec1DNA mismatch repair endonuclease96516387/1,011(0,00,00)(1,00,00)rec1DNA mismatch repair endonuclease96516387/1,011(0,00,00)(1,00,00)rec1DNA mismatch repair endonuclease96516387/1,011(0,00,00)(1,00,00)rec1DNA mismatch repair endonuclease965163$	ct10671 (ct414) ^h	pmpC	Polymorphic outer membrane protein	802593	4,242/5,326	PQKGY <u>N</u> RLDDKSPVX	
rec/Single-stranded DNA-specific exonuclease8363801,311/1,755DFAGLNRLDDKSFW $[M438L]$ 1,005Binnetional preprotein translocase submit833064,005/4,203 $[QrtTGWMBFR5DAQWWENSRX[1,3171]sec/FClucose-1-phosphate adenyltransferase833064,005/4,203[QrtTGWMBFR5DAQWWENSRX[1,105X]sec/FClucose-1-phosphate adenyltransferase83304492/132[SSTNX][T140X]sec/FClucose-1-phosphate adenyltransferase83483492/132[SSTNX][T140X]PypotheticalClucose-1-phosphate9348342/456[GrtMMSFR5DAQWWENSRX][T140X]*PypotheticalDryning (31)-2'-0]-methyltransferase9348342/426[STNX][T140X]*PypotheticalMinopeptidase F family protein955163371,071[GrtMMSFR5DAQWWENSRX][T1287]*PipotheticalSaffSaffX[T1,071][GrtMMSFR5DAQWWENSRX][T1287]*Minopeptidase F family protein965163871,071[GrtMMSFR5DAQWWENSRX][T1287]*Minopeptidase F family protein965163871,071[GrtMMSFR5DAQWWENSRX][T1287]*Minopeptidase F family protein965163871,071[GrtMMSFR5DAQWWENSRX][T1287]*MinopeptidaseMinopeptidase892,075871,071[GrtMMSFR5DAQWWENSRX][T1287]*MinopeptidaseMinopeptidase802,01871,071[GrtMMSFR5DAQWFSDAQWFSDAQWFSDAQWFSDAQWFSDAQWFSDAQWFSDA$	ct10678 (ct421)		Hypothetical	804491	686/702	TSPFITGWMISPRSDAQWNENSRX	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	C+10707 (C+447)	rec.T	single-stranded DNA-snecific exonnclease	836380	1 311/1 755		
secure mean secure mean mea mean mean	Ct10708a (Ct448))) 	Bifinctional preprotein translocase subunit	838006	4,005/4,203		[G1337T: 1.355/
rec0DNA repair protein865604 $432/732$ ESTIXKT165X $gigC$ Gutocset -Thomsphate adenyltransferase 84304 $469/1,326$ $8NOX$ $Y140X$ $Y140X$ Putative tealTervitatione (34) - 2'-0]-methyltransferase 934433 $42/426$ $RRSINLDKSYX$ $[T10897, 2]$ PrycontericalTervitatione (34) - 2'-0]-methyltransferase 934433 $42/426$ $RRSINLDKSYX$ $[T10897, 2]$ Pryconterical 934433 $3.260/3, 600$ $RGSI_GWMSPRSDAQWNENSRX$ $[T10897, 2]$ $recpP$ Aminopeptidase P family protein 965163 $87/1, 071$ $RCEINRLDKSYX$ $[T1087, 2]$ e^{1} Minopeptidase P family protein 965163 $87/1, 071$ $RCEINRLDKSYX$ $[T1087, 2]$ e^{1} Minopeptidase P family protein 965163 $87/1, 071$ $RCEINRLDKSYX$ $[T1287, 2]$ e^{1} Minopeptidase P family protein 965163 $87/1, 071$ $RCEINRLDKSYX$ $[T1287, 2]$ e^{1} Minopeptidase $Randomuclease96516387/1, 081RGGFTGWMSPRSDAQWNENSRX[T1287, 2]e^{1}Minopeptidase861/2, 20078661, 731RGGFTGWMSPRSDAQWNENSRX[T1287, 2]e^{1}Minopeptidase89/266580/2665ROOLTGWMSPRSDAQWNENSRX[T1287, 2]e^{1}Minoterical99230781/2, 007RRPMSPRSDAQWNENSRX[T1287, 2]e^{1}Minoterical99230781/2, 087ROOLTGWMSPRSDAQWNENSRX[T1287, 2]e^{1}Minoterical$			SecDF				
$g_{1}g_{7}$ Glucose-1-phosphate adenyltransferase884304 $469/1,326$ $RSNDA$ $[Y157X]$ $Icative tRMA$ $[Cytidine[34)-2'-0]$ -methyltransferase938433 $42/456$ $RSNDA$ $[Y157X]$ $Icytidine[34)-2'-0]$ -methyltransferase938433 $42/426$ $RRSINLDKSPXX$ $[T15N]$ 210871 $Hypothetical9464083,260/3,600FGSLTGWMISPRSDAQWENSRX1.10871epepAminopeptidase P family protein96516387/1,071KOEIIGWMISPRSDAQWENSRX1.10871epepAminopeptidase P family protein96516387/1,071KOEIIGWMISPRSDAQWENSRX1.10871epepAminopeptidase P family protein96516387/1,071KOEIIGWMISPRSDAQWENSRX1.10871epepAminopeptidase P family protein96516387/1,071KOEIIGWMISPRSDAQWENSRX1.10871epepMinopeptidase F favoprotein96516382/1,07182/1,73182/2707bhypothetical988197380/286582/2,00782/2707bprotine dehydrogenase114/86114/86112877bprotine dehydrogenase112873128734112877bprotine dehydrogenase1128731124/261124/26bprotine dehydrogenase11287311287321128772bprotine dehydrogenase112873411287321124/26bprotine dehydrogenase$	ct10730 (ct470)	recO	DNA repair protein	863604	492/732	ESSTIX	
Putative taxprior $11/456$ 000 $11/456$ 000 $11/456$ 000 $11/405$ <	Ct10750 (Ct489)	מןמנ	Glucose-1-phosphate adenvltransferase	884304	469/1.326	RSIVDX	
Perturbation 946408 3,260/3,600 FRSNRIDNCSYVX [T15N; 3 Hypothetical 946408 3,260/3,600 FGSLTGWMISPSDAQWIENSRX [T15N; 3 Hypothetical 946408 3,260/3,600 FGSLTGWMISPSDAQWIENSRX [T1087] PepP Aminopeptidase P family protein 955163 87/1,071 KCELTGWMISPSDAQWIENSRX [1,1087] DRA mismatch repair endonuclease 965365 626/1,731 KCELTGWMISPSDAQWIENSRX [1,1087] Wypothetical 98413 2,164/2,865 RNDLDKSPX [1,2323) Wypothetical 98413 2,164/2,865 RNDLDKSPX [1,237] Wypothetical 98413 2,164/2,865 RNDLDKSPX [1,237] Succinate dehydrogenase 990457 812/2,085 RNDLDKSPX [1,237] Succinate dehydrogenase 1002459 114/862 PNKFTGWMISPSDAQWIENSRX [1,237] Succinate dehydrogenase 1002459 131/1,602 HLTNMRLDKSPX [1,1287] Succinate dehydrogenase 1002459 131/1,602 HLTNMRLDKSPX [1,1287] Succinate dehydrogenase 102459 131/1,602 HLTNMRLDKSPX [1,1287] Succinate dehydrogenase 102459 131/1,602 HLTNMRLDKSPX [1,1287] Succinate dehyd		0	0.44041.440 - Z	00100 005001	A10/A56		
Hydratical ArP-dependent helicase938483 $42/426$ FRSINLDDKSPVX $[T150]$ PepPAminopeptidase F family protein946408 $3, 260/3, 600$ FIGSLTGWNISPRSDAQWNENSRX $[1,19]$ PepPAminopeptidase F family protein965163 $87/1, 071$ KOEDINLDKSPVX $[1,19]$ PepPAminopeptidase F family protein965163 $87/1, 071$ KOEDINLDKSPVX $[1,19]$ PepPAminopeptidase F family protein965163 $87/1, 071$ KOEDINLDKSPVX $[1,19]$ PepPBytochetical966365 $626/1, 731$ KOGFTGWNISPRSDAQWNENSRX $[1,19]$ Bytochetical9900457 $848/2, 007$ 6413 $2,164/2, 865$ RNMISPRSDAQWNENSRX $[1,2321, 230]$ SdhASuccinate dehydrogenase990457 $816/2, 865$ RNOLTGWNISPRSDAQWNENSRX $[1,2321, 230]$ SdhASuccinate dehydrogenase990457 $875/1, 881$ PWYFLTGWNISPRSDAQWNENSRX $[1,2321, 230]$ SdhASuccinate dehydrogenase990457 $875/1, 881$ PWYFLDKSPVX $[1,1287]$ SdhASuccinate dehydrogenase990457 $875/1, 882$ PWYFLDKSPVX $[1,1287]$ StrandMolecular chaperone GroEL 1002499 $410/1, 602$ $178/792$	UCTOONS (CC)		fucative truva [cvtidine(34)-2/-0]-methv]transferase	T000%			
Tarp-dependent helicase 945408 $3,560/3,600$ $FIGSLTGWMISPRSDAQWNENSRX$ $1,1090$ ATP-dependent helicase 945408 $3,560/3,600$ $FIGSLTGWMISPRSDAQWNENSRX$ $1,1091$ pepPAminopeptidase P family protein 965163 $87/1,701$ $KOEDNRDKSPX$ 13003 $mutb$ Excinuease ABC submit B 979090 $8482,007$ 66700 12000 12000 $hypotheticalExcinuease ABC submit B9790908482,0076670012000122232hypotheticalBycothetical964132,164/2,865RVDGMISPRSDAQWNENSRX [E2077)Hypothetical90457812,00766700122232Succinate dehydrogenase9045781271,881PWFTGWMISPRSDAQWNENSRX [11227)sdhSuccinate dehydrogenase9045781751,881PWFTGWMISPRSDAQWNENSRX [11272)sdhSuccinate dehydrogenase9045781751,881PWFTGWMISPRSDAQWNENSRX [11272)sdhSuccinate dehydrogenase100245913787921000000000000000000000000000000000000$	C+10812 (C+550)		Hvnothetical	938483	42/426	FRRSINRI DIDKSPVX	[T15N: 24/141]
$1,199$ $1,199$ $1,199$ $pepP$ Aminopeptidase P family protein 965163 $87/1,071$ KDEDINRDKSPVX $1,1091$ $mutL$ DNA mismatch repair endonuclease 965365 $626/1,731$ KDEDINRDKSPVX $[82307;$ $uvrB$ Excinuclease ABC submit B 999090 $848/2,007$ $[848/2,007]$ $[82307;$ $HypotheticalHypothetical990457818/2,007[67PTGWMISPSDAQWNENSRX[12223]HypotheticalHypothetical990457816/1,731KQETGWMISPSDAQWNENSRX[12223]HypotheticalHypothetical990457816/1,731KQETGWMISPSDAQWNENSRX[17223]sdhASuccinate dehydrogenase990457815/1,881PurFLGWMISPSDAQWNENSRX[17223]sdhCSuccinate dehydrogenase990457815/1,881PurFLGWMISPSDAQWNENSRX[17223]sdhCSuccinate dehydrogenase114/07114/02PurFLGWMISPSDAQWNENSRX[12303]sdhCNolecular chaperone droEL1002459431/1,602HLINMIDDKSPVX[12303]protLatMolecular chaperone droEL1002459431/1,602HLINMIDDKSPVX[12303]protLatPasmid hypothetical protein992950178/792PurFLGWMISPSPAQWNENSRX[12303]protLatPasmid hypothetical protein156/79500012PurLMIRDKSPVX[1414V]protLatPasmid virulence protein12529^627/1,963AuhLMIRDKSPVX[17111]protLat<$	ct10818 (ct555) e		ATP-dependent helicase	946408	3,260/3,600	FIGSLTGWMISPRSDAQWNENSRX	[L1088T; 1,106/
pepPAminopeptidase P family protein965163 $87/1,071$ KOEDINRLDKSPVX[S30N;muttDDA mismatch repair endonuclease966365 $626/1,731$ KOEFIGWMISPRSDAOWNENSRX $E2307$;muttDDA mismatch repair endonuclease979090 $848/2,007$ $EGRPUTGWMISPRSDAOWNENSRXE2347;HypotheticalHypothetical9864132.164/2,865DXSAIXI1722X;Hypothetical9864133.164/2,865DXSAIXI1722X;Hypothetical990457875/1,881PWCHTGWMISPRSDAOWNENSRXE2937;sdhaSuccinate dehydrogenase990457875/1,881PWCHTGMISPRSDAOWNENSRXE2937;sdhcSuccinate dehydrogenase992056114/862PULTNMRLDDKSPVX[123W]sdhcSuccinate dehydrogenase1002459431/1,602LHTVX[144V]sdhcSuccinate dehydrogenase136240 OR404/2,868PWCHTXMILDKSPVX[131W]sdhcSuccinate dehydrogenase136240 OR404/2,868PWCHTXMILDKSPVX[131W]sdhcSuccinate136240 OR404/2,868PWCTXMILDKSPVX[144V]proden138/206178/102LHTVX[144V][144V]proden136240 OR404/2,868PWCTXMILDKSPVX[1714V]proden136200178/102LHTVX[121W]proden229^{9}158244270/305ALMLNRLDKSPVX[121W]pgp3Plasmid hypothetical protein$			1			I	1,199]
muthDNA mismatch repair endonuclease 96365 $626/1,731$ $KQGFIGWMISPRSDAQWNENSRX$ $E2107$; $uvrB$ $Excinuclease ABC submit B979090848.2,00766FIGWMISPRSDAQWNENSRXE2247;uvrBExcinuclease ABC submit B979090848.2,00766FIGWMISPRSDAQWNENSRXE22075;Hypothetical9904579864132,164/2,865RVQDLGWMISPRSDAQWNENSRX[12287]Hypothetical990457875/1,881PWPLIGWMISPRSDAQWNENSRX[12397]sdhCSuccinate dehydrogenase990457875/1,881PWPLIGWMISPRSDAQWNENSRX[1247]sdhCSuccinate dehydrogenase990457875/1,881PWPLIGWMISPRSDAQWNENSRX[12397]sdhCSuccinate dehydrogenase990457875/1,881PWPLIGWMISPRSDAQWNENSRX[124V]sdhCSuccinate dehydrogenase1002459431/1,602HLITNNLDDKSPVX[144V]tarDMolecularchaperone922960178/792DWMFYMICDKSPVX[144V]groEL2Molecularchaperone1002459431/1,602LHITNNLDKSPVX[144V]pgp55Plasmid hypothetical protein1002459431/1,602LHITNY[174V]pgp74Plasmid hypothetical protein1002459104/2,868IIMLDKSPVX[191N;pgp3Plasmid hypothetical protein1052^29^91,354/1,356KVVMX[191N;pgp2Plasmid hypothetical protein2215^9$	ct10837 (ct574) ^e	pepP	Aminopeptidase P family protein	965163	87/1,071	KDEDINRLDDKSPVX	[S30N; 39/356]
uvrBExcinclease ABC subunit B979090 $848/2,007$ $EGRPTGWMISPSDAQWNENSRX$ HypotheticalHypothetical 986413 $2,164/2,865$ $DKSAIX$ $DKSAIX$ Hypothetical 988197 $380/2865$ $DKSAIX$ $DKSAIX$ Hypothetical 984197 $380/2865$ $DKSAIX$ $DKSAIX$ Subcinate dehydrogenase flavoprotein 990457 $875/1,881$ $PHLTNMISPRSDAQWNENSRX$ sdhCSuccinate dehydrogenase 9920766 $114/862$ $PHLTNMILDKSPXX$ sdhCSuccinate dehydrogenase 922950 $178/792$ $DWMFNRSPXX$ sdhCSuccinate dehydrogenase 1002459 $431/1,602$ $LHNX$ sdhC 235 rRNA 1002459 $431/1,602$ $LHNX$ srond 158284 $158/792$ $DWMFNRSPXX$ $158/792$ spf5Plasmid hypothetical protein 229^{6} $165/795$ $SGLGANRLDKSPXX$ spf3<	ct10838 (ct575) eh	mutL	DNA mismatch repair endonuclease	966365	626/1,731	KQGFITGWMISPRSDAQWNENSRX	[E210T; 228/576]
Hypothetical986413 $2,164/2,865$ DKSAKHypothetical988413 $2,164/2,865$ DKSAKHypothetical988197 $380/2865$ RVODLTGWMISPRSDAQWNENSRXsdhaSuccinate dehydrogenase flavoprotein 990457 $875/1,881$ PWFLTGWMISPRSDAQWNENSRXsdhcSuccinate dehydrogenase 990457 $875/1,881$ PWFLTGWMISPRSDAQWNENSRXsdhcSuccinate dehydrogenase 992076 $114/862$ HLHTNNRLDKSPVXhydrolase 992050 $171/1,602$ $HHLTNNRLDKSPVX$ sdrb 1002459 $431/1,602$ $HHTNNRLDKSPVX$ groEL2 235 rRNA 1002459 $431/1,602$ $HHTNNRLDKSPVX$ groEL2 235 rRNA 1002459 $431/1,602$ $HHTNNRLDKSPVX$ groB5Plasmid hypothetical protein 2596 $165/795$ $SGLGAMRLDKSPVX$ ggp3Plasmid hypothetical protein 229^{6} $1,354/1,356$ ALIMLNRLDKSPVXggp3Plasmid hypothetical protein 2715^{6} $1,354/1,356$ ALIMLNRLDKSPVXggp3Plasmid hypothetical protein 2715^{6} $1,354/1,356$ MNGNNENSRX	<i>ct10849</i> (<i>ct586</i>)	uvrB	Excinuclease ABC subunit B	040070	848/2,007	EGRPVTGWMISPRSDAQWNENSRX	
Hypothetical988197380/2865RVQDLTGWMISPSDAQWNENSRXsdhASuccinate dehydrogenase flavoprotein990457 $875/1,881$ PWYFLTGWMISPSDAQWNENSRXsdhCSuccinate dehydrogenase9902950 $114/862$ HLTNNRLDKSPVXsdhCSuccinate dehydrogenase9922950 $178/792$ DWFYLTGWMISPSDAQWNENSRXsdhCSuccinate dehydrogenase9922950 $178/792$ DWFYLTGWMISPSDAQWNENSRXgroEL2Molecular1002459 $431/1,602$ LHTVXgroEL2136240.0K $404/2,868$ $404/2,868$ Lpgp5Plasmid hypothetical protein 239^{4} $165/795$ SGLGANRLDKSPVXpgp3Plasmid hypothetical protein $270/309$ ALIMLNRLDKSPVXpgp3Plasmid hypothetical protein $270/309$ ALIMLNRLDKSPVXpgp1Plasmid hypothetical protein 2715^{6} $1,354/1,356$ MVTGWMISPSPAQWNENSRXpgp2Plasmid hypothetical protein 2715^{6} $5/1,065$ MVTGWMISPRSPAQWNENSRX	ct10853 (ct590) ^h		Hypothetical	986413	2,164/2,865	DKSAIX	
sdhaSuccinate dehydrogenase flavoprotein990457 $875/1,881$ PWYFLTGWMISPSDAQWNENSRXsdhcSuccinate dehydrogenase92076 $114/862$ HLLTNMRLDNSPVX1sdhcSuccinate dehydrogenase992950 $178/792$ DWMFYMRLDNSPVX1starDHydrolase992550 $178/792$ DWMFYMRLDNSPVX1groEL2Molecular chaperone GroEL 1002459 $431/1,602$ LEHTVX123S rRNA 1382400 $404/2,868$ $161/12$ LEHTVX1Pseudogene 514407 551400 $165/795$ SGLGAMRLDNSPVX1pgp5Plasmid hypothetical protein 229^{6} $165/795$ SGLGAMRLDNSPVX1pgp4Plasmid hypothetical protein 260^{6} $270/309$ ALIMLMRLDNSPVX1pgp3Plasmid hypothetical protein 2715^{6} $1,354/1,356$ MKVWX1pgp1Plasmid hypothetical protein 2715^{6} $5/1,065$ MTGWMISPRSPAQWNENSRX1	ct10853 (ct590) ^h		Hypothetical	988197	380/2865	RVQDLTGWMISPRSDAQWNENSRX	
sdhcSuccinate dehydrogenase992076114/862HLLTNMRLDKSPVX $tatD$ Hydrolase992950178/792DWMFYNRLDKSPVX $groEL2$ Molecular chaperone GroEL1002459431/1,602LEHYX $23S$ rRNA158284 158284 158739 LHYX $pgp5$ Plasmid hypothetical protein 5229^6 $165/795$ Scl.GAMRLDKSPVX $pgp4$ Plasmid hypothetical protein 222^9 $1,354/1,565$ ALIMLMRLDKSPVX $pgp1$ Plasmid hypothetical protein 260^6 $331/795$ ALIMLMRLDKSPVX $pgp1$ Plasmid hypothetical protein 2715^6 $1,354/1,356$ MKVWX $pgp2$ Plasmid hypothetical protein 2715^6 $1,354/1,356$ MKNWX	<i>ct10855</i> (<i>ct592</i>)	sdhA	hydrogenase	990457	875/1,881	PWYFLT GWMISPRSDAQWNENSRX	
tatDHydrolase992950178/792DWMFYNRLDDKSPVX $groEL2$ Molecular chaperone GroEL1002459431/1,602LEHTVX $23S$ rRNA136240 OR404/2,868LEHTVX1 $pgp5$ Plasmid hypothetical protein514407165/795SGLGANRLDDKSPVX1 $pgp3$ Plasmid hypothetical protein229 ^b 165/795SGLGANRLDDKSPVX1 $pgp1$ Plasmid hypothetical protein229 ^b 165/795SGLGANRLDDKSPVX1 $pgp3$ Plasmid hypothetical protein226 ^b 331/795ALINLINRLDKSPVX1 $pgp1$ Plasmid hypothetical protein2715 ^b 1,354/1,356MKVWX1 $pgp2$ Plasmid hypothetical protein2715 ^b 5/1,065MYGWMISPRSDAQWNENSRX1	ct10856 (ct593) e	sdhC		992076	114/862	HLLTNNRLDDKSPVX	[I39N; 48/287]
groEL2 Molecular chaperone GroEL 1002459 431/1,602 LEHTVX 235 rRNA 136240 OR 404/2,868 L 235 rRNA 136240 OR 404/2,868 L 235 rRNA 136240 OR 404/2,868 L 235 Plasmid hypothetical protein 514407 L L 297 Plasmid hypothetical protein 229 ^b 165/795 SGLGANRLDDKSPVX L 297 Plasmid virulence protein 220 ^b 231/795 ALIMLINCDKSPVX L 297 Plasmid hypothetical protein 1262 ^b 331/795 ALIMLINCDKSPVX L 2715 ^b Plasmid hypothetical protein 2715 ^b 1,354/1,356 MVVWX L	ct10858 (ct594)	tatD		992950	178/792	DWMFYNRLDDKSPVX	[H61N; 69/261]
235 rRNA 235 rRNA 136240 OR 404/2,868 158284 158284 158284 Pseudogene 514407 158284 pgp5 Plasmid hypothetical protein 214407 200 pgp4 Plasmid hypothetical protein 2296 165/795 SGLGAMRLDDKSPVX 1 pgp3 Plasmid hypothetical protein 226 331/795 ALIMLINRLDDKSPVX 1 pgp1 Plasmid hypothetical protein 27156 1,354/1,356 MKVWX 1 pgp2 Plasmid hypothetical protein 27156 5/1,065 MVTGWMISPRSPAQWNENSRX 1	ct10867 (ct604)	groEL2	chaperone Gr	1002459	431/1,602	LEHTVX	[Y144V; 144/533
I58284 I58284 Pseudogene 514407 I55/795 SGLGAMRLDDKSPVX I pgp5 Plasmid hypothetical protein 229 ⁶ 165/795 SGLGAMRLDDKSPVX I pgp4 Plasmid hypothetical protein 229 ⁶ 370/309 ALIMLMRLDDKSPVX I pgp3 Plasmid virulence protein 1262 ⁶ 331/795 ALIMLRLDKSPVX I pgp1 Plasmid hypothetical protein 2715 ⁶ 1,354/1,356 KKVWX I pgp2 Plasmid hypothetical protein 2715 ⁶ 5/1,065 MUTGWMISPRSDAQWNENSRX I	<i>ct1_r03/04</i>		23S rrna	136240 OR	404/2,868		
Pseudogene 514407 514407 pgp5 Plasmid hypothetical protein 229 ^b 165/795 SGLGA <u>M</u> RLDDKSPVX pgp4 Plasmid hypothetical protein 229 ^b 370/309 ALIML <u>NRLDDKSPVX pgp3 Plasmid hypothetical protein 260^b 270/309 ALIML<u>NRLDDKSPVX pgp1 Plasmid hypothetical protein 262^b 331/795 ALIML<u>NRLDDKSPVX pgp1 Plasmid helicase 2715^b 1,354/1,356 IKKVW<u>X</u> pgp2 Plasmid hypothetical protein 2715^b 5/1,065 MVTGW<u>M</u>ISPRSDAQWNENSRX </u></u></u>				158284			
$pgp5$ Plasmid hypothetical protein 229^{b} $165/795$ $SGLGAMRLDDKSPVX$ $pgp4$ Plasmid hypothetical protein 460^{b} $270/309$ $ALIMLMRLDDKSPVX$ $pgp3$ Plasmid virulence protein 1262^{b} $331/795$ $ALIMLMRLDKSPVX$ $pgp1$ Plasmid helicase 2715^{b} $1,354/1,356$ $IKVWN\underline{X}$ $pgp2$ Plasmid hypothetical protein 2715^{b} $5/1,065$ $MVTGW\underline{M}ISPRSDAQWNENSRX$	ct10425 (ct172)		Pseudogene	514407			
$pgp4$ Plasmid hypothetical protein 460^b $270/309$ ALIMLMRLDKSPVX $pgp3$ Plasmid virulence protein 1262^b $331/795$ ALIMLMRLDKSPVX 1 $pgp1$ Plasmid helicase 2715^b $1,354/1,356$ IKKVWX $pgp2$ Plasmid hypothetical protein 2715^b $5/1,065$ MVTGWMISPRSDAQWNENSRX 1	CDS7 (pgp5)	pgp5	Plasmid hypothetical protein	2296	165/795	SGLGA <u>N</u> RLDDKSPVX	[S52N; 61/264]
$pgp3$ Plasmid virulence protein 1262^b $331/795$ ALIMLMRDKSPVX $pgp1$ Plasmid helicase 2715^b $1,354/1,356$ IKKVWX $pgp2$ Plasmid hypothetical protein 2715^b $5/1,065$ MVTGWMISPRSDAQWNENSRX	CDS6 (pgp4)	pgp4	Plasmid hypothetical protein	460 ^b	270/309	ALIMLMRLDDKSPVX	[I91N; 100/102]
pgp1 Plasmid helicase 2715 ^b 1,354/1,356 IKKVW <u>X</u> pgp2 Plasmid hypothetical protein 2715 ^b 5/1,065 MVTGW <u>MISPRSDAQWNENSRX</u>	CDS5 (pgp3)	pgp3	Plasmid virulence protein	1262 ^b	331/795	ALIMLNRLDDKSPVX	[I91N; 100/102]
pgp2 Plasmid hypothetical protein 2715 ^b 5/1,065 MVTGW <u>M</u> ISPRSDAQWNENSRX I	CDS3 (pgp1)	pgp1	Plasmid helicase	27150	1,354/1,356	IKKVWX	[X451X; 451/451]
	CDS4 (pgp2)	pgp2	Plasmid hypothetical protein	2715 ^b	5/1,065	MVTGW <u>M</u> ISPRSDAQWNENSRX	[N6M; 21/354]

^cC. trachomatis serovar D (NC_000117) gene nomenclature.

^dHimar insertion delineated by underscore; first amino acid shift delineated by bold highlighting and shown in square brackets; stop codon delineated by X. Data were calculated as follows: (protein length after insertion)/ (wild-type protein length).

^eSlow-growing mutants (mutants that required six or more passages to achieve visibly infectious stocks).

Complete C-terminal sequence, QFRIVTGWMISPRSLVAQRTFEKPPCKAVFSFSEQEITRRPKRSQEDHLVNQIKYFX.

Complete C-terminal sequence, EAGKINRLDDKSPVFGSSENLRKTALQGGFFVFRARDYAQTKTISRSSCX.

"Denotes coding regions that were shared as nonsense mutants as reported previously by Kokes et al. (36).

TABLE 1 (Continued)

within the first 60% of the coding region, providing higher confidence that the Tn insertion is disruptive to the normal protein function. Four of the insertions (*ct015*::Tn, *ct054*::Tn, *ct088*::Tn, and *ct107*::Tn; Table 1) extended the normal protein sequence, which may have little effect on protein function. Sixteen of the Tn insertions occurred in hypothetical proteins, while the rest occurred in a variety of genes with contributions to diverse biological functions. For example, five Tn insertions (*ct298*, *ct333*, *ct470*, *ct586*, and *ct575*) were involved in DNA repair mechanisms, four (*ct054*, *ct248*, *ct489*, and *ct592*) were were involved in central metabolism, and four (*ct404*, *ct540*, *ct829*, and *ct830*) encoded methyl modification enzymes. Two polymorphic membrane protein-coding regions (*ct867* [*cdu2*] and *ct868* [*cdu1*]). Of note, 16 of the Tn insertions occurred in genes that also incurred nonsense mutations following chemical mutagenesis (36), for a total of 54 new gene disruptions generated.

Twenty-three mutant strains had Tn insertions within an intergenic region (Table 2). Many of these insertions occurred between genes with divergent coding directions as well as between those with shared coding directions, both of which could result in disruptions to gene expression. Insertions upstream of eight (*ct690, ct792, ct793, ct182, ct328, ct343, ct387,* and *ct472*) of the diverging genes occurred within 80 nucleotides (nt) of start codons. On the basis of the determinations of transcriptional start sites located on average 50 nt upstream of start codons (40) and promoters covering at least an additional 50 nt, these Tn insertions likely disrupt transcription initiation and gene expression. For insertions between genes with shared coding directions, three (*ct343, ct373,* and *ct423*) have transcriptional start sites reported upstream of or near (within 40 nt) the insertion potentially disrupting gene expression. Three Tn insertions also occurred between genes with convergent coding directions. While the possibility of disruption of gene expression (effecting termination or noncoding RNAs [ncRNAs]) cannot be ruled out, it is less likely that these flanking genes are affected by these Tn insertions.

Tn insertions also occurred within the chlamydial plasmid. Four (*pgp1*, *pgp2*, *pgp4*, and *pgp5*) of the coding regions incurred an insertion, although the Tn insertion in *pgp1* was at the second to last codon and may have little effect on the protein generated. Two Tn insertions were also found in the intergenic region of the convergent *pgp7* and *pgp8* genes. Two prior studies have investigated the requirement of individual genes for plasmid maintenance (41, 42). Both studies supported the idea that products of the *pgp1*, *pgp4*, and *pgp5* genes are not required; however, the presence of almost all of the *pgp2* coding region was found to be required for plasmid maintenance. As such, it was unexpected for a Tn insertion in *pgp2* which results in a severely truncated coding region to be identified. This may indicate that there is a product (e.g., ncRNA) within the coding region, instead of the *expected* Pgp2 protein product, that is key for plasmid replication. In support of this, the *pgp2*::Tn mutant strain was grown without antibiotics for two passages and the plasmid was found to still be present by PCR analysis (data not shown).

In vitro growth characteristics of transposon mutants. While most of the transposon mutant clones did not exhibit noticeably slow growth or poor production of infectious progeny during initial selection and tissue culture propagation, more-subtle growth rates or morphologic differences may be associated with certain mutants. To discover potential defects in infection, growth, or developmental cycle processes associated with transposon mutant clones, temporal analyses of infectious progeny production and bacterial morphologies and quantitative assessment of inclusion sizes were performed for a subset of 16 Tn mutants (Fig. 2; see also Fig. 3 and Fig. S2 and S3). In addition to the parental strain, a clone with a Tn insertion between converging genes (*ct383/4*::Tn) was also evaluated.

Analyses of the production levels of infectious progeny (EB) of parental (wild-type [WT]) and individual Tn mutant clones were performed on lysates in 6-h increments between 18 and 42 h postinfection (hpi) (Fig. 2). Progeny production levels reflect

mBio

Flanking CTL genes (CT ³)::Tn bla Flanki ct10024/0025 (ct655/656) Conv ct10029/0060 (ct690/691) Dive ct10070/0071 (ct701/702) Conv ct10111/0112 (ct792/793) Shar ct10160/0162 (ct792/793) Dive ct10322/0323 (ct076/077) Dive ct10339/0340 (ct084/085) Shar	Flanking gene orientation	Genomic position	Gene insert site/total gene	
	king gene orientation			
		of TN insertion ^a	length (bp)	Potential gene function disruption
	Converging	32332		
	Diverging	72505	50/110 nt upstream of	<i>dppD</i> (oligopeptide ABC transporter ATP-
	Converging	87381	dppD/phoU	binding protein) and <i>phoU</i> (phosphate
				transport)
	Shared direction	142632	98 nt upstream of <i>trm</i> A	trmA; 23S rRNA (uracil-5-)-methyltransferase
			(CTL0111)	
	Diverging	208013	57/12 nt upstream of	mutS; DNA mismatch repair protein
			mutS/hypothetical	
	Diverging	401583	176/484 upstream of	
			hypothetical/troA	
	Shared direction	419884	13 nt upstream of	<i>CTL0339;</i> Phopholipase D
			CTL0339	
ct10408/0411 (ct154) Shar	Shared direction	501211	646 nt upstream of	
			CTL0408	
ct10417/0418 (ct161/162) Shar	Shared direction	508108	56 nt upstream of	
			hypothetical (CTL0417)	
ct10433/0434 (ct181/182) Dive	Diverging	522045	287/80 nt upstream of	kdsB; CMP-2-keto-3-deoxyoctulosonic acid
			hypothetical/kdsB	synthetase
ct10482/0483 (ct230/231) Shar	Shared direction	576139	134 nt upstream of <i>yocR</i>	yock; Sodium-dependent transporter
			(CTL0483)d	
ct10581/0582 (ct327/328) Dive	Diverging	687877	161/34 nt of <i>trpC/tpiA</i>	<i>trpC</i> (phosphoribosylanthranilate isomerase)
				and <i>tpiA</i> (triosephosphate isomerase)
ct10596/0597 (ct342/343) ^e Shar	Shared direction	709636	110 nt upstream of <i>rpsUd</i>	<i>rpsU</i> ; S21 ribosomal protein
	Diveraina	710369	13/297 nt upstream of	
	n 		tsaB/lon	
C+10614/0615 (C+360/361) Shar	shared direction	730550	67 nt unstream of	
CT10033/0034 (CT3/8/3/9) SNAF	snared airection	755000 755000	53 nc upstream <i>pg1</i>	
	, et gitte			
	Diverging	759051	218/69 nt upstream of	
	Converging	765276	hypothetical proteins	
ct10682/0683 (ct423/424) Shar	Shared direction	811934	25 nt upstream of rsbV	rsbV; anti-sigma factor antagonist
			(CTL0683)	
tt471/472)	Diverging	864902	460/18 upstream of	
CDS1/2 ($pgp7/8$) Conv	Converging	5189 ^b	hypothetical proteins	
	Converging	5232 ^b		
Prosition generated using C trachomatic GV 434/Bu (NIC 010387)	/Biii (NC 010287)			
^b Position generated using C. <i>trachomatis</i> LGV 434/Bu plasmid (NC 021051	/Bu plasmid (NC 021051.1).			
^c C. <i>trachomatis</i> serovar D (NC_000117) gene nomenclature.				
^d Transcription start site reported (40) upstream of coding region.	f coding region.			
eSlow-growing mutants (mutants that required six or more passages to achieve visibly infectious stocks).	k or more passages to achieve	visibly infectious stocks).		

LaBrie et al.

TABLE 2 C. trachomatis intergenic region transposon insertion mutants




FIG 2 Progeny production of Tn mutants from 18 to 42 hpi. L929 cells were infected with the WT (parental) strain or a Tn insertion mutant clone (gene with Tn insertion is indicated) in triplicate. Quantities of inclusion-forming units (IFU) were determined from lysates at 18, 24, 30, 36, and 42 hpi. Mutants showed progeny production patterns similar to those of the WT parental L2 clone (A), those with significantly decreased progeny production at multiple time points (B), or those with significantly enhanced progeny production at one or more time points (C). Data are shown as means and SD of results from triplicate wells. Statistical significance was calculated using Student's two-tailed unpaired *t* test with a superscript "a") or at 24, 30, 36, and 42 hpi (indicated with a superscript "b"). Progeny production was significantly increased at 30 and 42 hpi (indicated with a superscript "c") or 24 and 30 hpi (indicated with a superscript "e").




FIG 3 Inclusion sizes of Tn mutant strains. Inclusion size was measured at 24, 36, and 42 h postinfection for each Tn mutant and parental strain (WT). Mutant strains are displayed as stacked bars showing inclusions larger than the WT inclusions (checked), equal to the WT inclusions in size (solid), or smaller than the WT inclusions (striped). Triplicate samples were evaluated, with 250 to 1,000 inclusion areas measured per sample. **, P < 0.005; *, P < 0.05 (unpaired Student's t test).

bacterial replication as well as ability to convert into the infectious EB form. Defects in either of these can be detected with this approach, enabling a more focused analysis of candidate mutant strains. Three distinct growth phenotypes were observed among In mutants; normal, decreased, and increased progeny production relative to the parent strain. Almost half (7 of 16) of the Tn mutants displayed EB production levels and timing similar to those seen with the WT, as did the clone with a Tn insertion between two converging genes (ct383/4::Tn) (Fig. 2A). However, four mutants (ct036::Tn, ct350:: Tn, ct590::Tn, and ct732::Tn) displayed significant deficiencies in progeny production at two or more time points (Fig. 2B). At 24 hpi, strain ct590::Tn (hypothetical) displayed progeny production levels that were almost 2 log-fold lower whereas ct036::Tn and ct732::Tn (ribH) mutants displayed progeny production levels that were about 1 log-fold lower. An interesting observation was the enhanced progeny production of four mutant clones (ct153::Tn, ct148::Tn, ct339::Tn, and ct550::Tn), which was most notable at 24 hpi. Clones ct153::Tn and ct148::Tn maintained this enhanced level at 30 hpi, with all of the mutant clones matching the parental clone at 36 and 42 hpi (Fig. 2C). Of the Tn mutants evaluated, ct696::Tn displayed the most contrasting and slowest growth phenotype, with propagation requiring up to 5 days before passage was successful and with undiluted cell lysate and levels of inclusion-forming units (IFU) below 10/ml (data not shown). Overall, progeny production analysis revealed that defects were observed for many of the Tn insertion clones, albeit most of the data were within a log-fold difference range.

Defects in the temporal expansion of an inclusion could suggest that a gene product plays a role in many aspects of chlamydial growth, and so, the area of inclusions was calculated at 24, 36, and 42 hpi. The data shown in Fig. 3 highlight that the inclusions for 5 Tn mutants (*ct015*::Tn, *ct383/4*::Tn, *ct392*::Tn, *ct404*::Tn, and *ct868*::Tn) were significantly smaller than that for the parental strain at 24 hpi. Only mutant *ct015*::Tn maintained smaller inclusions sizes at 36 and 42 hpi, with *ct392*::Tn, *ct404*::Tn, and *ct590*::Tn displaying smaller inclusions at 42 hpi. Two Tn mutants (*ct339*::Tn and *ct550*::Tn) had inclusions larger than the parental inclusions at 24 hpi, with the *ct550*::Tn

inclusions maintaining a larger size than the parental inclusions at 36 hpi. Interestingly, *ct550*::Tn was the only mutant to display a correlation between progeny production and inclusion size (Fig. 2C; see also Fig. 3), both of which showed increases relative to the parental data.

To discover if any abnormal morphologic phenotypes (bacterial or inclusion) are associated with this subset of transposon mutant clones, confocal microscopy was applied to immunostained parental and transposon mutants at 24, 36, and 42 hpi (Fig. S2). Almost all of the Tn mutants displayed inclusions that were localized near the nucleus as well as general shapes of the inclusion and reticulate bodies (RBs) that were similar to those seen with the parental strain. Notable exceptions included mutant *ct048*::Tn, which contained larger but fewer RBs within the inclusion at 42 hpi. Similarly to the growth assessments, the *ct696*::Tn inclusions and bacterial morphologies were among those that were the most highly contrasting. The inclusions were ill defined, and the few reticulate bodies present were dispersed in the cytoplasm (Fig. S3).

In all, cell culture growth and phenotype assessments revealed that many Tn mutant strains displayed defects that represented significant differences from the parental strain. However, these defects were relatively subtle, with peak EB titers fluctuating by approximately with 1 log fold, and inclusion sizes were often within 10% to 15% of sizes seen with the parental strain, although the inclusions seen with the *ct015*::Tn mutant were over 30% smaller than the parental inclusions. The extreme exception to these trends was mutant *ct696*::Tn, with gross defects in EB production and in bacterial and inclusion morphologies. Moreover, there was little correlation between EB production titers and inclusion sizes, with the exception of the hypothetical *ct550* encoding gene, which displayed more and larger inclusions.

In vivo assessment of infectivity. While the majority of the Tn mutants analyzed showed minimal morphologic or growth differences under *in vitro* cell culture conditions, some gene products may be of greater significance under the more physiologically relevant, diverse, and challenging conditions associated with mammalian infection. In order to assess this, a mouse model of *C. trachomatis* infection was implemented. Unfortunately, *C. trachomatis* L2 administered vaginally in mouse infections is readily cleared, rarely and unreliably ascends to the upper genital tract, and is not associated with the development of pathology (43, 44). As such, the transcervical model was used to deliver infectious doses directly into uterine horns of the upper genital tract (45). Previous experiments have shown that transcervical *C. trachomatis* infection and that the bacteria cleared (nearly 3 log-fold) after ~9 days postinfection (45). Therefore, to discover potential deficiencies in infection and replication in the upper genital tract, mice were infected with individual Tn mutants and harvested on day 5, within the period of the peak of *C. trachomatis* L2 infection.

Twelve Tn mutants that were evaluated for growth and morphology, including the parental strain and ct383/4::Tn clones, were used to infect mice and assess bacterial burden (Fig. 4). Most of the Tn mutants displayed infection levels similar to those seen with the parental C. trachomatis strain; however, two Tn mutant clones showed statistically significant decreases in levels of detectable organisms in the uterine horns compared to parental L2 (P < 0.05; Fig. 4). Disruptions in a FAD-dependent monooxygenase (FDM) (ct148) and the cdu1 deubiquitinase (ct868) were followed by a nearly 0.5 log-fold to 1 log-fold decrease in the levels of detectable organisms compared to the WT. Mutant ct148::Tn showed a striking deficiency with respect to detectable organisms, with 4 of 10 infected animals showing infection levels falling 2-log below the median of infection for WT-infected animals. Interestingly, mutant ct148::Tn displayed a slightly enhanced level of production of infectious progeny in vitro (Fig. 2C) relative to the parental strain. Conversely, mutant ct868::Tn showed no decreased growth rates in vitro, suggesting that cdu1 is dispensable for optimal growth in cell culture but that the absence of the corresponding gene product is important for growth in vivo. Importantly, the




FIG 4 *In vivo* infections using Tn mutants with a transcervical mouse infection model. Groups of 10 female C57BL/6 mice were infected transcervically with 5×10^5 IFU of either parental (WT) *C. trachomatis* or Tn mutants as indicated. Five days postinfection, genital tracts were harvested and DNA was purified from uterine horns. Bacterial burdens were calculated as levels of *Chlamydia* genomes relative to host genomes, and ratios are shown as box-and-whisker scatter plots representing data from 10 mice. *, P < 0.05 (unpaired Student's *t* test).

bacterial burdens seen with *ct868*::Tn infections were very similar to the levels previously reported from a study performed with this mutant strain (46), providing additional confidence in the reproducibility of these observations. While the results were not statistically significant, two additional mutants exhibited a noticeable decrease in bacterial burden, namely, mutants *ct036*::Tn (hypothetical) and *ct153*::Tn (membrane attack complex/perforin [MACPF]). Mutant *ct036*::Tn was among the clones that displayed lower levels of progeny production whereas mutant *ct153*:Tn produced more infectious progeny than the parental clones.

Clearly, further temporal and spatial analyses in mice, detailed molecular and cellular studies, and genetic complementation are required for a more complete understanding of the role and function of gene products with demonstrated deficiencies in mice. However, these comparative *in vitro* and *in vivo* observations highlight that certain gene products may exhibit a more pronounced fitness defect in mice, prompting a focus on these gene products.

In silico analyses of CT339 support functional identification of CT339 as DNA uptake protein ComEC. *Chlamydia* bacteria have been demonstrated to acquire and integrate DNA within or between certain *Chlamydia* species (24, 25, 47–49). Given the expected importance of lateral gene transfer in the evolution and adaptation of *Chlamydia*, as well as the paucity of identifiable gene candidates that may play a role in this fundamental process, the Tn insertion in *ct339* was of particular interest for a more in-depth analysis among the members of the subset of Tn mutants. CT339 shares similarity with multiple competence-associated protein families and conserved domains, including ComEC (E values ranging from 2.33e–03 to 4.40e–24). In both Gram-negative and Gram-positive bacteria, ComEC plays a key role as an inner membrane protein, transporting single-stranded DNA (ssDNA) into the cytosol of the bacterial cell during natural DNA acquisition (50, 51). To further investigate the hypothesis that *ct339* encodes a ComEC homolog, *in silico* analyses were performed.

ComEC is an integral membrane protein that typically has 9 to 12 transmembrane helices and a conserved metal-binding motif, $H\Phi xx\Phi SG\Phi H$ (" Φ " indicates hydrophobic residues; Fig. S5A) (50). Topology modeling of CT339 using five hydropathy programs resulted in a range of 8 (SPLIT) to 11 (MEMSAT) predicted transmembrane segments, which is similar to the proposed 9 to 12 transmembrane regions of ComEC (50). As previously described for ComEC (50), HMMTOP prediction identified a large N-terminal loop within CT339 spanning residues 94 to 256 with a potentially stabilizing disulfide bond formed by C148-C167, as well as the competence domain containing the conserved metal-binding motif $H\Phi xx\Phi SG\Phi H$. For all five hydropathy programs, an extracellular N-terminal domain and intracellular C-terminal domain were predicted, similar to those of ComEC (50). In contrast to the predicted topology of ComEC, none of the predictive transmembrane helices for CT339 display an amphipathic character and no segments are predicted to be buried parallel to the membrane surface (Fig. S5B) (50). On the basis of these in silico data, a transmembrane topology model was designed (Fig. S5C) supporting the structural homology between CT339 and ComEC, specifically within conserved competence domains and the N-terminal loop. Using this model, the Tn insertion site was identified within the last transmembrane segment, eliminating G490 through the carboxyl end of the protein, L509. It has been proposed that ComEC from Bacillus exists as a homodimer within the bacterial membrane and forms a pore for DNA uptake (50). Consequently, disruption of either the N-terminal loop or the C-terminal loop, as is observed with ct339::Tn insertion, may prevent proper folding and formation of this pore, therefore abolishing the ability to acquire DNA.

Requirement of CT339 for DNA uptake via lateral gene transfer. As previously mentioned, the transposon insertion in *ct339* provided an opportunity to experimentally evaluate the importance of this gene product in lateral gene transfer and to support the *in silico* prediction of CT339 as a functional homolog to ComEC. Lateral gene transfer, including the transfer of specific antibiotic resistance genes, has been demonstrated to occur readily during coinfections with *C. trachomatis* strains (intraspecies) that encode different OmpA serotypes (25, 47). To evaluate the importance of CT339 in lateral gene transfer, intraspecies coinfections with different parental OmpA serovar strains (L1 or L2) encoding different antibiotic markers (L1 *tetr* or L2 *bla*) under conditions of dual antibiotic selection were performed (Fig. 5A). Each L2 strain used had either an intact (*ct383/4*::Tn *bla*) or a disrupted (*ct339*::Tn *bla*) *ct339* gene. The relative levels of genetic transfer, particularly of the antibiotic marker, of the OmpA serovar strains were assessed by determining the quantity of progeny generated that exhibited each parental OmpA serotype (e.g., *L1* versus *L2*).

Intraspecies coinfections and dual antibiotic selection with tetracycline-resistant C. trachomatis L1 (L1::tetR) and either the transposon control mutant L2 ct383/4::Tn bla or the proposed ComEC homolog disrupted clone L2 ct339::Tn bla were performed (Fig. 5) (Table 3). When C. trachomatis L1::tet^r and L2 ct383/4::Tn bla were used for coinfections, high levels ($>6 \times 10^5$ IFUs) and nearly equal amounts of recombinant progeny displaying either parental OmpA (58% L1 and 42% L2) were observed. The relatively equal frequencies support the idea that DNA uptake and lateral transfer of the tetR gene from the L1 strain into to L2 genome occurred as efficiently as that of the *bla* gene from the L2 strains into the L1 strain. In contrast, when the same L1::tet^r parent was used in a coinfection with L2 ct339::Tn bla, similar levels of L1 OmpA-expressing progeny with dual resistance were detected (5.17×10^5 IFUs) but nearly 100-fold-lower levels of progeny displaying L2 OmpA were observed (7×10^3 IFUs) (Table 3). This supports the idea that DNA uptake and transfer of the bla gene into L1, which has an intact ct339 gene, were as efficient as the previous cross. In contrast, tetR was found to be incorporated into the L2 genome with the ct339::Tn bla mutation at a 2 log-lower level. While this supports the idea of the importance of CT339 (comEC) in DNA acquisition, the low level of tetR resistance suggests that the comEC gene product may not be essential for the process.




FIG 5 Graphic depiction of intraspecies recombination to evaluate functional role of CT339 in lateral gene transfer. (A) Parental C. trachomatis with L1 ompA (blue circle, blue tick) encoding tetr (red tick) crossed with C. trachomatis with L2 ompA (gray circle, gray tick) containing either ct383/4::Tn bla (green tick) or ct339::Tn bla (green tick) to enable lateral gene transfer of resistance markers and selection of dual resistance chimeric clones (blue and gray circles). (B) Similar experiment using parental C. trachomatis with F ompA (yellow circle, yellow tick) encoding tetr (red tick) crossed with C. trachomatis with L2 ompA (gray circle, gray tick) containing either ct383/4::Tn bla (green tick) or ct339::Tn bla (green tick). Serovarspecific antibodies revealed the relative distributions of resulting dually resistant chimera organisms (yellow and gray circles). Quantitative evaluations of resulting chimeras are provided in Table 3. The resulting mix of L1 (blue) and L2 (gray) or of F (yellow) and L2 (gray) reflects the almost equal amounts of resulting OmpA serovar seen when the control ct383/4::Tn was used. In contrast, virtually all of the resulting organisms contained a L1 (blue) or F (yellow) ompA when ct339::Tn was used, indicating that the tet^r gene, near ompA, was unable to be transferred into the L2 ct339::Tn mutant (gray). (C) Recombinants resulting from the experiment represented in panel A containing L1 ompA (blue circle, blue tick) encoding tetr (red tick) and the ct339::Tn bla (green tick) were crossed with the L2 ct339::Tn bla mutants. All resulting progeny contained the L1 ompA (blue tick).

An alternative hypothesis to explain the low level of L2 OmpA-positive samples seen following the L1::*tetR* and L2 *ct339*::Tn *bla* crosses is that, instead of poor uptake of the *tetR* gene into L2 *ct339*::Tn *bla* organisms, a region of DNA that included the L2 *ompA* gene and the *ct339*::Tn *bla* marker was transferred and integrated into L1 parent organisms. This would "convert" the L1 to an L2 OmpA serotype. To investigate this hypothesis, whole-genome sequencing was performed on several individual recombinants from each coinfection (L1::*tet*^r versus L2 *ct339*::Tn *bla* or L2 *ct383*/4::Tn *bla*). As

TABLE 3 Frequency of C. trachomatis	serotype (OmpA) following coinfectio	n and dual antibiotic selection
-------------------------------------	--------------------------------------	---------------------------------

C. trachomatis genotype	C. tractomatis serotype and frequ	C. tractomatis serotype and frequency (%)		
L1:: $tet^r \times L2 \ ct383/4$::Tn bla	L1 OmpA; 8.67 (\pm 0.58) $ imes$ 10 ⁵	L2 OmpA; 6.33 (\pm 0.58) $ imes$ 10 ⁵	L2 OmpA progeny; 42.2 (±1.99)	
L1:: $tet^{ m r}$ $ imes$ L2 ct339::Tn bla	L1 OmpA; 5.17 (±0.43) $ imes$ 10 ⁵	L2 OmpA; 7.00 (\pm 1.00) $ imes$ 10 3	L2 OmpA progeny; 1.12 (±0.40)	
F:: $tet^{ m r}$ $ imes$ L2 ct 383/4::Tn bla	F OmpA; 4.33 (\pm 1.15) $ imes$ 10 ⁵	L2 OmpA; 3.33 (\pm 0.58) $ imes$ 10 ⁵	L2 OmpA progeny; 44.0 (±6.26)	
F:: $tet^{ m r}$ $ imes$ L2 $ct339$::Tn bla	F OmpA; 1.33 (\pm 0.61) $ imes$ 10 ⁴	L2 OmpA; 5.33 $ imes$ 10 $^{ m o}$ (±1.53)	L2 OmpA progeny; 0.05 (±0.01)	




FIG 6 Schematic representation of regions and genome compositions of *C. trachomatis* recombinant clones following lateral gene transfer with selected Tn mutants. Blue bars represent the regions of the genome from the L1/*tet*^r parent. Gray bars represent regions from either L2 *ct383/4::*Tn *bla* or L2 *ct339::*Tn *bla* parent. Percentages of the *C. trachomatis* L2 genome present are indicated (right). (A) Progeny genomes from crosses between tetracycline-resistant *C. trachomatis* L1 and *ct383/4::*Tn *bla*. (B) Progeny genomes from crosses between tetracycline-resistant *C. trachomatis* L1 and *ct339::*Tn *bla*.

indicated in Fig. 6A, L1:: tet^r and L2 ct383/4::Tn bla crosses yielded genomes that predominantly reflected the OmpA serotype (mostly blue for L1 OmpA and mostly gray for L2 OmpA). Specifically, L1 or L2 OmpA-positive samples had an average of 78% L1 or 84% L2 genomic composition, respectively. In contrast, L2 OmpA-positive samples generated after a L1:: $tet^r \times L2 ct339$::Tn bla coinfection had minimal L2 genome in the resulting clones (L2 [gray]; Fig. 6B), with an average genomic L2 composition of 36%, representing less than half the level observed in L1:: $tet^r \times L2 ct383/4$::Tn bla crosses. Matching the levels of antibiotic resistance transfer in ct339 intact samples (L2 ct383/4::Tn bla), L1 positive OmpA samples showed an average of 80% L1 genomic composition (blue; Fig. 6B). These data support the hypothesis that DNA regions containing an L2 *ompA* gene and the ct339::Tn bla marker were most likely acquired by L1 parent clones through lateral gene transfer instead of tetR acquisition of a L2 *ompA* ct339::Tn bla organism.

The generation of L1::*tet'/ct339*::Tn *bla* recombinant clones provided an additional opportunity to further investigate the essentiality of *ct339* for DNA acquisition and genome incorporation. These clones were used in coinfections with the parent L2 *ct339*::Tn *bla* clone with dual antibiotic selection (Fig. 5C). If *ct339* were essential for DNA acquisition and incorporation, then all resulting clones should be only L1 OmpA positive, as the L2 *ompA* gene would not have the ability to be transferred and incorporated into the L1 genome to enable a serotype conversion. However, if *ct339* is only partially required, then a mix of L1 and L2 OmpA populations would be expected to be observed following coinfection and antibiotic selection (i.e., with the *tetR* marker taken up and incorporated into the L2 genome or L2 OmpA transferred and incorporated into the L1 genome). Three independent coinfections revealed that only L1 OmpA-positive inclusions were observed with extensive (~5 × 10⁷) levels of IFUs utilized per evaluated cross (data not shown). Additionally, transformation of the L2 *ct339*::Tn *bla* mutant was also attempted using an inducible green fluorescent protein (GFP) plasmid (pTLR2-GFP) and chloramphenicol for selection. Every attempt to transf

form parental L2 samples that had an intact chromosomal *ct339* gene was successful using the inducible plasmid. In contrast, none of the attempts to transform L2 *ct339*::Tn *bla* with the plasmid were successful (data not shown).

To further address the functionality of CT339 in lateral gene transfer, similar coinfections and dual-selection experiments were performed with tetracycline-resistant *C. trachomatis* serovar F (F::*tet*^r). Using strains that are more phylogenetically distant (52) reduces the challenge of delineating highly similar genomic crossover regions. Three independent crosses and selections were performed with *C. trachomatis* F::*tetR* and either *C. trachomatis* L2 *ct383*/4::Tn *bla* or *C. trachomatis* L2 *ct339*::Tn *bla* (Fig. 6B). As observed in the L1 × L2 *ct383*/4::Tn *bla* experiments (Fig. 6A) (Table 3), approximately half of the inclusions with an intact *ct339* exhibited either OmpA F (56%) or L2 (44%) seroreactivity (Table 3). Similarly to the L1::*tet*^r versus L2 *ct339*::Tn crosses, more than 99.94% of the F::*tet*^r × L2 *ct339*::Tn inclusions were positive for only OmpA F (Table 3). Taken together, these data support the hypothesis that *ct339* is critical for DNA uptake and is likely serving as a ComEC functional homolog in *C. trachomatis*.

DISCUSSION

There have been many recent firsts in the area of genetically modifying *Chlamydia* trachomatis, including chemical mutagenesis (35-37), group II intron gene disruption systems (29), allele replacement (33, 34, 53), inducible gene expression (28, 54), and targeted gene repression (32). The development and validation of a transposon mutagenesis system using the Himar1 transposase, as presented here, provide another first and a key advance for the Chlamydia field. The data presented demonstrate that the transposase is functional within Chlamydia and that the use of the nonreplicative plasmid results in mutant C. trachomatis clones containing a single genomic insertion. The insertion sites are readily discovered and can be characterized by common PCR-sequencing-based techniques. These insertion mutations are stable, even without antibiotic selection, limiting the chances of genetic reversion. Support for this stability was provided by the multiple passages and large-scale growth conditions (3 to 5 passages for expansion and spinner flask cultivation), without antibiotics, employed prior to animal studies as well as by the confirmation of Tn insertions in samples prior to and after animal infections. A primary benefit of this single-insertion, random mutagenesis approach is the ability to associate a specific genetic disruption with a resulting phenotype. While polar effects can occur as the result of a Tn insertion, such effects can be viewed as a benefit, as an insertion can enable researchers to focus on a selected but known pool of candidates associated with a particular phenotype. As demonstrated by the insertion disruption of ComEC homolog CT339 and by the subsequent biological studies related to lateral gene transfer in Chlamydia presented here, the scientific contributions of this molecular tool and approach are expected to be very useful for Chlamydia studies.

Notwithstanding these benefits, the present report also highlights the relatively low efficiency associated with Chlamydia transposon mutagenesis and its current limitations for large-scale studies. While most of this restriction is thought to be due to the extremely poor transformation efficiency associated with C. trachomatis, the low insertional efficiency may also suggest that high numbers of genes are essential for growth and completion of the chlamydial developmental cycle under cell culture conditions. A total of 70 genes incurred a Tn insertion in this study, while the results of a random chemical mutagenesis study performed by Nguyen and Valdivia (37) indicated that 84 protein-coding genes incurred a nonsense mutation with limited in vitro growth effects. Fifteen of the 84 genes were also disrupted in that Tn insertion analysis, providing a total of 139 genes that have disruptions in the coding region following ethyl methanesulfonate (EMS) mutagenesis or Tn insertion. This represents around 15% of the encoding gene products. While the number of genes that are essential for growth under tissue culture conditions is currently unknown, the relative low level of overlap of disruptive Tn and EMS mutations suggests that many more C. trachomatis genes may tolerate disruption.

Among the more striking observations were the enhanced in vitro growth of a ct148::Tn mutant clone and the almost log-fold decreased infectivity in mice (Fig. 2C; see also Fig. 4). The Tn insertion occurs in the first third of the coding region, providing higher expectations that the function of this gene product is indeed disrupted. The gene downstream from ct148 is oriented in the opposite direction, although there is a gene 200 bp upstream. This distance and the reported location of the transcriptional start site 85 bp upstream of ct148 (40) support the idea that there is a single gene operon and that polar effects from this Tn insertion are limited. The ct148 gene encodes a FAD-dependent monooxygenase (FDM). Monooxygenases are known to play roles in multiple metabolic pathways, and, as Iliffe-Lee and McClarty showed previously (55), C. trachomatis contains an almost complete and functional Embden-Meyerhof glycolysis and pentose phosphate pathway. For a number of other bacteria, it has been shown that metabolic proteins are nonessential for growth *in vitro* and yet play vital roles *in* vivo (8, 56-58). Many of the key nutrients required for survival are provided in media used to grow these pathogens. Thus, any detrimental effect that a mutation may have may not be as easily identified in vitro. In contrast, in vivo infections provide physiological conditions for growth which are not provided via media, enabling the effects of these mutations to be detected. While the specific role of ct148 in infectivity remains unknown, the in vivo data provide support for the idea that components that are seemingly nonessential for Chlamydia growth in tissue culture may, in fact, play significant roles in mammalian models of infection. A similar discrepancy between in vitro and in vivo growth outcomes was also observed with the ct868::Tn clone which disrupts *cdu1*. Cdu1 is a deubiguitinase, and it has been shown that disruption of this protein results in an increase of ubiquitination of Mcl-1 (46). Cdu1 has also been demonstrated to be capable of inhibiting host NF- κ B, which represents a central regulator of numerous immune responses, including cytokine secretion and T-cell proliferation, and a vital host defense against intracellular pathogens (59-61). Overall, these observations highlight the challenges and potential discrepancies of functional studies performed in tissue culture, strengthening the necessity for analysis using in vivo models of infection.

The most striking phenotype was that of the observable growth and morphological deficiencies of strain ct696::Tn (see Fig. S2 in the supplemental material). First classified as a slow grower, approximately 8 days of growth of ct696::Tn were required for for detection of visible inclusions by phase microscopy, and subsequent analysis by confocal microscopy identified decreased numbers of RBs/EBs as well as the absence of the nuclear localization typically observed with Chlamydia inclusions. Due to its genetic location near the genes encoding the known type III secretion (T3S) effector proteins CT694 and CT695, it has been hypothesized that ct696 may also play a role in T3S; however, studies have suggested that this may not be the case. Secretion of CT696 was not observed in previous studies employing a heterologous T3S system with Yersinia enterocolitica (62, 63), and ct696 transcription was found to occur independently of ct694 (64, 65). The ct696 gene (ct/0065) was also disrupted using allelic exchange (33); however, growth phenotypes were not provided. CT696 is a conserved Chlamydiaceae hypothetical protein with no sequence or conserved domains shared outside the members of this family. Using the bacterial localization tool PSORTb (66), CT696 was predicted to be a cytosolic protein. While additional in-depth analysis is required to evaluate the role and function of CT696 in growth and inclusion formation, this observation provides support for these efforts as well as a good example of the utility of this transposon approach for discovery of genes important to the biology of Chlamydia.

Along with gaps in understanding the mechanisms of development and *in vivo* infectivity of *Chlamydia*, there is also limited information regarding the components and mechanisms for lateral gene transfer. The absence of lateral gene transfer in organisms that contain the *ct339*::Tn insertion provides compelling support for the essential contribution of this gene product to this fundamental evolutionary process. CT339 is predicted to be a multipass transmembrane protein with domain similarity to

ComEC, the competence uptake protein seen in many bacteria. According to the protein family database (pfam) architecture, genes encoding proteins with this competence motif often exist near genes encoding proteins that include lactamasesuperfamily domains, which are predicted to regulate the competence operon (67). Baker et al. recently showed the ComEC from *Bacillus* contains a β -lactamase-like domain within its C-terminal loop (approximately residues 494 to 763), potentially functioning as a nuclease (68). While it is widely accepted that double-stranded DNA (dsDNA) must first be converted into ssDNA for uptake and incorporation into recipient genomes, the nuclease responsible for this activity in Bacillus remains unknown; thus, it has been hypothesized that this lactamase-like domain within ComEC may be fulfilling this role. As a potential homolog of ComEC, a Tn disruption in the C terminus of CT339 may prevent the degradation of dsDNA into ssDNA and would decrease the ability of Chlamydia to undergo lateral gene transfer. However, Pfam and SMART (69) analyses of CT339 did not identify a similar lactamase-like domain near the C terminus. Rather, genome analysis of C. trachomatis identified RNase Z (CT346), a lactamasesuperfamily protein neighboring CT339—suggesting that this protein may instead be fulfilling that role in the chlamydial competence system. Future studies assessing the dimerization and pore formation of CT339 and potential nuclease activity of CT346 will assist in identifying how CT339 enables DNA uptake.

Other potential components involved in DNA uptake in Chlamydia are less evident. Pili or pseudopili predominantly facilitate binding and transport of DNA to the bacterial surface, although no proteins sharing any sequence similarity to pilus homologs were identified in Chlamydia. Interestingly, Helicobacter pylori is unique among naturally transformable bacteria in that it does not use pili but instead relies on a dedicated type IV secretion system for DNA uptake (70). Gram-negative bacteria typically transport dsDNA through an outer membrane secretin channel (e.g., PilQ) and then process the dsDNA into ssDNA with a periplasmic protein, ComEA. Single-stranded DNA is then transported through inner membrane protein ComEC and into the bacterial cytoplasm, where it is bound by RecA or DprA (71). Direct pairwise BLAST analysis of C. trachomatis with numerous Gram-negative secretin homologs (PilQ) revealed sequence similarity (E values $<10^{-9}$) to only type II and type III secretion outer membrane proteins, GspD (CT572) and YscC (CT674), respectively. Similarly, no protein with similarity to various ComEA or DprA homologs was identified through sequence-based pairwise analysis. Clearly, there is much to be learned about the Chlamydia DNA uptake system, although it is safe to state that, similarly to H. pylori, Chlamydia is likely an exception to the general DNA uptake model.

In summary, the development and characterization of a transposon system that is functional in Chlamydia represent a substantial advance and a valued addition to the growing repertoire of genetic manipulations in this field. Such a transposon system is expected to have an enabling effect on the discovery of biological and pathogenesis-related genes, allowing the association of single-gene insertions with evaluated phenotypes. Only a subset of the initial Tn insertion mutant clones was evaluated for in vitro and in vivo growth and infectivity. An expanded analysis of the remainder of the Tn insertional clones by the use of these and other phenotypic screens will elucidate the contribution and role of various gene products. This report has also highlighted the current inefficiency in transformation in *Chlamydia*, which will need to be overcome for large-scale mutagenesis studies. Despite this shortcoming, there is much promise for this technique and its associated applications, as evident from the support for CT339 in the fundamental evolutionary process of lateral gene transfer in *Chlamydia*. There are also high expectations that this system will be applicable and functional for studies in other *Chlamydia* species and serovars (e.g., C. muridarum and C. trachomatis serovar D), thus enabling animal studies and analysis of more clinically relevant strains for the discovery of virulence factors and potential therapeutic targets.

MATERIALS AND METHODS

Chlamydial strains and propagation. *C. trachomatis* serovar L2 434/Bu was propagated in L929 mouse fibroblast cells (ATCC CCL-1) using RPMI 1640 medium (Invitrogen, Grand Island, NY) supplemented with 5% heat-inactivated fetal bovine serum (FBS) plus 10 μ g/ml gentamicin (Fisher Scientific, Pittsburgh, PA). Briefly, L929 monolayers were grown to confluence in spinner flasks ($\sim 8 \times 10^5$ cells/ml) and infected with purified EBs at a multiplicity of infection (MOI) of 1. Cultures were allowed to grow for up to 48 h at 37°C and 5% CO₂. Percent infectivity was assayed by IFA microscopy (described below). EBs were harvested as previously described (72) using a series of centrifugation and sonication steps to disrupt the host cells and release EBs. Once isolated, EBs were either frozen immediately or further purified using Omnipaque (Barrington, IL) and ultracentrifugation. All EBs were stored in sucrose-phosphate-glutamic acid (SPG) media at -80° C. Clonal isolates were obtained as previously described (73).

Development of pCMA transformation plasmid. pUC19 (GenBank accession no. L09137) was used as the initial backbone for pCMA generation and primers used are listed in Table S1 in the supplemental material. The C9 hyperactive transposase was amplified from pBADC9 (kind gift from D. Lampe of Duquesne University [3]) and cloned between the EcoRI and AatII sites. An Eagl site was incorporated for subsequent promoter cloning. Initially, a vector (pCMT) that contained a tetracycline-encoding transposon was generated for application in C. muridarum by the use of pACYC184 (GenBank accession no. X06403) as the template. Primers incorporated Himar inverted repeats and restriction sites for cloning into the Xmal site. To remove the β -lactamase gene carried on pUC19, the transposase, tetracycline transposon, and ori region were amplified with primers containing Ncol sites for self-ligation. Ligaseindependent cloning and HindIII sites were used to replace the tetracycline transposon with one encoding the β -lactamase and the associated promoter from pSW2 (27). To assist with selective expression of the transposase within Chlamydia and with less expression during plasmid propagation in E. coli, the chlamydial ct559 promoter and ribosomal binding sites were cloned upstream of the transposase gene using the Eagl site (38). The complete DNA sequence for pCMA is provided in the supplemental material. The graphical depiction of the plasmid (see Fig. S1 in the supplemental material) was generated using Savvy Scalable vector graphics (74).

Transposon mutagenesis. The method used for transformation of C. trachomatis was modified from previously described methods (27, 39). L929 cells were seeded to confluence in 6-, 12-, or 24-well plates and allowed to adhere overnight. The Chlamydia-DNA transformation reaction mixture (200 μ l total volume) was prepared with 10 μ l of C. trachomatis L2 434/Bu EB seed stock, 1× SPG (~1×10⁷ IFU), 15 μ g of pCMA plasmid DNA, and 100 μ l of 2× CaCl₂ buffer (20 mM Tris-HCl [pH 7.5], 100 mM CaCl₂), with double-distilled water (ddH₂O) added to reach the final volume. Following gentle pipette mixing, the reaction mixtures were incubated for 30 min at room temperature (RT). The mixture was added to 12 ml of 1× CaCl₂ buffer (10 mM Tris-HCl [pH 7.5], 50 mM CaCl₂) before being overlaid onto a L929 monolayer that was washed once with 1 \times CaCl₂ buffer (10 mM Tris-HCl [pH 7.5], 50 mM CaCl₂). Plates were spun at 550 \times q for 30 min at RT. Fresh RPMI medium supplemented with FBS, gentamicin, and 1 μ g/ml cycloheximide was added, and the plates were incubated at 37°C and 5% CO₂ overnight. Ampicillin (Fisher Scientific, Pittsburgh, PA) (1 μ g/ml) was then added for antibiotic selection at 16 to 18 h postinfection. Cultures were kept under conditions of selection using increasing concentrations of antibiotics and serially passaged every 48 hpi. After the final passage, EBs were harvested for identification of insertion site and subsequent analyses. Transformation efficiencies were estimated using 1×10^7 IFU input organism and 15 μ g plasmid DNA, resulting in an average of 4 unique clonal isolates from each transformation (4 IFU/15 μ g DNA). Twenty-three transformations were performed, resulting in 105 ampicillin-resistant cultures. The levels of transformation efficiency were separately assessed with five independent transformations using pGFP::SW2 plasmid under similar conditions and the same stocks of C. trachomatis as were used in transposon mutagenesis.

Whole-genome sequencing. DNA was extracted from purified EBs using a Qiagen blood and tissue kit (Qiagen, Valencia, CA). Manufacturer's instructions were used with minor modifications. In brief, purified EBs were aliquoted with buffer AL before proteinase K was added and the reaction mixtures were incubated at 56°C for 1 h. After incubation, buffer AL and ethanol (96% to 100%) were added and mixed thoroughly by the use of a vortexing mixer. The reaction mixtures were added onto a provided DNeasy Mini spin column and collection tube and were centrifuged at 6,000 \times g. Two wash steps were then performed using buffer AW1 and AW2, each with centrifugation. Finally, the reaction mixtures were incubated with buffer AE for 20 min at room temperature and centrifuged and the eluate was saved. For quality control, each sample was verified using a spectrophotometer (Denovix Ds-11 FX+) to quantify DNA. Extracted DNA was prepared for sequencing at the Genome Sequencing Core at the University of Kansas, where library preparation and further quality control were completed. Samples were multiplexed and run on an Illumina Miseg PE100 platform. Paired-end reads were generated with a Phred score (>Q30) of 95.44%. Reads were then demultiplexed and analyzed using the Geneious software suite. Total read coverage was calculated as a function of the proportion of reads that mapped to the WT reference genome (the total of chlamydial reads) over the total number of reads generated for the sample, including host DNA and other contaminant DNA. A threshold of 10 reads was created to check for the depth of coverage at each base pair (75).

Assembly and analysis of the transposon mutant genomes. The *C. trachomatis* LGV 434/Bu ("Hefty") parental clone sequence (NCBI sequence accession no. CP019386.1) was generated through assembly guided by reference to the previously published genome *Chlamydia trachomatis* 434/Bu (NCBI sequence accession no. NC_010287.1). The Hefty parental genome sequence contained three mutations relative to the reference strain, namely, two nonsynonymous mutations (G946945A [H1121N] and

C942546A [R274H]) and one intergenic indel (indel in lowercase; 127353/4 [AGGCCCattctaaaggccCC CTT]). After the parental draft was generated, each of the other samples were generated using the parental sequence as the reference sequence. In each case, read depth and potential loss of read continuity were considered for potential duplications or rearrangements. The reads were also mapped to the transposon sequence for each sample to ensure that the transposon was inserted into the correct site at the genome. Alignment files were generated for alignments between each mutant genome draft and the parental draft. Any mutations corresponding to these that might have accumulated through the study were annotated and verified using the reads. Host DNA contamination within each sample was mitigated using the reference-guided assembly techniques. Transposon insertion sites were analyzed both through the use of the reference-guided mapping of the genomes and separately through the use of reference-guided assembly of the raw reads to the transposon sequence. In each case, these were analyzed separately from the hypothesized insertion sites to prevent bias. The read quality of the transposon assemblies was proportional to the size of each genome in every case. Plasmid sequences were generated for each sample by using the C. trachomatis LGV plasmid (NCBI sequence accession no. NC_021051.1). Plasmid gene assignments incorporated both pqp1-8 (42) and cds1-8 (76) nomenclature. All alignments were performed in Geneious using global alignment with free end gaps and a cost matrix corresponding to 65% similarity. Completed sequences were submitted to GenBank and assigned accession numbers (see "Data accessibility" section below). The transposon mutant genomes were evaluated for new single nucleotide polymorphisms (SNPs), and no mutations were discovered after the transformation and cultivation processes. While all studies were performed using C. trachomatis LGV 434/Bu, C. trachomatis serovar D gene nomenclature is utilized due to recognition and field familiarity.

Assembly and analysis of the recombinant progeny genomes. Each recombinant genome was generated using assembly guided by reference to the OmpA parental genome. Genomes were then aligned to both parental genomes and scanned for regions of homology using the Geneious global alignment tool with free end gaps and a cost matrix corresponding to 65% similarity. Initial sequence assembly was verified through assembly guided by reference to the minority parent. Regions of homology were annotated, and margins were estimated based on similarity to the individual parents.

In vitro growth analysis of Tn mutants. For temporal assessment of progeny production, L929 mouse fibroblast cells were infected in triplicate with C. trachomatis parental or Tn mutant clones with a multiplicity of infection (MOI) of 0.5 in 24-well plates. At 18, 24, 30, 36, and 42 h postinfection (hpi), wells were washed once with Hanks' balanced salt solution (HBSS) and then immediately frozen in $1 \times$ SPG at -80° C within the 24-well plate. The 24-well plates were then thawed on ice and transferred to 1.5-ml Eppendorf tubes and sonicated in a Q500 Qsonica cuphorn sonicator (Qsonica) with the following settings: 75% amplitude; 4 pulses; 30-s ON/30-s OFF cycle in chilled (~5°C) water. To determine titers of inclusion-forming units, samples were then serially diluted and used to infect confluent monolayers of L929 mouse fibroblast cells in 96-well μ Clear CellStar plates (catalog no. 655090; Greiner Bio-One, Frickenhausen, Germany) or 8-well µ-Slides (Ibidi, Martinsried, Germany). After 24 h postinfection, the cells were washed with HBSS and then fixed with 100% methanol. Cells were washed with phenol-free HBSS before staining was performed with a MicroTrak C. trachomatis culture confirmation kit (Trinity Biotech, Wicklow, Ireland). After at least 1 h of room temperature incubation, 1 µM DAPI (4',6-diamidino-2-phenylindole) diluted in phosphate-buffered saline (PBS) was added and allowed to stain wells for 10 min. A final overlay of 0.1 M Tris-glycerol was added, and cells were imaged on an Olympus IX71 inverted microscope (Olympus, Waltham, MA) with both $10 \times$ and $40 \times$ objectives. Inclusions were enumerated manually for each sample by immunofluorescence microscopy. For calculation of progeny production, titers were also determined for the inoculum that was initially used to infect the 24-well plates at the time of infection to incorporate subtle differences in starting infectivity for each mutant relative to the parental strain (see Fig. S4 in the supplemental material). To normalize variations in Tn mutant progeny production that would result from differences in starting infectivity levels, the ratio of starting inoculum of the parental strain to the starting inoculum of the Tn mutant was individually multiplied by each Tn mutant's titers at each time point (18, 24, 30, 36, or 42 hpi). Data are shown as means and standard deviations (SD) for triplicate wells, generated in GraphPad Prism 7, and statistical differences were calculated using the two-tailed Student's t test. With a P value of <0.05, ct732::Tn had significantly reduced progeny production at 24, 30, 36, and 42 hpi; ct590::TN and ct036::Tn had significantly reduced progeny production at 24, 30, and 42 hpi; ct350::Tn had significantly reduced progeny production at 30 and 42 hpi; ct153::Tn and ct550::Tn had increased progeny production at 24 hpi; ct339::Tn had increased progeny production at 24 and 42 hpi; and ct148::Tn had increased progeny production at 30 and 42 hpi.

Confocal immunofluorescence microscopy. L929 cells were grown to confluence in an 8-well ibiTreat μ -Slide (lbidi, Martinsried, Germany) and were infected with the respective *C. trachomatis*/Tn mutants. At ~24 hpi, infected cells were fixed with 100% methanol for 10 min at RT. Cells were washed once with HBSS and again with PBS and then stained using the preparation supplied in the MicroTrak *C. trachomatis* culture confirmation test (Syva Co., Palo Alto, CA) (180 µl) diluted 1:40 in PBS for 1 h 50 min at RT in the dark or overnight at 4°C. A 2-µl volume of 1 µM DAPI (4',6-diamidino-2-phenylindole) diluted 1:100 in PBS was then added to wells and allowed to stain for 10 min at RT in the dark. The stain was then removed, and the cells were washed with PBS. A final overlay of Vectashield antifade mounting medium (Burlingame, CA) was added, and slides were stored at 4°C in the dark until the imaging step. Cells were visualized on an Olympus IX81/31 spinning disk confocal inverted microscope at ×150 csoftware (Intelligent Imaging Innovations, Denver, USA). Exposure time remained consistent for all fields captured, with the exposure time for DAPI set at 2 s, for OmpA at 4 s, and for cytoplasm at 6 s. Three to

seven Z stack images were taken at 0.3- μ m intervals per cell imaged. Images were processed in SlideBook 6, and No Neighbors deconvolution (with a subtraction constant of 0.4) was applied to all images.

In vitro inclusion size analysis for Tn mutants. L929 mouse fibroblast cells were infected at low MOI (~10% of cells infected) in triplicate on two separate 96-well plates with parental population or a clonal population of Tn mutant *Chlamydia trachomatis*. At 24 hpi, cells were fixed with methanol for 10 min. Cells were then stained using a MicroTrak *C. trachomatis* culture confirmation kit for 1 h at room temperature. DAPI (4',6-diamidino-2-phenylindole) (1 μ M) was diluted in PBS and allowed to stain wells for 10 min. A final overlay of 0.1 M Tris-glycerol was added, and cells were imaged on an EVOS FL Auto 2 microscope (Thermo Scientific, Waltham, MA) using a 20× objective. A total of 16 fields were imaged for 6 wells for each sample, including more than 200 inclusions per sample (range, approximately 200 to 1,000). Each inclusion area was then measured using MIPAR (MIPAR, Worthington, OH). Within MIPAR, segmentation of inclusions was performed by applying a threshold to images to identify inclusions based on a range of pixel values that was standardized to parental images. After segmentation of inclusions, the total area was measured and quantified as the total number of pixels. This output was then exported to GraphPad, and statistical analysis was performed. Statistical analysis consisted of a one-way analysis of variance (ANOVA) with Dunnett's multiple-comparison test (statistical significance *P* value, <0.05).

Mouse transcervical infections. Female C57BL/6 mice (6 to 8 weeks old) were purchased from Jackson Laboratories and housed in accordance with the requirements specified by the University of Kansas Institutional Care and Use Committee. Mice were treated subcutaneously with 2.5 mg medroxy-progesterone acetate (Depo-Provera, Pfizer, NY) upon arrival (day -7). Fresh aliquots of parental or Tn mutant *C. trachomatis* clones were diluted in sucrose-phosphate-glutamic acid (SPG) buffer and kept on ice until use. Using a nonsurgical embryo transfer device (NSET; ParaTechs, Lexington, KY), mice were inoculated transcervically with 10 μ l diluted stock (final concentration, 5 × 10^s IFU/mouse) by insertion of the device into the genital tract beyond the opening of the cervix. For each infection, samples used to infect mice were also evaluated for titer to ensure delivery of the expected infectious dose. The infections and analyses performed with *ct868*::Tn were repeated from the initially reported experiments (46).

ddPCR assessment of *Chlamydia* infection *in vivo*. Mice were humanely euthanized 5 days postinfection, and the genital tracts were collected in SPG. Uterine horns were homogenized using a rotor/stator homogenizer (Biospec, Bartlesville, OK). Aliquots (100 μ l) were frozen at -20° C until use. The remaining stocks of homogenized tissues were stored at -80° C. DNA isolation was performed using the 100- μ l aliquots and a DNeasy blood and tissue kit (Qiagen). Isolated DNA was then used for droplet digital PCR (ddPCR) analyses. Primers and probes for *C. trachomatis secY* and murine *rp30* (see Table S1 in the supplemental material) were used with ddPCR Supermix for Probes (Bio-Rad, Hercules, CA) to set up the PCRs. Oil-for-Probes droplet emersions were generated using a droplet generator cassette (Bio-Rad). The PCR conditions were as follows: 95°C for 10 min ad0 cycles of 94°C for 30 s and 98°C for 10 min followed by cooling to 4°C. Fluorescent reads of individual droplets were calculated after PCR was performed using a QX200 droplet reader (Bio-Rad). Data were analyzed using QuantaSoft Software (Bio-Rad), and the results are reported as log_{10} ratios of *Chlamydia* DNA to host DNA (*secY/rp30* copies/ μ). Box and whisker scatter plots were generated in GraphPad Prism 7, and recoverable organisms were compared using upaired multiple *t* tests with no correction for multiple comparisons.

Bioinformatic analysis of CT339 and chlamydial competence. BLAST analyses and subsequent queries within the Conserved Domain Database resulted in hits within the competence superfamily and multidomain hits for ComEC. Multiple-sequence alignments were generated using ClustalW and 10 variable species hits within the Clusters of Orthologous Groups of proteins (COG0658) (77). The following proteins were used (NCBI accession numbers shown in parentheses): competence protein ComEC family protein Shigella dysenteriae 1617 (YP008850592.1), competence locus E Helicobacter pylori Hp P-26 (EJC51989.1); competence protein ComEC Enterococcus faecium DO (YP006375852.1); ComE Synechocystis sp. PCC 6803 (BAA17126.1); ComEC Listeria monocytogenes EGD-e (CAC99560.1); ComE operon protein 3 Bacillus subtilis subsp. subtilis strain 168 (NP 390435.1); hypothetical protein AGR C 2573 Agrobacterium tumefaciens sp. strain C58 (NP354400.1); competence protein Neisseria meningitidis MC58 (NP273744.1); hypothetical protein CT339 Chlamydia trachomatis D/UW-3/CX (NP 219846.1); ComEC/Rec2 family protein Clostridium botulinum A strain ATCC 3502 (YP 001255462.1); ComEA Neisseria meningitidis (CAB44958); ComEA protein Helicobacter bilis (WP_004084273); competence ComEA Shigella dysenteriae 1617 (EFP70107); competence protein ComGA Enterococcus faecium (WP_002304768); competence protein ComGA Listeria monocytogenes (WP_009933475); ComGA Bacillus subtilis (BAA12533); (multispecies) competence protein ComGB (WP_002286180); (multispecies) competence protein ComGB Bacilli (WP_048681721); competence protein ComGB Listeria monocytogenes (WP_010990101). (multispecies) type IV pilus secretin PilQ Neisseria (WP_016686778); type 4 pilus secretin PilQ (outer membrane porin) Shigella dysenteriae 1617 (AHA67697); (multispecies) pilus assembly protein PilE Neisseria (WP_002214937); and ComGC Bacillus subtilis (BAA12535). The following five hydropathy prediction programs were used to predict topology for CT339: HMMTOP v2.0 (78); MEMSAT-SVM (79); TMHMM2.0 (80); TOPPRED (81); and SPLIT (82). Transmembrane illustrations were generated and modified using Protter v1.0 (83).

Generation of recombinant clones for assessment of bacterial competence. All experiments performed with tetracycline-resistant *Chlamydia* as described in this work were reviewed and approved by the National Institutes of Health Recombinant DNA Advisory Committee (University of Washington). Recombination experiments were performed as previously described (47). Briefly, sets of individual shell vials were seeded with McCoy cells and subsequently coinfected with the following combinations of

drug-resistant strains: *C. trachomatis* L1/*tet*^r (NCBI accession number ACUI01000000), *C. trachomatis* serovar F/*tet*^r, and either *C. trachomatis* LGV2 (*ct383*/4::Tn *bla*) or *C. trachomatis* LGV2 *ct339*::Tn *bla*. Cultures were incubated for 40 h postinfection in the absence of antibiotics and were then detached using -80° C/37°C freeze-thaw. Recombinants were isolated by infection of 96 new shell vial monolayers with 1 ml freeze-thaw lysates and treatment with both penicillin and tetracycline and were passaged until dually resistant clones were detected. Recombinant clones were propagated and cloned by limiting dilution and subsequently evaluated for identification of serovar-specific OmpA. DNA from clones was harvested and subjected to WGS as described above.

Data accessibility. Completed sequences were submitted to GenBank and assigned the following accession numbers (shown in parentheses): *CT015*::Tn (NHAT01000000); *CT036*::Tn (NHAU01000000); *CT333*::Tn (NHAV01000000); *CT333*::Tn (NHAV01000000); *CT339*::Tn (NHAX01000000); *CT392*::Tn (NHAY01000000); *CT350*::Tn (NHAZ01000000); *CT319*::Tn (NHAX01000000); *CT392*::Tn (NHAZ01000000); *CT319*::Tn (NHAX01000000); *CT392*::Tn (NHAZ01000000); *CT392*::Tn (NHAX01000000); *CT392*::Tn (NHAX01000000); *CT392*::Tn (NHAZ01000000); *CT392*

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/mBio .01343-19.

FIG S1, PDF file, 0.1 MB. FIG S2, PDF file, 1.7 MB. FIG S3, PDF file, 0.3 MB. FIG S4, PDF file, 0.2 MB. FIG S5, PDF file, 0.2 MB. TABLE S1, PDF file, 0.2 MB.

ACKNOWLEDGMENTS

We are highly appreciative of constructive feedback and assistance from Kevin Hybiske (University of Washington) and Daniel Rockey (Oregon State University). We are appreciative of Michael Starnbach and Rebeccah Lijek (Harvard University) for guidance and adaptation with respect to the transcervical animal model. We thank David J. Lampe (Duquesne University) for providing the C9 hyperactive transposase. We acknowledge the contributions of Michael Barta and Gregory Peterson with respect to assistance in characterizing *ct015*::Tn, *ct339*::Tn, *ct392*::Tn, and *ct550*::Tn. We are grateful for the efforts of Nancy Schwarting with respect to mouse infections and organ isolations.

S.D.L., Z.E.D., K.S.H., S.B., R.J.S., and P.S.H. were funded by NIH (AI126785). J.W. and P.S.H. were supported by NIH AI125929. P.S.H. was also supported by P20GM113117. Support for genomic sequencing was supplemented by P20GM103638.

REFERENCES

- Picardeau M. 2010. Transposition of fly mariner elements into bacteria as a genetic tool for mutagenesis. Genetica 138:551–558. https://doi.org/ 10.1007/s10709-009-9408-5.
- Hamer L, DeZwaan TM, Montenegro-Chamorro MV, Frank SA, Hamer JE. 2001. Recent advances in large-scale transposon mutagenesis. Curr Opin Chem Biol 5:67–73. https://doi.org/10.1016/S1367-5931(00)00162-9.
- Lampe DJ, Akerley BJ, Rubin EJ, Mekalanos JJ, Robertson HM. 1999. Hyperactive transposase mutants of the Himar1 mariner transposon. Proc Natl Acad Sci U S A 96:11428–11433. https://doi.org/10.1073/pnas .96.20.11428.
- Keravala A, Liu D, Lechman ER, Wolfe D, Nash JA, Lampe DJ, Robbins PD. 2006. Hyperactive Himar1 transposase mediates transposition in cell culture and enhances gene expression in vivo. Hum Gene Ther 17: 1006–1018. https://doi.org/10.1089/hum.2006.17.1006.
- 5. Finnegan DJ. 1992. Transposable elements. Curr Opin Genet Dev 2:861–867. https://doi.org/10.1016/S0959-437X(05)80108-X.
- Wood DO, Wood RR, Tucker AM. 2014. Genetic systems for studying obligate intracellular pathogens: an update. Curr Opin Microbiol 17: 11–16. https://doi.org/10.1016/j.mib.2013.10.006.
- Lampe DJ, Churchill ME, Robertson HM. 1996. A purified mariner transposase is sufficient to mediate transposition in vitro. EMBO J 15: 5470–5479. https://doi.org/10.1002/j.1460-2075.1996.tb00930.x.
- Cheng C, Nair ADS, Indukuri VV, Gong S, Felsheim RF, Jaworski D, Munderloh UG, Ganta RR. 2013. Targeted and random mutagenesis of Ehrlichia chaffeensis for the identification of genes required for in vivo

infection. PLoS Pathog 9:e1003171. https://doi.org/10.1371/journal.ppat .1003171.

- Beare PA, Howe D, Cockrell DC, Omsland A, Hansen B, Heinzen RA. 2009. Characterization of a Coxiella burnetii ftsZ mutant generated by Himar1 transposon mutagenesis. J Bacteriol 191:1369–1381. https://doi.org/10 .1128/JB.01580-08.
- Newton HJ, Kohler LJ, McDonough JA, Temoche-Diaz M, Crabill E, Hartland EL, Roy CR. 2014. A screen of Coxiella burnetii mutants reveals important roles for Dot/Icm effectors and host autophagy in vacuole biogenesis. PLoS Pathog 10:e1004286. https://doi.org/10.1371/journal .ppat.1004286.
- Clark TR, Lackey AM, Kleba B, Driskell LO, Lutter El, Martens C, Wood DO, Hackstadt T. 2011. Transformation frequency of a mariner-based transposon in Rickettsia rickettsii. J Bacteriol 193:4993–4995. https://doi.org/ 10.1128/JB.05279-11.
- Benjamin HW, Kleckner N. 1992. Excision of Tn10 from the donor site during transposition occurs by flush double-strand cleavages at the transposon termini. Proc Natl Acad Sci U S A 89:4648–4652. https://doi .org/10.1073/pnas.89.10.4648.
- Yahara K, Didelot X, Ansari MA, Sheppard SK, Falush D. 2014. Efficient inference of recombination hot regions in bacterial genomes. Mol Biol Evol 31:1593–1605. https://doi.org/10.1093/molbev/msu082.
- Sota M, Tsuda M, Yano H, Suzuki H, Forney LJ, Top EM. 2007. Regionspecific insertion of transposons in combination with selection for high plasmid transferability and stability accounts for the structural similarity

- Martinez E, de la Cruz F. 1990. Genetic elements involved in Tn21 sitespecific integration, a novel mechanism for the dissemination of antibioticresistance genes. EMBO J 9:1275–1281. https://doi.org/10.1002/j.1460-2075 .1990.tb08236.x.
- 16. Stephens RS. 1999. Chlamydia: intracellular biology, pathogenesis, and immunity. American Society for Microbiology, Washington, DC.
- Gottlieb SL. 2010. Summary: the natural history and immunobiology of *Chlamydia trachomatis* genital infection and implications for Chlamydia control. J Infect Dis 201(Suppl 2):S190–S204. https://doi.org/10.1086/ 652401.
- Thomson NR, Holden MTG, Carder C, Lennard N, Lockey SJ, Marsh P, Skipp P, O'Connor CD, Goodhead I, Norbertzcak H, Harris B, Ormond D, Rance R, Quail MA, Parkhill J, Stephens RS, Clarke IN. 2007. *Chlamydia trachomatis*: genome sequence analysis of lymphogranuloma venereum isolates. Genome Res 18:161–171. https://doi.org/10.1101/gr.7020108.
- Stephens RS. 1998. Genome Sequence of an Obligate Intracellular Pathogen of Humans: *Chlamydia trachomatis*. Science 282:754–759. https:// doi.org/10.1126/science.282.5389.754.
- Gomes JP, Bruno WJ, Borrego MJ, Dean D. 2004. Recombination in the genome of *Chlamydia trachomatis* involving the polymorphic membrane protein C gene relative to *ompA* and evidence for horizontal gene transfer. J Bacteriol 186:4295–4306. https://doi.org/10.1128/JB.186.13 .4295-4306.2004.
- Eder T, Kobus S, Stallmann S, Stepanow S, Köhrer K, Hegemann JH, Rattei T. 24 November 2017, posting date. Genome sequencing of *Chlamydia trachomatis* serovars E and F reveals substantial genetic variation. Pathog Dis https://doi.org/10.1093/femspd/ftx120.
- Joseph SJ, Didelot X, Gandhi K, Dean D, Read TD. 2011. Interplay of recombination and selection in the genomes of *Chlamydia trachomatis*. Biol Direct 6:28. https://doi.org/10.1186/1745-6150-6-28.
- 23. DeMars R, Weinfurter J. 2008. Interstrain gene transfer in *Chlamydia trachomatis* in vitro: mechanism and significance. J Bacteriol 190: 1605–1614. https://doi.org/10.1128/JB.01592-07.
- DeMars R, Weinfurter J, Guex E, Lin J, Potucek Y. 2007. Lateral gene transfer in vitro in the intracellular pathogen *Chlamydia trachomatis*. J Bacteriol 189:991–1003. https://doi.org/10.1128/JB.00845-06.
- Jeffrey BM, Suchland RJ, Eriksen SG, Sandoz KM, Rockey DD. 2013. Genomic and phenotypic characterization of in vitro-generated *Chlamydia trachomatis* recombinants. BMC Microbiol 13:142. https://doi.org/ 10.1186/1471-2180-13-142.
- Jeffrey BM, Suchland RJ, Quinn KL, Davidson JR, Stamm WE, Rockey DD. 2010. Genome sequencing of recent clinical *Chlamydia trachomatis* strains identifies loci associated with tissue tropism and regions of apparent recombination. Infect Immun 78:2544–2553. https://doi.org/ 10.1128/IAI.01324-09.
- Wang Y, Kahane S, Cutcliffe LT, Skilton RJ, Lambden PR, Clarke IN. 2011. Development of a transformation system for *Chlamydia trachomatis*: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog 7:e1002258. https://doi.org/10.1371/journal.ppat .1002258.
- Wickstrum J, Sammons LR, Restivo KN, Hefty PS. 2013. Conditional gene expression in *Chlamydia trachomatis* using the *tet* system. PLoS One 8:e76743. https://doi.org/10.1371/journal.pone.0076743.
- Johnson CM, Fisher DJ. 2013. Site-specific, insertional inactivation of *incA* in *Chlamydia trachomatis* using a group II intron. PLoS One 8:e83989. https://doi.org/10.1371/journal.pone.0083989.
- Hooppaw AJ, Fisher DJ. 2015. A coming of age story: *Chlamydia* in the post-genetic era. Infect Immun 84:612–621. https://doi.org/10.1128/IAI .01186-15.
- Bastidas RJ, Valdivia RH. 2016. Emancipating Chlamydia: advances in the genetic manipulation of a recalcitrant intracellular pathogen. Microbiol Mol Biol Rev 80:411–427. https://doi.org/10.1128/MMBR.00071-15.
- Ouellette SP. 2018. Feasibility of a conditional knockout system for *Chlamydia* based on CRISPR interference. Front Cell Infect Microbiol 8:59. https://doi.org/10.3389/fcimb.2018.00059.
- Mueller KE, Wolf K, Fields KA. 2016. Gene deletion by fluorescencereported allelic exchange mutagenesis in *Chlamydia trachomatis*. mBio 7:e01817-15. https://doi.org/10.1128/mBio.01817-15.
- Binet R, Maurelli AT. 2009. Transformation and isolation of allelic exchange mutants of *Chlamydia psittaci* using recombinant DNA introduced by electroporation. Proc Natl Acad Sci U S A 106:292–297. https:// doi.org/10.1073/pnas.0806768106.

- Kari L, Goheen MM, Randall LB, Taylor LD, Carlson JH, Whitmire WM, Virok D, Rajaram K, Endresz V, McClarty G, Nelson DE, Caldwell HD. 2011. Generation of targeted *Chlamydia trachomatis* null mutants. Proc Natl Acad Sci U S A 108:7189–7193. https://doi.org/10.1073/ pnas.1102229108.
- Kokes M, Dunn JD, Granek JA, Nguyen BD, Barker JR, Valdivia RH, Bastidas RJ. 2015. Integrating chemical mutagenesis and whole-genome sequencing as a platform for forward and reverse genetic analysis of *Chlamydia*. Cell Host Microbe 17:716–725. https://doi.org/10.1016/j .chom.2015.03.014.
- Nguyen B, Valdivia R. 2014. A chemical mutagenesis approach to identify virulence determinants in the obligate intracellular pathogen *Chlamydia trachomatis*. Methods Mol Biol 1197:347–358. https://doi.org/10.1007/ 978-1-4939-1261-2_20.
- Hefty PS, Stephens RS. 2007. Chlamydial type III secretion system is encoded on ten operons preceded by sigma 70-like promoter elements. J Bacteriol 189:198–206. https://doi.org/10.1128/JB.01034-06.
- Barta ML, Battaile KP, Lovell S, Hefty PS. 2015. Hypothetical protein CT398 (CdsZ) interacts with sigma(54) (RpoN)-holoenzyme and the type III secretion export apparatus in *Chlamydia trachomatis*. Protein Sci 24:1617–1632. https://doi.org/10.1002/pro.2746.
- Albrecht M, Sharma CM, Reinhardt R, Vogel J, Rudel T. 2010. Deep sequencing-based discovery of the *Chlamydia trachomatis* transcriptome. Nucleic Acids Res 38:868–877. https://doi.org/10.1093/nar/ gkp1032.
- Gong S, Yang Z, Lei L, Shen L, Zhong G. 2013. Characterization of *Chlamydia trachomatis* plasmid-encoded open reading frames. J Bacteriol 195:3819–3826. https://doi.org/10.1128/JB.00511-13.
- Song L, Carlson JH, Whitmire WM, Kari L, Virtaneva K, Sturdevant DE, Watkins H, Zhou B, Sturdevant GL, Porcella SF, McClarty G, Caldwell HD. 14 January 2013, posting date. *Chlamydia trachomatis* plasmid-encoded Pgp4 is a transcriptional regulator of virulence-associated genes. Infect Immun https://doi.org/10.1128/IAI.01305-12.
- O'Meara CP, Andrew DW, Beagley KW. 2014. The mouse model of *Chlamydia genital* tract infection: a review of infection, disease, immu- nity and vaccine development. Curr Mol Med 14:396–421. https://doi .org/10.2174/15665240113136660078.
- 44. De Clercq E, Kalmar I, Vanrompay D. 2013. Animal models for studying female genital tract infection with *Chlamydia trachomatis*. Infect Immun 81:3060–3067. https://doi.org/10.1128/IAI.00357-13.
- 45. Gondek DC, Olive AJ, Stary G, Starnbach MN. 2012. CD4⁺ T cells are necessary and sufficient to confer protection against *Chlamydia trachomatis* infection in the murine upper genital tract. J Immunol 189: 2441–2449. https://doi.org/10.4049/jimmunol.1103032.
- 46. Fischer A, Harrison KS, Ramirez Y, Auer D, Chowdhury SR, Prusty BK, Sauer F, Dimond Z, Kisker C, Hefty PS, Rudel T. 28 March 2017, posting date. *Chlamydia trachomatis*-containing vacuole serves as deubiquitination platform to stabilize Mcl-1 and to interfere with host defense. Elife https://doi.org/10.7554/eLife.21465.
- 47. Suchland RJ, Sandoz KM, Jeffrey BM, Stamm WE, Rockey DD. 2009. Horizontal transfer of tetracycline resistance among *Chlamydia* spp. in vitro. Antimicrob Agents Chemother 53:4604–4611. https://doi.org/10 .1128/AAC.00477-09.
- Hayes LJ, Yearsley P, Treharne JD, Ballard RA, Fehler GH, Ward ME. 1994. Evidence for naturally occurring recombination in the gene encoding the major outer membrane protein of lymphogranuloma venereum isolates of *Chlamydia trachomatis*. Infect Immun 62:5659–5663.
- Marti H, Kim H, Joseph SJ, Dojiri S, Read TD, Dean D. 2017. Tet(C) gene transfer between *Chlamydia suis* strains occurs by homologous recombination after co-infection: implications for spread of tetracyclineresistance among *Chlamydiaceae*. Front Microbiol 8:156.
- Draskovic I, Dubnau D. 2004. Biogenesis of a putative channel protein, ComEC, required for DNA uptake: membrane topology, oligomerization and formation of disulphide bonds. Mol Microbiol 55:881–896. https:// doi.org/10.1111/j.1365-2958.2004.04430.x.
- Muschiol S, Balaban M, Normark S, Henriques-Normark B. 2015. Uptake of extracellular DNA: competence induced pili in natural transformation of *Streptococcus pneumoniae*. Bioessays 37:426–435. https://doi.org/10 .1002/bies.201400125.
- Nunes A, Nogueira PJ, Borrego MJ, Gomes JP. 2008. Chlamydia trachomatis diversity viewed as a tissue-specific coevolutionary arms race. Genome Biol 9:R153. https://doi.org/10.1186/gb-2008-9-10-r153.
- 53. Keb G, Hayman R, Fields KA. 26 November 2018, posting date. Floxedcassette allelic exchange mutagenesis enables markerless gene deletion

in *Chlamydia trachomatis* and can reverse cassette-induced polar effects. J Bacteriol https://doi.org/10.1128/JB.00479-18.

- Bauler LD, Hackstadt T. 2014. Expression and targeting of secreted proteins from *Chlamydia trachomatis*. J Bacteriol 196:1325–1334. https:// doi.org/10.1128/JB.01290-13.
- 55. Iliffe-Lee ER, McClarty G. 1999. Glucose metabolism in *Chlamydia trachomatis*: the 'energy parasite' hypothesis revisited. Mol Microbiol 33:177–187. https://doi.org/10.1046/j.1365-2958.1999.01464.x.
- Jelsbak L, Hartman H, Schroll C, Rosenkrantz JT, Lemire S, Wallrodt I, Thomsen LE, Poolman M, Kilstrup M, Jensen PR, Olsen JE. 2014. Identification of metabolic pathways essential for fitness of *Salmonella* Typhimurium in vivo. PLoS One 9:e101869. https://doi.org/10.1371/journal .pone.0101869.
- 57. Sassetti CM, Rubin EJ. 2003. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A 100:12989–12994. https://doi.org/10.1073/pnas.2134250100.
- Martinez E, Cantet F, Fava L, Norville I, Bonazzi M. 2014. Identification of OmpA, a *Coxiella burnetii* protein involved in host cell invasion, by multi-phenotypic high-content screening. PLoS Pathog 10:e1004013. https://doi.org/10.1371/journal.ppat.1004013.
- Misaghi S, Balsara ZR, Catic A, Spooner E, Ploegh HL, Starnbach MN. 2006. *Chlamydia trachomatis*-derived deubiquitinating enzymes in mammalian cells during infection. Mol Microbiol 61:142–150. https://doi.org/ 10.1111/j.1365-2958.2006.05199.x.
- Le Negrate G, Krieg A, Faustin B, Loeffler M, Godzik A, Krajewski S, Reed JC. 2008. ChlaDub1 of *Chlamydia trachomatis* suppresses NF-kappaB activation and inhibits lkappaBalpha ubiquitination and degradation. Cell Microbiol 10:1879–1892. https://doi.org/10.1111/j.1462-5822.2008 .01178.x.
- Gerondakis S, Fulford TS, Messina NL, Grumont RJ. 2014. NF-[kappa]B control of T cell development. Nat Immunol 15:15–25. https://doi.org/ 10.1038/ni.2785.
- Hower S, Wolf K, Fields KA. 15 May 2009, posting date. Evidence that CT694 is a novel *Chlamydia trachomatis* T3S substrate capable of functioning during invasion or early cycle development. Mol Microbiol https://doi.org/10.1111/j.1365-2958.2009.06732.x.
- da Cunha M, Milho C, Almeida F, Pais SV, Borges V, Maurício R, Borrego M, Gomes J, Mota L. 2014. Identification of type III secretion substrates of *Chlamydia trachomatis* using *Yersinia enterocolitica* as a heterologous system. BMC Microbiol 14:40–14. https://doi.org/10 .1186/1471-2180-14-40.
- Belland RJ, Zhong G, Crane DD, Hogan D, Sturdevant D, Sharma J, Beatty WL, Caldwell HD. 2003. Genomic transcriptional profiling of the developmental cycle of *Chlamydia trachomatis*. Proc Natl Acad Sci U S A 100:8478–8483. https://doi.org/10.1073/pnas.1331135100.
- Nicholson TL, Olinger L, Chong K, Schoolnik G, Stephens RS. 2003. Global stage-specific gene regulation during the developmental cycle of *Chlamydia trachomatis*. J Bacteriol 185:3179–3189. https://doi.org/10.1128/ JB.185.10.3179-3189.2003.
- Gardy JL, Laird MR, Chen F, Rey S, Walsh CJ, Ester M, Brinkman FSL. 2005. PSORTb v.2.0: expanded prediction of bacterial protein subcellular localization and insights gained from comparative proteome analysis. Bioinformatics 21:617–623. https://doi.org/10.1093/bioinformatics/bti057.
- Charpentier X, Faucher SP, Kalachikov S, Shuman HA. 2008. Loss of RNase R induces competence development in *Legionella pneumophila*. J Bacteriol 190:8126–8136. https://doi.org/10.1128/JB.01035-08.
- 68. Baker JA, Simkovic F, Taylor HMC, Rigden DJ. 2016. Potential DNA

binding and nuclease functions of ComEC domains characterized in silico. Proteins 84:1431–1442. https://doi.org/10.1002/prot.25088.

- Schultz J, Milpetz F, Bork P, Ponting CP. 1998. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci U S A 95:5857–5864. https://doi.org/10.1073/pnas.95.11.5857.
- Hofreuter D, Odenbreit S, Haas R. 2001. Natural transformation competence in *Helicobacter pylori* is mediated by the basic components of a type IV secretion system. Mol Microbiol 41:379–391. https://doi.org/10 .1046/j.1365-2958.2001.02502.x.
- Johnston C, Martin B, Fichant G, Polard P, Claverys J-P. 2014. Bacterial transformation: distribution, shared mechanisms and divergent control. Nat Rev Microbiol 12:181–196. https://doi.org/10.1038/nrmicro3199.
- Mukhopadhyay S, Clark AP, Sullivan ED, Miller RD, Summersgill JT. 2004. Detailed protocol for purification of *Chlamydia pneumoniae* elementary bodies. J Clin Microbiol 42:3288–3290. https://doi.org/10.1128/JCM.42.7 .3288-3290.2004.
- Suchland RJ, Bourillon A, Denamur E, Stamm WE, Rothstein DM. 2005. Rifampin-resistant RNA polymerase mutants of *Chlamydia trachomatis* remain susceptible to the ansamycin rifalazil. Antimicrob Agents Chemother 49:1120–1126. https://doi.org/10.1128/AAC.49.3.1120-1126.2005.
- Bond SR, Naus CC. 8 May 2012, posting date. RF-Cloning.org: an online tool for the design of restriction-free cloning projects. Nucleic Acids Res https://doi.org/10.1093/nar/gks396.
- 75. Illumina. 2013. MiSeq sample sheet quick reference guide. Illumina, San Diego, CA. https://support.illumina.com/downloads/miseq_sample_sheet_quick_reference_guide_15028392.html.
- 76. Seth-Smith HM, Harris SR, Persson K, Marsh P, Barron A, Bignell A, Bjartling C, Clark L, Cutcliffe LT, Lambden PR, Lennard N, Lockey SJ, Quail MA, Salim O, Skilton RJ, Wang Y, Holland MJ, Parkhill J, Thomson NR, Clarke IN. 2009. Co-evolution of genomes and plasmids within *Chlamydia trachomatis* and the emergence in Sweden of a new variant strain. BMC Genomics 10:239. https://doi.org/10.1186/1471-2164-10-239.
- 77. Tatusov RL, Galperin MY, Natale DA, Koonin EV. 2000. The COG database: a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Res 28:33–36. https://doi.org/10.1093/nar/28.1.33.
- Tusnady GE, Simon I. 2001. The HMMTOP transmembrane topology prediction server. Bioinformatics 17:849–850. https://doi.org/10.1093/ bioinformatics/17.9.849.
- Buchan DWA, Ward SM, Lobley AE, Nugent TCO, Bryson K, Jones DT. 2010. Protein annotation and modelling servers at University College London. Nucleic Acids Res 38:W563–W568. https://doi.org/10.1093/nar/ gkq427.
- Krogh A, Larsson B, von Heijne G, Sonnhammer ELL. 2001. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305:567–580. https://doi.org/10 .1006/jmbi.2000.4315.
- Claros MG, von Heijne G. 1994. TopPred II: an improved software for membrane protein structure predictions. Comput Appl Biosci 10: 685–686. https://doi.org/10.1093/bioinformatics/10.6.685.
- Juretić D, Zoranić L, Zucić D. 2002. Basic charge clusters and predictions of membrane protein topology. J Chem Inf Comput Sci 42:620–632. https://doi.org/10.1021/ci010263s.
- Omasits U, Ahrens CH, Müller S, Wollscheid B. 24 October 2013, posting date. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics https://doi.org/10 .1093/bioinformatics/btt607.